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Abstract
This thesis describes a set of studies of the use of near infrared spectroscopy to measure 
cerebral oxygenation in obstructive sleep apnea (OSA) and chronic hypoxia. Cerebral 
oxygenation depends on cerebral blood flow and arterial oxygen saturation. The 
hypothesis underlying these studies was whether measurement of cerebral oxygenation 
using near infra-red spectroscopy (NIRS) gives additional valid information compared 
to measuring arterial oxygen saturation alone. We also hypothesized that this technique 
could be used to assess overnight cerebral oxygenation in sleep studies.
Our first validation study in 13 subjects with significant OS A showed that the fall in 
cerebral tissue saturation (measured as tissue oxygenation index, TOI) during sleep 
apnoea is related to arterial saturation (Sa0 2 ) (p=0.012), apnoea duration (p=0.001) and 
sleep stage (p<0.001) in a multiple regression in 1036 apnoeas. We also demonstrated 
changes in cerebral blood volume (range 0.41 - 0.09 ml/lOOg) and cytochrome oxidase 
oxidation state (range 0.48 - 0.13pM) occurring during apnoeas in 8 of these subjects.
In a second validation study in 8 subjects we demonstrated correlations between 
changes in TOI and both arterial saturation (p=0.001), apnoea duration (p=0.001) and 
cerebral blood flow velocity (p=0.012) measured using carotid Doppler.
We derived area under the curve (AUC) measures and dip rates for TOI and Sa02 
during overnight studies and compared them to conventional polysomnographic 
measures, showing significant correlations of pretreatment apnoea hypopnoea index 
(AHI) with dip rates for both TOI and Sa02. AUC TOI correlations with pretreatment 
AHI were weak. Mean AUC for TOI was 339.4 (161-675) and mean AUC for Sa02 
was 308.5 (89-944). Mean 4% Sa02 dip rate was 32.6 (1.5-90.6) and mean 4% TOI dip 
rate was 24 (0.1-95.7).
Pilot studies were also carried out on 11 subjects with chronic obstructive pulmonary 
disease (COPD) during oxygen challenge. Calculated cerebral blood volume 
measurements varied from 1.51 ml/lOOg to 3.65 ml/lOOg. Changes in TOI in response 
to supplementary oxygen in patients with COPD and chronic hypoxia are related to both 
cerebral blood volume (p=0.001) and arterial saturation (p=0.001).
The most important new findings in these studies are that cerebral blood flow changes 
appear to exacerbate rather than compensate for arterial hypoxia during sleep apnoea, 
and so it is plausible that TOI measurement (which picks up both Sa02 and cerebral 
blood flow velocity (CBFV) changes) may be more closely related to changes in
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neuropsychological function than pulse oximetry. The changes in cerebral oxygenation 
are profound enough to affect intracerebral redox state measured as cytochrome oxidase 
oxidation. Pilot work in COPD patients suggests that changes in cerebral blood volume 
affecting cerebral oxygenation occur during supplementary oxygen administration. 
NIRS provides a non-invasive method of measuring cerebral oxygenation suitable for 
use in sleep studies, and during oxygen administration.
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1. BACKGROUND TO THE THESIS
i . i  ABBREVIATIONS
ABG arterial blood gas 
ABP arterial blood pressure 
ADC analogue to digital converter 
AHI apnoea hypopnoea index 
AI arousal index 
ATP adenosine triphosphate 
AUC area under the curve
BMI body mass index
C3/A2, C4/A1 EEG positions
CBFV cerebral blood flow velocity
CBF cerebral blood flow
CBV cerebral blood volume
CPAP continuous positive airway pressure
CO2 carbon dioxide
COPD chronic obstructive pulmonary disease 
CSF cerebrospinal fluid 
Ctox cytochrome oxidase 
CVP central venous pressure
2,3 DPG 2,3diphosphoglycerate 
DPF differential pathlength factor
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ECA external carotid artery 
ECG electrocardiogram 
EEG electroencephalogram 
Elpsec elapsed seconds 
EMG electromyogram 
ENT ear nose and throat 
EOG electro-oculogram 
Et CO2 end tidal carbon dioxide
Hb haemoglobin
Hbdiff difference between oxy and deoxyhaemoglobin concentrations 
HHb deoxyhaemoglobin
Hhbthbmax value of Hhb at maximum total haemoglobin 
Hhbthbmin value of Hhb at minimum total haemoglobin
ICA internal carotid artery
ICP intracranial pressure
IPPB intermittent positive pressure breathing
IOS intra optode space
ITU intensive therapy unit
Km substrate concentration at which an enzyme is 50% saturated
LDF laser doppler flowmetry 
LTOT long term oxygen therapy
MCA middle cerebral artery 
MRC medical research council 
MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy
NIR near infra-red 
NIRS near infra-red spectroscopy 
NIRO near infra-red oximeter 
NOTT nocturnal oxygen therapy trial
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Ohb Oxyhaemoglobin
Ohbratio proportion of oxyhaemoglobin in the total haemoglobin change during apnoea 
Ohbthbmax value of Ohb at maximum total haemoglobin 
Ohbthbmin value of Ohb at minimum total haemoglobin 
OSA obstructive sleep apnoea
pC02 partial pressure of carbon dioxide
PET positron emission tomography
pet C 02 partial pressure of carbon dioxide (end tidal)
p02 partial pressure of oxygen
R&K Rechtschaffen and Kales
RDI respiratory disturbance index (event rate measured without EEG)
REM rapid eye movement
rS02 regional saturation measured by INVOS NIR spectrometer
Sa02 arterial oxygen saturation
SCI severe cerebral ischaemia
SIT saturation impairment time
Sj02 Jugular bulb oxygen saturation
SPECT single photon emission computed tomography
SRS spatially resolved spectroscopy
T90 Time (in a sleep study) spent with Sa02 <90%
TCD trans cranial doppler 
THb Total haemoglobin 
Tip02 tissue oxygen concentration 
TOI tissue oxygenation index
UARS upper airway resistance syndrome 
UCL University College, London 
UCLH University College, London, Hospitals 
VQ ventilation perfusion
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1.2 STATEMENT OF INVOLVEMENT
This thesis on the use of near infrared spectroscopy to measure cerebral oxygenation in 
respiratory disease includes data from two validation studies in OSA subjects, a 
prospective study using objective neuropsychological testing, and pilot studies in COPD 
subjects. Professor Spiro, Head of the Department of Respiratory Medicine, supervised 
my MD, and supported the sleep research work with regular meetings.
Professor L’Estrange (sleep prosthodontist, Middlesex Hospital) made the initial contact 
with Clare Elwell in the Department of Medical Physics and Bioengineering and 
performed a pilot study on one patient in her department, before I joined the sleep unit.
1.2.1 Validation study 1
I was not involved in the data recording of the initial 8 patients, which was performed 
by Dr Himender Makker, Consultant in Respiratory Medicine UCLH, Arschang 
Valipour, Visiting Research Fellow, and Stephen Emegbo, sleep technician. With 
Arschang I was involved in recruitment and data recording of the subsequent OSA 
patients, and data processing and analysis as reported in chapter 7. Statistical advice was 
provided by Caiomhe O’Sullivan from UCL. I was responsible for the final revision of 
the paper prior to publication (1) because Dr Valipour was no longer working in the 
department.
I was entirely responsible for data processing and analysis of the cytox and CBV traces 
as reported in chapter 8, published in Sleep (2), following initial advice from Clare 
Elwell on presentation of data.
1.2.2 Validation study 2
On the advice of Prof Delpy (Department of Medical Physics and Bioengineering,
UCL) I contacted Mr Kirkpatrick at Department of Neurosurgery, Addenbrookes (who 
had done the initial pilot work on NIRO300 which was awaiting publication), and was 
invited to give a presentation of our pilot work in Cambridge. Following this he offered 
us the necessary collaboration for Validation study 2, which included the loan of Pippa 
A1 Rawi, research physiologist, experienced in Doppler CBFV measurement. I wrote
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the protocol, obtained ethical approval and recruited subjects for this study with the 
support of Dr Makker and Professor Spiro. Pippa and I performed the study. The data 
was collected onto a database held by Pippa, I subsequently obtained a copy and 
performed the analysis reported in chapter 9.
1.2.3 Prospective neuropsychological study.
This was performed in collaboration with the Unit of Health Psychology UCL, led by 
Professor Stanton Newman, with whom I made contact with an initial one page 
proposal. The protocol was co-ordinated by me, with input from Prof Spiro, Dr 
Makker, Jan Stygall (research psychologist), Prof Newman, Prof Harrison (Professor of 
Neurology, National Hospital for Neurology and Neurosurgery, Queen Square) and Prof 
Delpy (Department of Medical Physics and Bioengineering, UCL). Grant applications 
and the ethical application were submitted by me. The research clinic was set up by Dr 
Makker and the two of us recruited patients. Kerri Mellehan was employed as an 
additional sleep technician to enable the study to continue recruiting during my period 
of maternity leave. Osier tests were performed by myself, Kerri Mellehan (sleep 
technician) and Chris Smith (sleep technician). Neuropsychological testing was 
performed by Jan Stygall, Jane Harrington and Shashi Hirani, all psychologists from the 
Unit of Health Psychology. Screening sleep studies were performed routinely by Kanta 
Gajria (lead sleep technician), Kerri Mellehan (sleep technician), Chris Smith (sleep 
technician). Research polysomnographies were performed by me, Kerri Mellehan,
Chris Smith and Ming Luo (previous research registrar). CPAP titration was performed 
routinely by the sleep technicians, compliance was read by me and the sleep technicians 
if necessary. Polysomnographies were staged by Kerri Mellehan or myself. All TOI 
analysis on polysomnography and digital output was performed by myself, following 
piloting of the methods used to calculate summary measures on the data from validation 
study 1 by myself and Arschang Valipour.
The neuropsychological database was held by the Unit of Health Psychology. All 
polysomnography analysis was performed blind to neuropsychological outcome and no 
neuropsychological results are reported in this thesis.
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1.2.4 COPD pilot studies
I wrote the protocol for these with advice from Prof Delpy and support from Dr 
Makker. I wrote the ethics submission and recruited patients. The studies were 
performed with Arschang Valipour and we analysed the data together.
1.3 PUBLICATIONS ARISING FROM THE THESIS
1.3.1 Publications arising from this Thesis (peer-reviewed)
Arschang Valipour, Anne D McGown , Himender Makker, Caiomhe O’Sullivan, 
Stephen G Spiro. Some factors affecting cerebral tissue saturation during obstructive 
sleep apnoea. European Respiratory Journal 2002 20 444-450 
Anne D McGown, Himender Makker, Clare Elwell, Pippa A1 Rawi, Arschang 
Valipour,Stephen G Spiro. Measurement of changes in cytochrome oxidase redox state 
during obstructive sleep apnoea using near infra-red spectroscopy. Sleep 2003 26 710- 
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1.3.2 Published abstracts arising from this thesis:
Valipour A, Makker H, Emegbo S, McGown A, Smith C, Spiro S.
Cerebral oxygenation in patients with obstructive sleep apnoea. Am J  Respir Crit Care 
Med 2000 161 A483
McGown AD, Valipour A, Makker HK, Emegbo S, Delpy DT and Spiro SG 
Measurement of changes in cytochrome oxidase redox state during obstructive sleep 
apnoea using near infrared spectroscopy. Eur Resp J2000 16 (S31) pi68s P I220 
Valipour A, McGown AD, O’Sullivan C, Makker HK and Spiro SG.
Non-invasive measurements of regional cerebral oxygenation during sleep in subjects 
with obstructive sleep apnoea (OSA). Thorax 2000; 55 (Suppl 3) A24 
McGown AD, Valipour A, Makker HK and Spiro SG
Measurement of cerebral oxygenation during oxygen challenge in chronic obstructive 
pulmonary disease (COPD) using near infra-red spectroscopy. Thorax 2000; 55 (Suppl
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3) A40
McGown AD, Al-Rawi PG, Makker HK, Spiro SG, Kirkpatrick PJ.
Cerebral oxygenation monitoring during obstructive sleep apnoea reflects changes in 
cerebral blood flow velocity as well as arterial oxygen saturation changes. Eur Resp J  
2002 20(S38) p295sP1867
Harrington J, McGown A, Stygall J, Hirani S, Makker H, Spiro SG, Harrison M, 
Newman S. The association between oxygen desaturation dip rate in obstructive sleep 
apnoea and neuropsychological function. Sleep Medicine 2003 4 (SI) S17 
McGown AD, Makker HK, Stygall J, Harrington J, Smith C, Mellehan K, Spiro SG. 
Relationship between polysomnographic measures of sleep fragmentation and 
hypoxaemia and measures of daytime sleepiness in consecutive patients with 
obstructive sleep apnoea referred to a sleep clinic. Thorax 2003 58 (suppl III) S16 (oral 
presentation at the BTS Winter Meeting 2003)
McGown A, Harrington J, Stygall J, Makker H, Hirani S, Harrison M, Spiro SG, 
Newman S. Cerebral oxygenation during REM sleep in obstructive sleep apnoea is 
associated with daytime neuropsychological function. Eur Resp J  2004 24 (Suppl 48) 
444s P2742.
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2. INTRODUCTION
Oxygen is necessary for all the cells in the body for the metabolism of fats and 
carbohydrates to produce energy for anabolic processes and cellular protein function. 
The brain is particularly susceptible to oxygen deprivation because of its rapid 
metabolic rate and inability to metabolise fatty acids, making it more reliant on 
mitochondrial aerobic respiration. Oxygen enters the blood through the nose and mouth 
via the gas exchange interface of the lungs. Diseases of the upper and lower respiratory 
tract may limit oxygen supply to the bloodstream. Pathological patterns of hypoxia 
include repetitive dips in obstructive sleep apnea (OSA) and constant compensated 
hypoxia in respiratory failure in chronic obstructive pulmonary disease (COPD). These 
naturally occurring models of hypoxia enable the effects of oxygen lack on the brain to 
be studied in humans, given appropriate validated non-invasive instruments to assess 
continuous cerebral oxygenation. Near infrared spectroscopy (NIRS) is a technique for 
non-invasive study of tissue oxygenation which has been available for about 20 years. 
This thesis describes preliminary studies of cerebral oxygenation in OSA and hypoxic 
COPD using near infra-red spectroscopy.
2.1 HISTORICAL PERSPECTIVE
Obstructive sleep apnoea is often considered to be a modem disease of the western 
world, but descriptions of cases of respiratory obstruction during sleep in association 
with daytime hypersomnolence are found in the nineteenth century literature. Without 
any formal overnight monitoring, these case studies are detailed observations of patients 
while asleep. The first description of mixed sleep apnoea was by Broadbent in 1877:
“ When a person, especially advanced in years, is lying on his back in heavy sleep and 
snoring loudly, it very commonly happens that every now and then the inspiration fails
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to overcome the resistance in the pharynx o f which stertor or snoring is the audible 
sign, and there will be perfect silence through two, three, or four respiratory periods, in 
which there are ineffectual chest movements; finally air enters with a loud snort, after 
which there are several compensatory deep inspirations before the breathing settles 
down to its usual rhythm. In the case to which I  allude there was something more than 
this. The snoring ceased at regular intervals, and the pause was so long as to excite 
attention, and indeed alarm; and I  found, on investigation, that there was not simply 
obstruction by the falling back o f the tongue & c, but actual cessation o f all respiratory 
movements; these then began gradually, but did not at first attain sufficient force to 
overcome the pharyngeal resistance.” (from (3)). Two further cases were described in 
1889, one by Richard Caton “ The thorax and abdomen are seen to heave from fruitless 
contractions o f inspiratory and expiratory muscles; their efforts increase in violence for 
about a minute or a minute and a half, the skin meantime becoming more and more 
cyanosed, until at last, when the condition to the onlooker is most alarming, the glottic 
obstruction yields, a series o f long inspirations and expirations follows, and cyanosis 
disappears. This acute dyspnoeic attack does not wake the patient.” and one by 
Morison “ I  have myself observed him asleep in bed with an intensely cyanotic 
countenance, a condition from which he was roused after a snorting and choking sound 
had issued from his respiratory passages, the cyanosis then gradually disappearing”(3). 
Both these two case studies included descriptions of excessive daytime sleepiness, the 
former, a poulterer, falling asleep while serving customers, and the latter falling asleep 
while playing cards, and dropping his cards on the table. These detailed descriptions of 
obstructive sleep apnoea are instantly recognizable to those of us who have used video 
sleep study systems (where often the video alone suffices for diagnosis), however then 
(as now among lay people) there was confusion as to whether “bad snoring” was 
actually pathological. When these descriptions were made, the nature and purpose of 
sleep was yet to be described, and the sleep state was deemed to be one of inactivity and 
lack of stimulation, defined behaviourally. Sleepiness was not considered a serious 
symptom. All subjects with what was considered pathological sleepiness were lumped 
together under the term narcolepsy. Major developments in the twentieth century were 
the development of polysomnography and the formal description of the Pickwickian 
syndrome as a case study (4). Sleep studies on Pickwickian patients followed, leading 
to the definitions of the sleep apnoea syndromes as distinct from the Pickwickian 
syndrome.
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The first EEG (electroencephalogram) was recorded in 1929 by Berger (5). 
Kleitman in Chicago pioneered the study of sleep electroencephalography in the 1930s 
and 40s (6). Initial descriptions of eye movements during sleep were observational, 
electro-oculography was then added to the system. These studies were completed using 
paper records, and initially intermittent recording was the norm because of the quantity 
of paper produced by continuous nocturnal recording. In 1957, Dement and Kleitman 
(7) described sleep stages organized in cyclic periods repeated 3-5 times a night, each 
one being completed by a period of desynchronized EEG and rapid eye movement 
sleep. Demonstration that electromyographic activity was completely suppressed 
during REM sleep followed in 1962 (8). The standard scoring manual for sleep staging 
was published in 1968 (9). Development of transistor technology allowing 
digitalization of multichannel data simplified storage problems. By 1972 the recording 
of respiratory and cardiac variables as part of the all-night sleep test (later called 
polysomnography) became routine, originating in Dement’s laboratory in Stanford (10). 
It is against this background of sleep studies taking place in research neurophysiology 
laboratories, that sleep apnoea emerged as a new diagnosis.
Charles Dickens describes a “wonderfully fat boy” with excessive daytime sleepiness in 
the Pickwick papers in 1837 (Figure 1).
Figure 1. Thomas Nast’s drawing of the fat boy in “The Pickwick Papers”(4).
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The term Pickwickian syndrome was used by Burwell in 1956 (4) to describe a case of 
an obese 51 year old business executive with daytime hypersomnolence, daytime 
cyanosis and cor pulmonale. Table 1 gives the clinical features of the Pickwickian 
syndrome as defined by this one case.
Table l. Clinical features of the Pickwickian syndrome (4)
1 Obesity, marked
2 Somnolence
3 Twitching
4 Cyanosis
5 Periodic respiration
6 Polycythemia, secondary
7 Right ventricular hypertrophy
8 Right ventricular failure
No sleep studies were performed on this case, and pulmonary function testing suggested 
a diagnosis of alveolar hypoventilation. Although this description is not of an 
uncomplicated sleep apnoea patient the term Pickwickian was subsequently used to 
describe the association of sleepiness and obesity. Jung and Kuhlo (11) performed 
sleep studies on three subjects with the Pickwickian syndrome and demonstrated 
apnoeas during sleep in 1965. These apnoeas were terminated by arousals and the 
subjects rarely reached slow wave sleep. This together with a second description by 
Gastaut (12) constitute the first polysomnographic descriptions of sleep apnoea. The 
cause of the apnoeas was thought to be an abnormal central response to hypercapnia, 
and hypercapnia was also blamed for the sleepiness initially.
The Stanford University Sleep Disorders Clinic was set up in 1970 and accepted 
referrals predominantly of subjects with excessive daytime sleepiness as possible 
narcolepsy. Between June 1972 and June 1975 62 subjects with sleep apnoea 
syndromes were diagnosed from approximately 350 referrals (13). The common 
clinical picture of loud snoring, abnormal behaviour during sleep, nocturnal enuresis, 
morning headaches and daytime sleepiness was then described. Even at this stage poor 
correlation between sleep apnoea severity and daytime symptoms was observed, and
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various mechanisms were postulated for the daytime symptoms, including sleep 
deprivation from repetitive sleep disturbance and a defect in the CNS structures that 
control sleep. The defining parameters of obstructive sleep apnoea were published in 
1976. Since then some treatments that reduce upper airway obstruction have been 
developed: initially tracheostomy, then nasal continuous positive airway pressure 
(CPAP), mandibular advancement devices and certain ENT procedures. None of the 
treatments that reverse the anatomical problem are simple and compliance is a major 
issue in both CPAP and dental devices. There is also a stimulant tablet modafinil which 
has been used to treat residual daytime symptoms in subjects compliant with CPAP (14) 
and has a central alerting effect without any effect on the obstruction.
It is important to define the rationale for treatment and the adverse effects of the various 
physiological changes which occur during OS A so that the right choices are made about 
who should be treated.
2.2 PATHOPHYSIOLOGY OF OBSTRUCTIVE SLEEP APNOEA 
2.2.1 Definitions
Sleep apnoea is a condition characterized by episodic absence of airflow during sleep. 
Obstructive sleep apnoea occurs due to transient closure of the upper airway during 
sleep. A clinical diagnosis of OSA requires a specified rate of obstructive episodes per 
hour usually with symptoms.
2.2.2 Physiology of upper airway collapse
The primary occurrence in obstructive sleep apnoea is collapse of the oropharyngeal 
airway during sleep. There is a fall in pharyngeal dilator tone during sleep in all people. 
Other common factors contributing to upper airway collapse are obesity and facial 
anatomy, in particular retrognathism. Neck circumference predicts OSA (15), so 
distribution of fat around the neck rather than just BMI is important in pathogenesis. 
Rarely, enlarged tonsils, pharyngeal tumours, endocrine disorders eg hypothyroidism or 
acromegaly and congenital conditions such as the mucopolysaccharidoses may increase 
risk of OSA in adults. Airway collapse is more common in the supine position, and 
muscle relaxation is increased by alcohol and hypnotic drugs.
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2.2.3 Apnoeas and hypopnoeas
Severity of OSA is measured by an event rate, classically the apnoea hypopnoea index 
or sum of apnoeas and hypopnoeas per hour. Episodes of complete (apnoea) and partial 
(hypopnoea) obstruction cause similar physiological effects. An apnoea is defined as 
absence of oronasal airflow for 10 seconds (16). Hypopnoeas have been variously 
defined, most commonly as a reduction in tidal volume to less than 50% of the previous 
values. The currently accepted definition for use in research studies is an airflow 
reduction of >50% compared to a 10s peak amplitude during the preceding 2 min, 
lasting>=10s and associated with either oxygen desaturation of >=3s or an arousal (16).
2.2.4 Effects on blood gas concentrations
Airway obstruction causes a fall in the partial pressure of oxygen in the alveoli, which 
results in a fall in arterial oxygen saturation with magnitude dependent on how steep the 
oxygen dissociation curve is at the starting point. There is similarly a rise in carbon 
dioxide. The extent of desaturation depends on lung volume at start of apnoea, 
underlying lung disease, sleep stage and duration of apnoea.
2.2.5 Effects on intrathoracic pressure
Attempts by the respiratory muscles to overcome the obstruction cause a reduction in 
intrathoracic pressure which may go as low as -100cmH2O. These pressure changes 
distinguish obstructive from central apnoeas, and affect cardiac output and venous 
return.
2.2.6 Apnoea termination and arousal
The rise in carbon dioxide may trigger the chemoreceptors to initiate respiration again, 
as may intrathoracic pressure changes acting on pulmonary stretch receptors. Apnoeas 
are terminated by arousal from a deeper to a lighter stage of sleep or wakefulness. 
Arousal is defined as 3 or more seconds of a significant change in the EEG (17).
Arousal is accompanied by sympathetic stimulation, catecholamine release and an 
increase in arterial blood pressure. An arousal index of arousals per hour may be 
calculated and is the best measure of sleep disturbance from polysomnography. The 
threshold for arousal varies with sleep stage and is highest in REM sleep. At the 
moment of arousal the activity of the upper airway dilator muscles returns. The airway
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often opens suddenly with a snorting noise.
2.2.7 Serial apnoeas
A brief period of hyperventilation follows arousal. This may lead to hypocapnia and a 
fall in respiratory drive initiating further airway collapse and a series of repetitive 
apnoeas.
2.2.8 Effects on heart rate
A brief bradycardia may accompany apnoea due to the diving reflex. Sympathetic 
outflow causes tachycardia accompanying arousal. Arrhythmias, may arise secondary 
to a combination of catecholamines and hypoxia, particularly in those with underlying 
ischaemic heart disease.
2.2.9 Effects on blood pressure
Cardiac output and blood pressure are reduced during apnoea due to the intrathoracic 
negative pressure, and then arousal causes an abrupt rise in arterial blood pressure due 
to sympathetic activation. Blood pressure then falls back again for the next apnoea.
2.2.10 Effects on cerebral blood flow
The effects on cerebral blood flow will be described in detail because of their bearing 
on cerebral oxygenation, which depends on arterial saturation and blood flow to the 
brain.
Cerebral blood flow in subjects with obstructive sleep apnoea has been previously 
assessed in a number of studies, mainly using Doppler cerebral blood flow velocity 
(CBFV)( 18-24), but also radioisotope techniques (25). During each obstructive apnoea 
CBFV both reduces below baseline (frequently by 50% or more) (22) and then increases 
above baseline (eg by as much as 110%) (24). Factors affecting CBFV during an 
apnoea include the passive effect of reduced intrathoracic pressure, blood pressure 
changes during arousal, and hypercapnoea and hypoxia as part of an autoregulatory 
response. Evidence for a role in intrathoracic pressure in the reduction of CBFV in 
obstructive apnoeas comes from the fact that a significant (50%) decline in CBFV 
occurred in 76% of 223 obstructive hypopnoeas and 80% of obstructive apnoeas, 
compared with only 14% of central apnoeas (22). Balfors and Franklin showed a close 
correlation between systemic blood pressure changes and CBFV changes (r = 0.67,
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p<0.001), initially increasing after apnoea, then decreasing below baseline (18). A blood 
pressure surge accompanies autonomic arousal at the end of an apnoea, and this 
systemic blood pressure increase appears to be transmitted to the cerebral circulation. 
Evidence that normal autoregulation does not operate as usual on this time scale also 
comes from a study of cerebral haemoglobin concentrations in spontaneously breathing 
volunteers (26). A role for hypercapnoea in the cerebral blood volume increase is 
suggested by the similarity between the CBFV traces in OSA and in voluntary apnoeas 
in healthy subjects (24); a direct relation between mean flow velocity increase and end- 
tidal pC02 in 10 patients (20), and a similar relation between endapneic transcutaneous 
pC02 and mean CBFV in one subject (24 apnoeas) (23). Subjects with severe OSA may 
have a blunted CBF response to hypercapnoea (27), although this finding has not 
always been replicated (28).
2.2.11 Effects on intracranial pressure
Changes in intracranial pressure (ICP) have also been observed during apnoeas. ICP 
has been measured in 3 patients with OSA by Sugita et al (29), who observed a marked 
episodic elevation of CSF pressure peaking at the end of each apnoea. They correlated 
the increase in pressure with apnoea duration and oxygen saturation dip. ICP elevation 
must be secondary to either an increase in CVP, an increase in ABP or 
hypoxic/hypercapnoeic vasodilatation increasing CBF (as the blood compartment is the 
only compartment that can change in volume on this timescale). A more detailed study 
by Jennum and Borgesen (30)showed a gradual increase in ICP during each apnoea, 
associated with an increase in pC02 and a decrease in p02, and then an abrupt further 
increase associated with an increase in ABP at the end of the apnoea. These two studies 
are generally in agreement with the findings using Doppler CBFV, and suggest that the 
observed changes in CBFV are true changes in CBF, rather than being related to 
changes in vessel calibre.
2.3 CLINICAL INVESTIGATION
As described above the initial descriptions of sleep apnoea were made in 
neurophysiology laboratories which had been primarily designed to investigate
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neuropsychiatric sleep disorders. Polysomnography was defined as the gold standard 
investigation for OSA before the causes and consequences of the spectrum of sleep 
disordered breathing were fully described. Hence new sleep study systems have all 
been validated against polysomnography rather than against clinical endpoints. The 
main physiological changes as detailed above include changes in airway resistance, 
respiratory muscle activity, heart rate, blood pressure, blood gas tensions and sleep 
interruption. Polysomnography using electroencephalogram (EEG), electromyogram 
(EMG), electrooculogram (EOG), oro-nasal flow, strain gauge plethysmography and 
pulse oximetry, enables characterization of sleep interruption using EEG arousals, as 
well as defining apnoeas and hypopnoeas and distinguishing central and obstructive 
events. It does not allow measurement of upper airway resistance. It is time consuming 
both to set up and to analyse. Correlations between classic polysomnography and 
daytime symptoms are poor, so although all sleep study equipment is validated against 
the polysomnography-derived apnoea hypopnoea index (AHI), it can be argued that this 
measure has never been properly validated itself as a measure of clinical sleep apnoea 
severity. However it does allow sleep staging which gives information on sleep quality 
and rapid eye movement (REM) sleep specific apnoea.
Screening sleep studies may be based on oximetry alone and are reliable when clinical 
probability is high. Oximetry combined with some way of measuring obstruction (eg 
sound recording of snoring or video) is commonly used for screening (31, 32). These 
systems lack methods of characterizing sleep interruption. There has been recent 
interest in using autonomic methods of characterizing arousals, for example heart rate or 
blood pressure measurements. Continuous non-invasive blood pressure monitoring is 
uncomfortable and so the pulse transit time is increasingly being used instead (33).
Pulse transit time is the time taken for the initial blood pressure shock wave to pass 
from the opened aortic valve to the periphery and depends on blood pressure. It can 
therefore be used to identify arousals in association with apnoeas.
The other group of new sleep study techniques attempt to characterize upper airway 
narrowing and inspiratory effort. These include sleep nasendoscopy, measurement of 
nasal flow, oesophageal pressure monitoring, and measurement of paradoxical ribcage 
and abdominal movements. Information about intrathoracic pressure can also be 
derived from blood pressure and pulse transit time measurements (32).
To summarise, the move away from polysomnography to simpler systems brings into 
focus the poor correlations between event rates and day time symptoms. There is a need
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for more information about the neurophysiological basis of the symptoms of sleep 
apnoea so that we measure the right things and treat the right people. Hence our interest 
in measuring cerebral oxygenation in OSA to see whether it predicts daytime function 
better than measurements based on pulse oximetry or sleep interruption.
2.4 CLINICAL CONSEQUENCES OF OSA
2.4.1 Sleepiness
The main presenting daytime symptom of obstructive sleep apnoea is sleepiness. The 
two early descriptions in the 1880s described the occupational and social consequences 
of this problem (3). In addition the medicolegal consequences of falling asleep at work 
were first referred to in 1909 in the case of a post boy: “The chief interest in this case,
from his master’s point o f view, is the possibility o f an accident  I f  an accident
occurred under these circumstances, his employer might have an action o f damage 
brought against him. He is probably insured against such risks; but his insurance 
company, i f  they knew that his employer was aware o f the fact that the patient is apt to 
go to sleep on the box, might naturally dispute the claim” The recent Selby rail crash 
where a car came off a motorway onto a railway track in the UK has served as a 
reminder to those who work in sleep clinics of the legal attitude to people that drive 
when sleepy. Objective measurement of sleepiness was initially performed using the 
Multiple Sleep Latency Test, defined by Mary Carskadon in 1975 (34). Maintenance of 
wakefulness tests are probably more relevant in the sleep apnoea population and both 
EEG based and behavioural versions have been standardized. The Osier test is a 
behavioural maintenance of wakefulness test where the subject is asked to stay awake in 
a darkened room and activate a touch sensitive button in response to a red light which 
comes on every 3s. It has been validated against the traditional polysomnography based 
MWT and is simpler to perform (35). Driving simulation tests eg Steerclear are also 
used in evaluation of OSA subjects. For routine clinic monitoring of sleepiness, 
validated sleep questionnaires for example the Epworth sleepiness scale are commonly 
used (36).
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2.4.2 Blood pressure and cardiovascular risk
After many years of debate evidence is now emerging that OSA is an independent risk 
factor for hypertension. Cross-sectional studies show an increased prevalence of 
hypertension in subjects with OSA (13). Because hypertension and OSA share common 
risk factors, it has been difficult to say whether OSA actually causes hypertension. The 
most important common risk factor is central obesity which is often poorly measured in 
studies, and contributes to vascular risk more than overall obesity does (37). Attempts 
can be made to reduce the effect of a common risk factor by using carefully matched 
controls in a case control study or by careful statistical adjustment in cohort studies. A 
case control study matching 45 patients with moderate to severe OSA with 45 controls 
showed increased ambulatory diastolic blood pressure both day and night and increased 
systolic blood pressure at night (38). A prospective cohort study of 709 subjects 
demonstrated a dose response association between sleep disordered breathing and the 
presence of hypertension 4 years later that was independent of known confounders (39). 
A recent review of 53 non-interventional studies supports this independent association 
between OSA and hypertension (40). If sleep apnoea causes hypertension then treating 
sleep apnoea should reduce blood pressure. Six randomised controlled trials of the 
effects of treatment on blood pressure are summarised in the review quoted previously 
(40). Some of these trials suggest benefit of CPAP (41, 42), and others do not (43, 44). 
Overall CPAP seems to produce a measurable reduction in BP in more severe OSA 
cases with excessive daytime sleepiness, but not in mild cases in the absence of EDS. 
This conflicts with the observational evidence that mild OSA is associated with raised 
BP in the community (39, 45), suggesting either that the clinical trials are underpowered 
or that some of the BP difference is not CPAP responsive.
Obstructive sleep apnoea may be associated with an increased stroke risk over and 
above that predicted by the blood pressure changes. Studies of patients presenting with 
stroke have shown that snoring (46) and sleep apnoea (47) are common. Fifty-three 
percent of 55 consecutive stroke patients had an AHI of greater than 10, compared with 
11% seen in control populations (47). Studying the association in incident stroke cases 
is complicated by the fact that stroke may cause sleep apnoea because of effects on 
upper airway tone. Pharyngeal dysfunction is common after cerebral and brainstem 
strokes (48), and measured OSA event rates decrease with time following a stroke (49). 
Attempts to determine the pathway of causation have included looking at stroke
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recurrence (50); a case control study of transient ischaemic attack where there is no 
neurological deficit (51); and a longitudinal population study of stroke incidence (52). 
Patients with stroke recurrence had a higher AHI than patients with first ever stroke 
(50), however there was no evidence of an increase in OSA in TIA patients compared 
with community-matched controls (51). In the prospective study sleep disordered 
breathing with an AHI >20 was associated with an increased risk of suffering a first 
ever stroke over the next 4 years (unadjusted odds ratio 4.31 (Cl 1.31-14.15); adjusted 
odds ratio 3.08 (Cl 0.74 -  12.81) (52). This is probably the first prospective evidence 
that sleep disordered breathing precedes stroke and may contribute to stroke causation. 
The quartet of risk factors: systemic hypertension, insulin resistance, hyperlipidaemia 
and central obesity (syndrome X, now the metabolic syndrome) are often found in 
association with OSA (53) and are a major risk factor for ischaemic heart disease (54, 
55). The pattern of central and upper body obesity associated with OSA (15) is that that 
carries the highest cardiovascular risk (55). One study comparing OSA subjects with 
controls suggests that OSA is independently associated with an increase in the 
cardiovascular risk factors that constitute the metabolic syndrome (56). There may be 
specific effects of OSA for example on blood viscosity, sympathetic drive and vascular 
endothelial function which further increase the cardiovascular consequences of this risk 
factor association (53).
2.4.3 Other health effects
There are also improvements in quality of life after treatment with CPAP (57, 58). One 
small non-randomised trial in 1988 suggested survival benefit on treatment.
2.4.4 Neuropsychological function in OSA
We are interested in studying cerebral oxygenation in OSA because of the well- 
described but poorly explained effects of OSA on neuropsychological function. 
Neuropsychological impairment is common in patients with OSA. Most patients 
complain of both excessive daytime sleepiness and cognitive impairment (59). Their 
driving competence and mood are also impaired. However, the mechanism of 
neuropsychological impairment in OSA is not known. The two main proposed causes 
are disturbed sleep and hypoxia. Various studies have attempted correlation between 
sleep study parameters eg AHI, extent of nocturnal hypoxia and arousal index; and
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aspects of neuropsychological performance, both before and after treatment.
Correlation between sleep study param eters and im paired day tim e performance.
Disturbed sleep does not seem to explain all the deficit, and correlations between 
hypoxaemia and cognitive deficit seem to be consistent. Cheshire et al (60) found that 
nocturnal hypoxaemia is more closely correlated with cognitive deficit than oxygenation 
while awake, and demonstrated that the frequency of apnoeas and hypopnoeas is 
independently associated with specific and global cognitive impairment in 29 patients. 
Bedard et al (61) in 20 OSA patients and 10 controls showed that attention performance 
was related to sleepiness, and IQ and executive function related to hypoxaemia.
Kotterba et al (62) in 31 OSA patients and 10 controls showed impairment of alertness, 
selective attention and continuous attention with no effect on vigilance, and showed that 
cognitive deficits correlated with the degree of nocturnal hypoxaemia. Naegele et al 
(63) using logistic regression correlated memory deficits with AHI and frontal lobe 
related abnormalities with nocturnal hypoxaemia in 17 subjects with OSA compared to 
17 controls. A larger study of 150 subjects with daytime sleepiness showed significant 
but weak (r2 <0.1) relationships between several nocturnal measures (AHI, Al and 
desaturation variables) and daytime measures of cognitive performance (64). A 
systematic review of studies of neuropsychological function in sleep disordered 
breathing has recently been published (65).
Treatment studies.
Neuropsychological deficits appear to be partially reversible with treatment. In the 
study of Kotterba et al (62) alertness and continuous attention improved significantly 
after 6 mths of treatment, but persistence of some neuropsychological deficits could be 
demonstrated relative to the control group. CPAP had been used for 5.4 +1-2.2 
hours/night and results were not stratified by compliance in the 15 patients who 
completed the study. Naegele et al re-examined 17 patients and 17 controls after 4- 
6mths of treatment and patients were found to have normalised most of their cognitive 
executive and learning disabilities, but all the short term memory tests remained 
unchanged (66). They did not find any difference in terms of neuropsychological results 
between compliant and non-compliant patients. There was no correlation between 
hours of nightly CPAP use (built in time counters) and daytime performance.
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There is also evidence that even subjects with mild OSA show neuropsychological 
improvement following CPAP treatment. Engleman et al (67) showed improvement in 
mental flexibility after treatment for 1 month in 16 patients with mild OSA (AHI 5- 
14.9), but with no significant improvement in subjective or objective sleepiness. 
Kingshott et al attempted to identify predictors of improvement in daytime function in 
62 subjects before and after CPAP and found that microarousal frequency and AHI 
were poor predictors of improvement in daytime function (68). Measures of 
hypoxaemia were better related but explained at most 22% of the variance.
Some of these treatment studies are now incorporating sham CPAP in a control arm.
One such study in 46 subjects showed that neuropsychological function improved with 
therapeutic CPAP treatment but that these changes were not different to those occurring 
with placebo CPAP treatment, however this study may have been inadequately powered 
(69).
Population based studies
There is a wide inter-individual variability in daytime symptoms of OSA for the same 
polysomnographic severity. It is therefore important to see if the same pattern of 
neuropsychological deficit is seen in the general population as in clinically diagnosed 
OSA. Data from the Wisconsin Sleep Cohort Study, a population based study, show a 
significant negative association between log AHI and psychomotor efficiency score 
independent of age, gender and educational status. According to this data, an AHI of 15 
(mild OSA) is equivalent to the decrement in psychomotor efficiency associated with 5 
additional years of age (70).
In summary, the aetiology of neuropsychological deficits is probably multifactorial 
because there are weak and moderate correlations between the primary measure of 
severity of the disease (AHI) and quantitative outcomes, as well as partial reversibility 
with treatment. Attempts to correlate neuropsychological outcomes with a single sleep 
study parameter are artificial as measures of breathing disruption, hypoxaemia and sleep 
fragmentation are highly intercorrelated.
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2.5 POSSIBLE MECHANISMS OF NEUROPSYCHOLOGICAL DEFICIT IN
OSA 
2.5.1 Sleep fragmentation
Studies of sleep fragmentation in which normal subjects were aroused by auditory 
stimuli regularly throughout the night show deficits in cognitive performance, 
specifically in attention based tests, and reduced rates of well-being. These changes are 
reversible (71).
2.5.2 Ischaemia and cell death
The detection of the presence or absence of structural lesions on brain imaging in OSA 
depends on the precise imaging modality used. Conventional magnetic resonance 
imaging in OSA shows no more ischaemic lesions than age matched controls. A case 
control study of magnetic resonance imaging (MRI) in 45 subjects with moderate to 
severe OSA and 45 controls matched for age, body mass index (BMI), alcohol and 
cigarette consumption, and treated hypertension showed a similar prevalence of sub- 
clinical cerebrovascular disease in the two groups (72). Hippocampal atrophy was seen 
in 25 patients with severe OSA and abnormal neuropsychological function, diagnosing 
atrophy by brain volumetric measures using quantitative MRI compared to a normative 
database (73). A further study of brain morphology by Macey et al using MRI showed 
diminished regional and often unilateral gray matter loss in sites including frontal and 
parietal cortex, temporal lobe, anterior cingulated, hippocampus and cerebellum in 21 
patients with OSA compared to 21 controls (74). The finding of reduced grey matter 
concentration in the hippocampus has been replicated by another group (75). These 
results were not however replicated in a more recent study by O’Donoghue et al using 
two quantitative MRI techniques (an optimized voxel based morphometry technique 
and manual tracing of anatomical borders) where no gray matter deficits nor focal 
structural changes were seen in 27 subjects with severe sleep apnoea (76). Similarly no 
longitudinal changes were seen in gray matter density or regional volumes with 6 
months CPAP treatment. The authors explain the discrepancy between their results and
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those of Macey et al because the latter group did not statistically correct for multiple 
comparisons.
2.5.3 Changes in cell metabolism caused by ischaemia
It is known that in mild to moderate hypoxia, cerebral levels of ATP and adenylate 
energy charge are normal. Two studies have recorded no change in the cerebral 
metabolic rate for oxygen in human volunteers with a Pa02 of 35-40mmHg (quoted in 
(77)). OSA differs from chronic hypoxia as recurrent short desaturations may not 
trigger the same compensatory mechanisms. Metabolic changes suggestive of cerebral 
white matter damage have been found in one series of 12 patients with moderate to 
severe OSA, using magnetic resonance spectroscopy (78). Further work on 55 subjects 
by the same group showed a significant relation between AHI and the degree of 
metabolic impairment in cerebral white matter (79). All these subjects had normal MRI 
imaging. They also carried out magnetic resonance spectroscopy (MRS) examinations 
during sleep and demonstrated lactate production, suggesting that hypoxia may cause 
anaerobic glycolysis in the brain of subjects with moderate to severe OSA (80).
2.5.4 Animal model of chronic episodic hypoxia
Rats exposed to chronic episodic hypoxia demonstrated marked increases in apoptosis 
in one of the hippocampal regions (CA1) and in the cortex which decreased towards 
normoxic levels by 14 days and were accompanied by marked architectural 
disorganization in these brain regions and impaired performance during acquisition of a 
cognitive spatial task, without affecting sensorimotor function (81). This model enables 
the effects of episodic hypoxia to be assessed in the absence of significant sleep 
fragmentation (the rats’ sleep patterns became normal after the first day). It also 
provides support to the volumetric MRI studies cited above showing hippocampal 
changes in subjects with OSA.
2.5.5 Neurotransmitters
Alteration of the cerebral redox state (reduction oxidation balance) in moderate hypoxia 
may cause alterations in neurotransmitter metabolism (47). Oxygen is utilised directly 
for the synthesis and degradation of dopamine, noradrenaline and serotonin. The Km 
(substrate concentration at which the enzyme is 50% saturated) of the synthetic enzymes
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for 02 is 12pM whereas brain levels of oxygen are estimated to be between 2 and 25pM 
and so variations in oxygen concentration in the physiological range may affect enzyme 
activity. There is also a tight linkage between the oxidation of glucose and pyruvate 
and the synthesis of acetyl choline. Induction of chemical hypoxia in mice reduced 
acetylcholine synthesis as did “hypoxic” hypoxia at an arterial Pa02 of 60mmHg. 
Therefore hypoxia may mediate its effect via neurotransmitter metabolism.
2.5.6 Hypertension and cerebrovascular disease
It is possible that the neuropsychological impairment in OSA is caused by subclinical 
cerebral vascular infarcts because of the increased risk of cerebrovascular disease. As 
discussed previously this increased risk is partly due to an increase in known risk 
factors: hypertension (39, 40, 42), and the metabolic syndrome (53, 56), but OSA also 
appears to be an independent risk factor for stroke (50, 52). However a case control 
study using MRI showed evidence of cerebrovascular disease to a similar extent in OSA 
patients and matched controls (72), so it is difficult to attribute the observed 
neuropsychological deficit to subclinical multi-infarct dementia on the basis of current 
evidence.
2.5.7 Summary
In summary there is evidence that both sleep fragmentation and hypoxaemia contribute 
to neuropsychological symptoms and objective deficit in OSA. Anatomical studies 
show both alterations in brain structure especially in the hippocampus, and metabolic 
changes in the brains of subjects with OSA. Few studies have combined objective 
neuropsychological testing with measures of cerebral physiology. We postulated that 
cerebral oxygenation measured directly may predict neuropsychological dysfunction 
better than measures based on pulse oximetry alone, as pulse oximetry will not measure 
changes in cerebral blood flow occurring during apnoea (see figure 2).
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Figure 2. Outline of how obstructive sleep apnoea may cause daytime neuropsychological symptoms
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2.6 THE USE OF NEAR INFRA-RED SPECTROSCOPY IN OSA
Near infra-red spectroscopy is a method of measuring cerebral oxygenation non- 
invasively and continuously, so that it is appropriate for use in overnight sleep studies. 
The theory behind the technique and its development and validation will be described in 
chapter 4. In brief, it is a spectroscopic technique based on the facts that body tissue is 
relatively transparent in the near infra-red spectrum, and that certain substances absorb 
light differently in the oxidized and reduced forms. The two substances imaged 
(chromophores) are haemoglobin and cytochrome oxidase.
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2.6.1 Chromophores
H aemoglobin
Haemoglobin is a protein found in red blood cells which binds oxygen in the lungs and 
releases it in the tissues. Figure 3 shows the reactions involving haemoglobin which 
take place in the tissue capillary bed where oxygenated haemoglobin is reduced to the 
deoxygenated form. Arterial and venous blood are different colours because the 
absorption spectra of oxidized and reduced haemoglobin are different. The 
measurement of tissue haemoglobin concentrations gives an idea of the oxidation state 
in the tissues, and in addition total haemoglobin can be used as a proxy for blood 
volume. Some spectrophotometers also provide a tissue saturation measurement from 
the ratio of oxygenated to total haemoglobin.
Figure 3. Reactions involving haemoglobin in the tissue capillary bed (82)
This diagram illustrates how haemoglobin gives up oxygen and takes up carbon dioxide to become 
deoxyhaemoglobin.
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Cytochrome oxidase
Cytochrome oxidase is a mitochondrial enzyme which takes part in oxidative 
phosphorylation, ie it is responsible for the metabolism of organic intermediates using 
oxygen to make adenosine triphosphate. Figure 4 illustrates the mitochondrial 
metabolic pathways of the electron transport chain and oxidative phosphorylation,
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where a series o f enzymes in the inner mitochondrial membrane pump out protons 
against a concentration gradient and the resultant proton motive force drives ATP 
formation by another set of membrane enzymes.
Figure 4. The mitochondrial electron transport chain and oxidative phosphorylation
This shows the position o f cytochrome oxidase on the inner mitochondrial membrane
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2.6.2 Previous use of NIRS in OSA
Hayakawa et al (83) studied 8 men with moderate to severe OSA (mean apnoea index 
35.7) using NIRS (OM-IOOA, Shimadsu) during nocturnal sleep (n=5) or daytime naps 
(n=3). They analysed 20 obstructive apnoeas during each of non-REM and REM sleep 
for each subject. They observed a consistent decrease of OHb and increases in HHb and 
total haemoglobin during each apnoea. Total haemoglobin change is obtained from the 
sum of OHb and HHb, and can be used as a measure of cerebral blood volume. An 
increase in cerebral blood volume is likely to be due to an increase in cerebral blood 
flow, unless venous return decreases. They interpreted their finding of a decrease in 
OHb despite an increase in total haemoglobin as suggesting that the increased cerebral 
blood flow during apnoea does not fully compensate for arterial desaturation and 
therefore a reduction in cerebral oxygenation occurs during apnoea.
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The machine used in this study did not have the facility to measure cerebral saturation. 
Hausser-Haw et al measured cerebral oxygenation in 4 subjects with severe sleep 
apnoea (AHI 68-125/hr) and 4 snorers using a different NIRS machine, the Criticon 
2020 (Johnson and Johnson Medical, England), (84). They reported that cerebral 
saturation paralleled peripheral oxygen saturation but was 20-30% lower in value in 
both snorers and subjects with OSA . These findings suggest that measurement of 
cerebral saturation added nothing to pulse oximetry, which is not what would be 
predicted from the literature on cerebral blood flow changes in apnoea discussed above. 
They did not quantify changes for individual apnoeas.
2.6.3 Aims of my work
Building on the limited available literature, the studies described in this thesis are 
studies intended to confirm changes in cerebral saturation during individual apnoeas 
using the NIRO300 (NIRO300, Hamamatsu Photonics K. K., Hamamatsu City, Japan), 
to show that this measurement could not be entirely predicted by pulse oximetry, and to 
demonstrate a relationship between both cerebral blood flow and oxygen saturation; and 
cerebral saturation measured as TOI, as would be predicted from the literature. I also 
planned to look at cytochrome oxidase changes during apnoea, which had not been done 
before.
Provided that these preliminary studies were satisfactory, I planned to go on to a large 
prospective clinical study to see if NIRS cerebral oxygenation measurements were 
clinically useful in predicting objective neuropsychological function in newly diagnosed 
subjects with OSA. In order to compare subjects I had to design ways of summarizing 
overnight NIRS recordings in a way similar to oxygen desaturation dip rates or T90 
(time spent with Sa02 <90%). Chapter 5 describes the methods used for data and 
statistical analysis. Chapters 6 to 11 describe the protocols and results of the validation 
studies and the protocol and measurements of the prospective study into cerebral 
oxygenation as a predictor of cognitive function in OSA. Chapters 12 and 13 describe 
pilot work on chronic hypoxia in COPD. All results are discussed in chapter 14.
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3. BASIC METHODS
This chapter describes the equipment used for the studies described in this thesis, except 
for the NIRO300, which is described in Chapter 4. The polysomnography system, 
visilab, and NIRO300 machines were from the Middlesex Hospital sleep laboratory. 
Middle cerebral Doppler probe, laser Doppler cutaneous probe and Finapres blood 
pressure monitor were loaned from the Department of Neurosurgery, University of 
Cambridge, as part of the collaboration in the validation studies. Capnosleep® was 
loaned by the manufacturer Weinmann.
3.1 POLYSOMNOGRAPHY
Full polysomnography is the classical neurophysiological technique used to study 
nocturnal sleep. It comprises measurement of EEG (C3/A2, C4/A1,) EMG, EOG, 
airflow, body plethysmograph, leg movements, body position, and oxygen saturation 
from a pulse oximeter. EEG, EOG and EMG are used to allow definition of sleep onset 
and sleep staging. Apnoeas and hypopnoeas are defined using saturation and airflow 
changes, with thoracic and abdominal movements allowing differentiation between 
obstructive and central apnoeas as well as being used in some definitions of hypopnoea. 
Body position is relevant as some subjects obstruct only when supine. Leg movements 
help to rule out alternative diagnoses.
The polysomnography system used in these studies was made by Compumedics® (S 
Series Sleep System, Compumedics, Melbourne, Australia). A heat sensitive thermistor 
was used to assess oro-nasal flow. Thoracic and abdominal respitrace bands were used 
to monitor chest and abdominal wall movements. The pulse oximeter was a Pulseox 7, 
(Pulseox 7, Minolta, now Anandic Medical Systems, Diessenhofen, Switzerland), which 
gives an analogue output every second to the polysomnography computer. The 
sampling rate should be set according to the rate of variation of the analogue signal.
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There is a theorem in signal theory which states that the sampling rate must be at least 
twice the highest frequency in the waveform. The highest frequency of apnoeas is 
around a hundred per hour or once every 36 seconds. Although fine changes in 
saturation will be smoothed by this sampling frequency, it should pick up all apnoeas 
reliably. The pulse oximeter sampling frequency was identical to the TOI sampling 
frequency to which it was being compared. Electrodes were applied to the scalp using 
collodion glue prior to the sleep study in the positions as shown in the diagram (Figure
5).
Figure 5. Electrode positions for polysomnography
Electrodes are applied using collodion glue at the sites shown. EOG, EOGL, Ref -  electro-oculogram 
positions; C4/A1, C3/A2 -  EEG positions; EMG land 2 -  EMG positions.
Ref
LOC
ROCEOG
EOGL +
EMG1 EMG2
EEG/2
BEG
BAG
ECG
Sleep staging was performed manually according to standard criteria, see Table 2 (9).
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Table 2. R & K sleep staging criteria
Sleep onset 3 or more continuous epochs of any stage of sleep
Stage 1 sleep Mixed voltage mixed frequency, possible rolling eyes, in the absence of 
spindles, K-complexes or other identifying markers of other sleep stages
Stage 2 sleep Spindles or k-complexes on a background of mixed voltage and frequency. 
Three minute rule adhered to.
Stage 3 sleep 20-50% of the epoch is comprised of delta waves (75 pV amplitude) or larger.
Stage 4 sleep 50% or more of the epoch is comprised of delta waves or larger
REM sleep Low voltage, mixed frequency EEG waves with rapid eye movements and a 
decrease in chin EMG. Three minute rule adhered to.
The three minute rule states that if there are no eg spindles or k complexes for up to 
three minutes, but there are some on epochs before and after, with no identifying 
markers of any other stage of sleep, then all of these epochs are scored as stage eg 2. 
An arousal was classed as 3 or more seconds of a significant change in the EEG. An 
arousal in REM sleep requires in addition an increase in chin EMG.
Obstructive apnoeas were defined as the cessation of airflow for more than 10 seconds 
in the presence of paradoxical movements of the rib cage and abdomen, accompanied 
by either a 1% desaturation or an arousal (85). Hypopnoeas were defined as a greater 
than 50 % reduction in thoraco-abdominal movement or airflow for at least 10 seconds 
accompanied by either a drop in oxygen saturation of at least 4 % or an arousal (86). 
The total number of respiratory events was divided by total sleep time to give an 
apnoea-hypopnoea index (AHI). Once manual staging has been completed, respiratory 
analysis is performed by the Compumedics® software to give an AHI and arousal 
index. The respiratory analysis can then be manually checked. When the cursor is 
clicked on a particular apnoea labeled on the airflow trace, a text box appears with the 
duration of the apnoea, sleep stage, saturation dip and minimum saturation within it.
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Figures 6 and 7 illustrate a subject connected to full polysomnography and the computer 
readout.
Figure 6. Subject connected to full polysomnography (with NIR0300) at the Middlesex hospital
Figure 7. The polysomnography computer at the Middlesex Hospital
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3.2 VISILAB SLEEP STUDY
This was the routine screening sleep study used to diagnose OSA in the Middlesex 
Hospital sleep clinic.
The Visilab sleep study (Visilab, Stowood Scientific Instruments, Oxford, UK) is a 
hospital sleep study system which consists of an infra-red video, microphone for 
snoring and pulse oximeter for heart rate and oxygen saturation. Body movement is 
calculated from the video and the system also calculates a 4% oxygen desaturation dip 
rate. Diagnosis of OSA is based on a dip rate of >10 with observation of obstructive 
apnoeas on the video. A dip rate of 10-30 constitutes mild OSA, 30-50 is moderate and 
>50 severe.
3.3 CEREBRAL BLOOD FLOW VELOCITY
Transcranial Doppler ultrasound can be used to measure middle cerebral artery cerebral 
blood flow velocity. Low frequency pulsed ultrasound waves penetrate the skull and 
the frequency shift of the waves reflected back from moving red cells at a specific depth 
can be used to calculate the flow velocity of particular intracranial vessels. Flow 
velocity is affected by changes in calibre of the imaged vessel as well as changes in 
blood flow, however radioisotope methods of measuring cerebral blood flow using 
xenon clearance or positron emission tomography are unable to pick up dynamic 
changes in CBF, so CBFV is measured as a proxy for CBF assuming the absence of 
changes in large vessel diameter. Doppler CBFV has been validated against 
radioisotope CBF measurement as a reliable measure of changes in CBF using blood 
flow response to hypercapnia (87). The technique has the advantages of being non- 
invasive and having rapid time resolution, and has been frequently used in the past for 
studies of haemodynamic changes during sleep and OSA (18-23, 27, 88). In our 
validation study the probe used was PCDop 842 (PCDop842, Scimed, Bristol, UK) 
positioned by an experienced user over the middle cerebral artery, and held in place by a 
custom-made head-band.
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3.4 SCALP BLOOD FLOW
Measurement of scalp blood flow in the region of the NIR probes using laser Doppler 
flowmetry (LDF) allows observed changes in TOI to be related to changes in both 
intracranial and extracranial circulations, to confirm that the signal predominantly 
originates from the brain rather than from more superficial tissues. LDF samples from 
the local microcirculation to a depth of about l-2mm, but this is probably representative 
of the extracranial block of tissue, as all are supplied from the external carotid artery. 
LDF does not provide an absolute value of skin blood flow and the readings are in 
arbitrary units, but provides a reliable measure of relative change. Most LDF devices 
use light at a wavelength that overlaps with the NIRS wavelengths, but the machine 
used in this study was specially modified to operate within the visible spectrum.
The instrument used was the MBF3D monitor and modified P3 probe (Moor Instrument 
Ltd, Axminster, Devon, UK) with the probe placed in the immediate vicinity of the NIR 
optodes (See Figure 8).
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Figure 8. Positioning of carotid Doppler (black flex), and laser Doppler (white flex) probes. The 
NIRO probe is deep to the bandage
3.5 ARTERIAL BLOOD PRESSURE MONITORING
Continuous blood pressure monitoring was performed using a Finapres (Ohmeda 2300, 
Boulder, Colorado, USA) device on the index finger. This is a non-invasive machine to 
measure beat-to-beat blood pressure. The device utilizes a rapidly responsive servo- 
controlled balloon cuff, matched to the pressure within the finger arteries to measure 
arterial blood pressure. It is accurate for short periods, but is subject to drift over time 
and is too uncomfortable for prolonged studies. Invasive blood pressure monitoring was 
not thought to be justified in subjects with OS A.
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3.6 CARBON DIOXIDE MONITORING
As partial pressure of carbon dioxide is one of the parameters which may affect the 
internal carotid circulation independently of the external carotid it was thought to be 
desirable to monitor pC02 by some means during the second validation study. Both 
non-invasive methods (endtidal CO2 and transcutaneous CO2) as well as arterial 
monitoring using paratrend were considered. One study has shown that neither non- 
invasive measure is consistently accurate when compared to arterial samples in sleeping 
patients (89). Paratrend is an invasive continuous intra-arterial monitor of pC02, p02 
and pH, which has not previously been used in OSA. It is accurate compared to arterial 
samples (90). We decided not to use it because of its cost (the probes are single use) 
and because we did not feel that its invasive nature was justified in our study 
population. We had access to a transcutaneous CO2 monitor using a silver electrode 
(TINA TCM3 capnograph, Radiometer®, Copenhagen, Denmark) but the response time 
of 50s for 90% response meant that it was not suitable for resolving rapid changes 
during individual apnoeas. A transcutaneous system has been used previously in 
studies of cerebral haemodynamics during OSA (18, 30) but quantitative comparisons 
with CBFV were not made. We elected to use an endtidal CO2 monitor (Capnosleep, 
Weinmann,Germany) which was designed for use in a sleep laboratory and has been 
validated against a thermistor as an apnoea marker in 121 subjects (91). It utilizes nasal 
cannulae which are much better tolerated during sleep than a tight fitting face mask, but 
have the disadvantages that they may entrain room air, and are inaccurate if the subject 
is mouth breathing (92). Apnoeas are defined by flattening of the etC02 trace to zero, 
so arterial pC0 2  during apnoea cannot be monitored using this technique, and maximum 
values before and after the apnoea are probably the most relevant readings. The 
increased dead space also complicates interpretation when nasal cannulae are used, 
especially in intermittently apnoeic patients. EtCC>2 monitoring has been used 
previously in studies of haemodynamics during OSA. PetC02 was found to be 
generally high in OSA patients compared to controls (19) and in one study a 
quantitative relationship between PetC02 and CBFV was observed (20).
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4. TECHNIQUE OF NEAR INFRA-RED
SPECTROSCOPY
Near infra-red spectrometry (NIRS) measures cerebral oxygenation non-invasively, 
based on absorption changes in chromophores which absorb in the NIR spectrum where 
body tissue is relatively transparent. NIR light from laser diodes is carried to tissue via 
optical fibres. Transmitted light is detected by a photomultiplier tube or photodiodes. 
The optodes, held in a small plastic holder, are attached to the forehead with a self- 
adhesive pad. Using incident and transmitted light intensities and knowing the specific 
extinction coefficients of the chromophores and the total optical pathlength, changes in 
concentration of the chromophores oxygenated and deoxygenated haemoglobin and 
cytochrome oxidase can be calculated (93). The technique enables concentration 
changes to be measured rather than absolute concentrations, some models eg the 
NIRO300 (NIRO300, Hamamatsu Photonics K.K., Hamamatsu City, Japan) also 
measure a regional tissue saturation, tissue oxygenation index (TOI), by spatially 
resolved spectroscopy (94)
4.1 INITIAL DESCRIPTION AND THEORY OF THE TECHNIQUE
The use of light in the near infrared spectrum to image tissue oxygenation was first 
described by Jobsis (95). Visible light (wavelength 450-700nm) is strongly attenuated 
by tissue and penetrates to a depth of less than 1cm. Light in the near infrared spectrum 
(wavelength 700 -  lOOOnm) penetrates to a greater depth, and can be detected at 8cm. 
Hence it can be used to image concentration changes of substances whose absorption
50
varies at these wavelengths according to oxidation state. Important compounds which 
can be imaged are oxyhaemoglobin (OHb), deoxyhaemoglobin (HHb) and cytochrome 
oxidase (Cytox). Other biological compounds also absorb light (eg water, bilirubin, 
melanin) but their concentration is unlikely to change during the measurement period. 
For an absorbing compound dissolved in a non-absorbing medium, measured 
attenuation can be converted into concentration using the Beer Lambert Law which 
states that the attenuation is proportional to the concentration of the compound, the 
specific extinction coefficient of the compound and the optical pathlength. Adaptation 
of this law to deal with an absorbing compound in human tissue is necessary and is 
described below. The specific extinction coefficient of the compound varies with 
wavelength. The absorption spectra for oxy and deoxy haemoglobin in the NIR 
spectrum are illustrated in Figure 9.
Figure 9. Absorption spectra for oxy and deoxy haemoglobin in the range (a) 450-1000nm and (b) 
in the near infrared region 650-1000nm (93)
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We know that oxygenated and deoxygenated blood can be visually distinguished -  this 
difference in absorption spectra persists in the NIR region and allows spectroscopic 
separation of the compounds using only a few wavelengths. The other compound 
which is measured using NIRS is cytochrome oxidase and the difference absorption 
spectrum between the oxidized and reduced forms is illustrated in Figure 10 (as the 
absolute concentration does not change knowledge of the individual absorption spectra 
of the oxidized and reduced forms is not required).
Figure 10. The difference absorption spectrum between the oxidized and reduced forms of cytochrome 
oxidase (93)
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Cytochrome oxidase is the terminal enzyme in the mitochondrial respiratory chain, and 
so changes in its oxidation state may reflect changes in the status of oxidative 
phosphorylation in the cell. However the enzyme has several redox centers, only one of 
which is imaged by NIRS, and this complicates interpretation. Although the magnitude 
of the specific absorption coefficients is similar to those of haemoglobin, the 
concentration in tissue is much less, and so separation of the absorption changes due to 
cytochrome from the haemoglobin changes is difficult. Validation of NIRS 
measurement of cytochrome oxidase will be discussed later.
As well as being absorbed in the tissue, light is also scattered within the tissue and so 
the distance it travels (pathlength) is not just the linear distance between emitter and 
detecter. Scattering occurs as light passes across boundaries between substances of 
different refractive indices. Both cell membranes and the macroscopic boundaries 
between different histological structures (bone, blood vessel, white matter) cause 
scattering. A differential pathlength factor (DPF) is therefore introduced into the Beer 
Lambert Law as a multiplier of the geometric pathlength to correct for tissue scattering. 
An unquantifiable amount of light is lost due to scattering, and so the modified Beer 
Lambert Law only allows calculation of changes in chromophore concentration, with
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the assumption that the scattering loss remains constant for the same individual during 
the recording period. There are several methods that have been used to calculate DPF 
for different tissues. The time an optical pulse takes to pass through tissue has been 
measured by splitting a pulse of light produced by a laser beam so that part of the output 
goes directly to a streak camera and the rest passes through the tissue first. This is 
known as the time of flight method and can only be carried out in an optical laboratory 
so cannot be used clinically. A second method uses an intensity modulated optical 
spectrometer to measure total pathlength from the phase shift occurring between light 
entering and exiting the tissue. This enables continuous real time measurement of total 
path length and is particularly necessary when there are changes in geometric pathlength 
during the study, for example when studying the fetus during labour or exercising 
muscle. Where geometric pathlength is fixed, the technique can be used to measure 
DPF. This technique has been used to measure DPF in neonatal head, and adult head, 
forearm and calf (96). The estimate of pathlength used in this thesis comes from a study 
of cranial DPF in 283 subjects, which showed a slight age dependence of DPF (97).
4.2 USE OF NIRS IN ADULTS
The earliest clinical use of NIRS was in neonates, where it was possible to transmit NIR 
light across the skull. This early work documented changes in NIR indices in response 
to alterations in arterial oxygen saturation, carbon dioxide tension and tilting (98, 99).
In neonates, although the precise path length may be imprecisely known, the fact that 
the major part of the tissue sampled is brain is not in question. It is not possible to use 
transcranial illumination in adults because of the bigger distances involved and so 
reflectance spectroscopy (scattered light sampled by an ipsilateral receiving probe) is 
employed instead. Figures 11 and 12 illustrate transcranial and reflectance 
spectroscopy.
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Figure 11. Example of basis NIRS circuit using transcranial illumination (lOS = intra -optode space) 
(93)
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Figure 12. Illustration of the principle of reflectance spectroscopy as used in adult NIRS
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The area imaged surrounds the interoptode dimension to a depth of a few cm. The 
penetration depth of NIR light depends on intraoptode spacing (100) and can be 
calculated using theoretical modelling to be 1.2 to 2cm at a spacing of 2.7cm (101). 
Penetration into the cerebral cortex has been confirmed using dye techniques (101).
The standard left frontal probe position is chosen because of practical considerations 
(lack of overlying muscle, sinuses or hair). Haemoglobin imaged is therefore
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predominantly within the left frontal cortical microcirculation, consisting on average of 
75% venous, and 25% arterial or capillary blood.
With the limitations of uncertain spatial resolution, and the inability to measure absolute 
concentrations, initial uses of NIRS in adults were to monitor trends, often in 
unconscious patients. Changes in NIRS parameters in response to normocapnic and 
hypocapnic hypoxia were documented by Hampson et al in adult volunteers (102). 
Observational studies showing changes in NIRS recordings in response to physiological 
insult in adults have been published in subjects undergoing carotid endarterectomy 
(103), in head injury (104, 105), during cardiopulmonary bypass (106) and during 
anaesthesia (107).
4.3 DEVELOPMENT OF THE TISSUE OXYGENATION INDEX OF THE 
NIR0300
As described above the NIRS machines used in early studies measured only changes in 
chromophore concentration from an arbitrary baseline. Absolute concentrations cannot 
be measured because of the complex light scattering in the tissue. Calculation of an 
absolute tissue haemoglobin saturation requires only an accurate measurement of the 
relative amounts of Hb and OHb in the tissue and this absolute measure is potentially 
easier to obtain. One problem in the NIRS literature is that different commercial 
companies have developed NIRS oximeters using different methodology and algorithms 
and validation of one machine cannot be extrapolated generally. Hence in this review I 
shall concentrate on the development of the tissue oxygenation index measure of the 
NIRO 300 (Hamamatsu, Japan). A method of calculating an absolute tissue saturation 
was developed using spatially resolved spectroscopy. This technique involves 
transmission of light at multiple wavelengths from a laser emitter and detection by 
multiple detectors at fixed distances from the emitter. The basic measurement made is 
the rate of increase of light attenuation with respect to the source detector spacing at 
different wavelengths, as illustrated in Figure 13.
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Figure 13. Principle o f spatially resolved spectroscopy in the N IR 0300
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Using assumptions from photon diffusion theory to calculate the scattering coefficient, 
these measurements are converted to relative absorption coefficients and then relative 
concentrations of OHb and HHb. TOI is given by the ratio of OHb to OHb + HHb. A 
prototype machine using this methodology was developed in 1993 (108), and it was 
incorporated into a commercial spectrometer, the NIRO 300 in 1999, (94). In the NIRO 
300 light emitted at four wavelengths by a laser is scattered by the tissue and reflected 
light is detected by 3 closely spaced photodiodes. Conventional measurements of OHb, 
HHb and cytox without spatially resolved spectroscopy are also taken.
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4.4 APPROACHES TO VALIDATION OF NIRS INSTRUMENTATION AS 
MEASURES OF CEREBRAL OXYGENATION
4.4.1 In vitro validation
There is little doubt that in uniform media NIRS instrumentation can measure 
chromophore changes accurately. The NIRO 300 has been validated against a blood gas 
analyzer using a phantom containing 6 different combinations of human blood, 
intralipid and water with a median R2 of 0.99 (94). The real issue in NIRS validation is 
whether when the instrument is placed on the forehead in an “intact human”, the 
majority (or even any) of the signal comes from the brain. Extracranial contamination if 
it is significant would be a major problem if there are differential changes in intracranial 
and extracranial blood flow during the recording period.
4.4.2 Experiments in Cambridge to separate effects from the external and 
internal carotid artery systems
An opportunity arises to separate the intracranial and extracranial contributions to the 
NIRS signal during the neurosurgical procedure of carotid endarterectomy, and Mr 
Kirkpatrick’s group in Cambridge have performed several validation studies in different 
NIRO machines using a formalized protocol and multiple monitoring modalities during 
the procedures. Their initial study using the NIRO 1000 (Takamatsu) was on 13 
subjects, 8 of whom showed a fall in MCA flow velocity on clamping the internal 
carotid artery. They showed a close relation between flow velocity changes and OHb, 
with no effect of clamping the external carotid on measured parameters (103). 
Subsequent studies were performed using the NIRO500, using a standardized protocol 
where the external carotid was clamped 2 minutes before the internal carotid in 
controlled intraoperative conditions where ABP, endtidal CO2 and Sa02 were kept 
constant. Continuous measurements of Doppler CBFV, cutaneous flow using a 
modified laser Doppler flowmeter, ABP, etC(>2, NIRO300 OHb and HHb , were made. 
This allowed monitoring of the intracranial cerebral circulation with TCD and 
monitoring of the extracranial circulation with the laser Doppler. The findings were that 
both the ECA and IC A vascular territories contribute to the NIRS changes during
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carotid endarterectomy (109), and that once the EC A component was removed, NIRO 
values could be used to predict severe cerebral ischaemia by established criteria (110). 
The initial results with the NIRO 1000 may be explained by the fact that the early 
machine required tight bandaging of the optodes to the head which may have rendered 
local skin ischaemic. At this stage the conclusion was that NIRS was capable of 
measuring intracranial ischaemia but only if the extracranial component was specifically 
monitored and removed.
The same experimental setup was used to validate the NIRO300 TOI measurement 
obtained by spatially resolved spectroscopy. Using sequential clamping of internal and 
external carotids in 60 patients during carotid surgery, TOI changes were seen in 49 
subjects; during external carotid clamping in 8, and during internal carotid clamping in 
41. TOI correlated significantly with cerebral blood flow velocity (r=0.56) but not with 
cutaneous laser-Doppler flowmetry (r=0.13). Discounting the 8 subjects in whom 
clamping the external carotid affected systemic blood pressure and CBFV, the 
sensitivity of TOI to intracranial and extracranial changes was 87.5% and 0% 
respectively, and specificity was 100% and 0% respectively (111). This was the first 
time that an NIR machine was rigorously shown not to have a significant extracranial 
contribution, and suggests that the algorithms used for the spatially resolved 
spectroscopy select for intracranial signal.
4.4.3 Cerebral activation measurements
Further evidence in support of an intracranial source for NIRS signals comes from 
functional imaging studies where changes in brain activity are assessed in response to 
stimuli. Activation of part of the brain is accompanied by a local increase in blood 
flow. Characteristic NIRS signal changes have been observed in response to motor 
activity, visual activation, auditory stimulation and performance of cognitive tasks, all 
observed non-invasively in adult humans (reviewed in (112)). Optode positioning for 
monitoring of frontal cognitive function is similar to that recommended when the 
instrument is used as a cerebral oximeter. Cognitive stimulation by performing 
calculations resulted in reproducible increases in OHb and decreases in HHb 
(NIRO500), with no change in cutaneous blood flow monitored using LDF (113). 
Similar studies have not been performed using the NIRO300. The fact that cerebral 
activation can be detected by NIRS confirms the depth of penetration, but is one of the
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reasons for the lack of reproducibility of the measurements. When the instrument is 
used as a cerebral oximeter the assumption is made that the local changes in cerebral 
oxygenation represent global changes occurring in response to a global hypoxaemic or 
haemodynamic challenge. Luckily most clinical uses of a cerebral oximeter are in 
subjects who are unconscious whether due to cerebral insult or anaesthesia, and this 
assumption probably holds true in these circumstances.
4.4.4 Jugular bulb saturations
Cerebral oxygenation is conventionally monitored by measuring the saturation of the 
venous effluent of the brain: jugular bulb saturation. When NIRS measurements are 
validated against jugular bulb saturations, correlation has not been good (114, 115). As 
the jugular bulb saturation gives a global measure and NIR is local, discrepancy 
between the values obtained may be real. When used as a tool to detect events causing 
change in cerebral perfusion pressure and MCA flow velocity in ventilated patients with 
head injury, NIRS (NIRO 1000) showed correlated changes in 37 of 38 events, and 
jugular venous saturation monitoring only showed correlated changes in 20 (105). The 
spatially resolved spectrometer (SRS) (prototype for the NIRO 300) was assessed 
against jugular bulb oxygen saturation in 24 subjects undergoing routine 
cardiopulmonary bypass and showed good correlation in 12 of the 24 subjects (116). 
The range of changes seen with the SRS was not as great as with the jugular saturation 
measurements, and tended to be 10-15% lower than the jugular saturations. Hence the 
SRS was no better than earlier models when compared with jugular bulb saturations on 
cardiopulmonary bypass, however interpretation of this lack of correlation is 
complicated as one method measures local tissue saturation, the other global venous 
saturation, and the conditions of non-pulsatile blood flow and hypothermia during 
bypass may affect the cortical microcirculation.
A similar study using the NIRO300 was published after I had completed the pilot work 
described in this thesis. Seventeen subjects undergoing warm coronary artery bypass 
surgery were studied, measuring TOI and jugular bulb saturation (Sj02) at various 
timepoints during cardiopulmonary bypass. Again there was a bias (TOI -  Sj02) of -  
6.7%, and wide limits of agreement between the two methods, suggesting that they are 
not interchangeable (117).
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4.4.5 Tissue oxygenation measurements
So is there any currently used method of measuring cerebral oxygenation against which 
NIRS can be validated that is more appropriate than jugular bulb saturation? One 
method introduced in neurosurgical intensive care units in 1993 is monitoring of local 
oxygen pressure in brain white matter (tip02). One group has compared this method 
with NIRS cerebral saturation (measured using the Invos 3100 NIRS machine (INVOS, 
Somanetics Corporation, Troy, Michigan, USA)) in 12 patients, 3 with subarachnoid 
haemorrhage and 9 with traumatic brain injury (118). Because they were comparing a 
p02 with a saturation they used frequency based mathematical methods to compare the 
two methods and concluded that the two signals contain similar information, with a 
band of significantly correlated frequencies in more than 90% of the data sets for 
coherence and overall density distribution. Cerebral blood flow and oxygenation is also 
monitored using PET scanning, however PET has very good spatial resolution and poor 
time resolution, in comparison with NIRS which has excellent time resolution and poor 
resolution in space. PET has therefore been used in an attempt to refine the spatial 
resolution of NIRS and 2 studies using PET and NIRS simultaneously have shown the 
best correlation between the two techniques in the outer 1cm of the brain tissue.
4.4.6 Against other machines
As there is no “gold standard” measure of local cerebral oxygenation for NIRS 
validation, an alternative approach is to compare cerebral saturation measurements 
simultaneously from 2 different NIRS machines. Five studies have been carried out 
using the NIRO300, 4 comparing it to INVOS 4100 and 5100 (119-122), and one to the 
OM-200 (123). Clearly interpretation of the results would be easier if there were good 
correspondence between values, than if, as is found, correspondence is poor, as the 
latter could mean that either or both machines are invalid as absolute measures. These 
studies do not therefore help much towards validation. The INVOS systems use 
different assumptions and algorithms to calculate a tissue saturation, involving two 
wavelengths of light, an assumption of a fixed partition ratio of blood between arterial 
and venous compartments, and elimination of extracranial contamination by simple 
subtraction. One study compared NIRO 300 and INVOS 5100 in juvenile swine 
undergoing cardiac bypass surgery and showed an overall correlation of 0.82 between 
the two systems, but a correlation of baseline readings of 0.62, with a non-linear
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relationship (120). Comparison of the same machines in paediatric surgical patients 
again showed poor agreement, with the INVOS measurements significantly higher 
(119). In adult volunteers the INVOS 5100 underread cerebral oxygenation compared 
to the NERO300, with an overall bias of -0.1% and limits of agreement of 14.7% (121). 
Two of these studies commented that the two machines demonstrated similar changes in 
response to challenge (120, 121). A study of the INVOS 4100 and the NIRO 300 in 19 
patients during CO2 challenge showed a bias o f-0.5% with 2 SD of 15.6% when 
comparing the INVOS regional saturation (rS02) with the TOI value, and a bias o f -  
3.4% with 2SD of 15.2% when comparing the percentage change of rS02 with 
percentage change of TOI, indicating unacceptable disagreement (122). Comparison of 
NIRO300 with OM-200 in forearm muscle at rest and during arterial occlusion, showed 
a significant correlation at rest (r2-  0.43, n=33) but not during arterial occlusion (123). 
Overall these studies suggest that the choice of algorithm and assumptions used for 
calculation of cerebral saturation from NIRS measurements does have an effect on the 
absolute values obtained, and so results obtained using different machines are not 
interchangeable.
4.4.7 Using clinical endpoints
Various attempts have been made to demonstrate clinical usefulness of NIRS machines 
to predict clinical outcomes in adults. The two main clinical situations where this has 
been attempted are carotid endarterectomy and cardiac surgery.
Nollert et al performed neuropsychological testing using the Mini-Mental-State test 
before and after cardiac surgery during which 41 subjects were monitored using NIRS 
(NIRO 500), (124). The 4 subjects who demonstrated a reversible neuropsychological 
deficit post operatively (score of 23 or below) had a bigger decrease in NIR measured 
oxidized cytochrome oxidase than the others. No other measured parameter was 
significantly associated with neuropsychological deficit. More recently Reents et al 
measured intraoperative regional cerebral oxygen saturation using NIRS (INVOS 4100) 
in 47 patients undergoing cardiopulmonary bypass for coronary artery surgery and 
found this not predictive for post operative cognitive performance measured using a five 
test battery (125). 16 patients in this study showed postoperative cognitive dysfunction 
and cytochrome oxidase results are not reported.
Kirkpatrick’s group have attempted to define thresholds for critical ischaemia during 
carotid endarterectomy using NIRS (126). Severe cerebral ischaemia (SCI) was defined
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as an intraoperative fall in Doppler measured MCA flow velocity of more than 60% 
accompanied by a sustained fall in cortical cerebral activity measured using a three-lead 
cerebral function monitor. The machine used did not have a cerebral saturation 
available and changes in OHb and HHb were resolved into external and internal carotid 
components using interrupted time series analysis following staggered clamping. The 
NIRS parameter chosen for comparison was the internal carotid (ICA) AHbdiff (AOHb- 
AHHb, which is a reasonable estimate of changes in oxygenation status independent of 
changes in blood volume). This value correlated with the percentage change in flow 
velocity (%AFV) (r=0.73). 16 subjects fulfilled the criteria for SCI and an ICA AHbdiff 
of 6.8pmol/l was 100% specific for SCI, whereas a value less than 5pmol/l was 100% 
sensitive for excluding SCI. Samra et al measured regional cerebral oxygen saturation 
(Invos 3100) in 94 subjects undergoing carotid endarterectomy and showed that the 
mean decrease in cerebral saturation was greater in 10 subjects who developed post 
operative neurological symptoms ( change in mental state or contralateral motor deficit) 
than in the others (127). A 20% fall in cerebral saturation had a sensitivity of 80% and 
specificity of 82.2% as a predictor of neurological compromise.
4.4.8 Summary
In the absence of a technique for direct validation of the technique of NIRS for cerebral 
oximetry in humans, a number of different validation methods have been developed. 
These include separation of the intracranial and extra cranial circulations during carotid 
endarterectomy, cerebral activation measurement, validation against jugular bulb or 
tissue oxygenation measurements, validation against clinical endpoints and against 
other NIRS machines. Each of these techniques has some drawbacks, but each has 
added useful information about the usefulness of NIRS measurements in clinical 
situations. Validity in vitro is not in question.
4.5 VALIDATION OF THE NIRO300
The TOI measurement of the NIRO300 is an absolute tissue saturation measurement 
which has been validated as intracranial during carotid endarterectomy (111), as well as 
validated against a blood gas analyzer in vitro and against time resolved spectroscopy in 
human arm (94). The main limitations of the technique are poor spatial resolution, lack
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of reproducibility and the possibility of extracranial contamination when the instrument 
is used in situations less controlled than operating theatres, ie when there are variations 
in blood pressure and oxygen saturation.
4.6 VALIDATION OF THE CYTOCHROME OXIDASE MEASUREMENT
The main theoretical problem in measurement of cytochrome oxidase using NIR is 
whether it is possible to resolve spectral changes due to cytochromes in the presence of 
much larger concentrations of haemoglobin. In animal models using inhalation of 
100% nitric oxide and exsanguination the cytochrome oxidase algorithm has been 
shown to be robust to large changes in haemoglobin oxidation and concentration (128). 
When cytochrome oxidase was fully reduced with cyanide, it was not possible to create 
spurious signals by manipulating haemoglobin concentrations (129). Hence in 
experimental conditions it is currently thought that NIRS can accurately measure 
changes in the cerebral cytochrome oxidase redox state (129).
The possibility of extracranial contamination is less of an issue with cytochrome 
oxidase measurement than with haemoglobin measurement, as mitochondrial content of 
tissues varies with metabolic activity, and is higher in brain than bone or skin, and 
absent in red cells. Thus the signal is unlikely to be significantly contaminated by the 
extracranial blood flow changes that occur during apnoea. Theoretical modeling 
suggests that the area imaged is restricted to the cerebral grey matter beneath the 
optodes. Functional imaging of occipital cortex during visual stimulation confirms an 
intracranial source for the cytochrome oxidase signal (112).
NIR cytochrome oxidase signals have also been validated against magnetic resonance 
spectroscopy (MRS) as a predictor for cerebral energy loss in hypoxic piglets (130). 
Decreases in phosphocreatine and nucleoside triphosphate compounds correlated 
closely with decreased cytochrome oxidase, but not with haemoglobin changes.
Another study using an animal model of cardiopulmonary bypass also showed 
correlation between cytochrome oxidase and high energy phosphates using MRS. 
Maximal cytochrome oxidase reduction during deep hypothermic respiratory arrest 
predicted histological brain damage (131).
4.7 THE TOTAL HAEMOGLOBIN MEASUREMENT
The sum of the OHb and HHb changes give a total haemoglobin change within the
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imaged area, which is related to a change in cerebral blood volume. Cerebral blood 
volume change can be calculated from THb using corrections for cerebral large to small 
vessel haematocrit ratio, cerebral tissue density and subject haemoglobin concentration 
as previously described (93). Changes in THb show significant correlation with 
changes in Doppler cerebral blood flow velocity in adult cerebrovascular reactivity 
testing (132). Therefore in the absence of more extensive monitoring the THb 
measurement available from NIRS has been used to give information about 
haemodynamic changes in brain tissue (26, 83).
4.8 CLINICAL USE OF THE NIR0300
The NIRO 300 consists of a measurement unit and a display unit, as well as emitter and 
detector probes connected to the measurement unit by optic fibres. Figure 14 is a 
photograph of this instrument.
Figure 14. Photograph of the NIRO 300 (Hamamatsu Photonics K.K., Japan)
A laser light source within the measurement unit emits light in the near infra-red 
spectrum. First both probes are slotted into position at the end of the measurement unit 
so that a probe test may be carried out. Probe testing fails if the probe is dirty or if optic 
fibres are damaged. After a successful probe test the probes are inserted into the probe 
holder which holds them at a fixed distance of either 4 or 5 cm. In general 5 cm is 
preferred as theoretically the greater the interprobe distance the more accurate are the 
assumptions that the scalp between them is flat. The probe is positioned high and 
laterally on the forehead towards the temporal region, away from the frontal air sinuses, 
and avoiding hair (see Fig 15).
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Figure 15. Probe positioning for the N IR 0300
display
unit
o
probe-
measurement holder
<= unit ^
A double sided self-adhesive sticker is used to secure the probe either before or after 
initialization. Initialisation is then carried out where the laser selects an output to suit 
the attenuation characteristics of the particular position selected. Various error 
messages may be seen at this stage. Signal underflow may be overcome by 
repositioning the probes at a distance of 4cm. Signal overflow at 5cm may be overcome 
by the use of the attenuator supplied with the machine, effectively a little spacer that 
increases the distance between the emitter cable and the source. Pressure over the probe 
site may also alter initialization readings, and simple repositioning often helps. On 
initialization the figures shown on the screen give some idea of how hard the laser is 
having to work at the different wavelengths, and figures of 31, suggest underflow, 
where figures of less than 10 suggest overflow. Light shielding is rarely a problem in 
sleep studies unless the bedside lamp is pointing towards the head in which case the 
error message “improve light shielding” appears and can be improved by repositioning 
or switching off the light. Following successful initialization the recording can be 
started. Once recording was started we initially had problems with loss of contact/poor 
light shielding, but these improved when we became more aware of the importance of
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keeping the room darkened and positioning the measurement unit on a drip stand as 
close to the head as possible. By the end of the studies we were able to complete full 
night unsupervised recordings in most cases where initialization was successful, both on 
and off CPAP.
I performed two daytime validation studies and one larger prospective treatment study 
with overnight recording using the NIRO300. Full protocols for these studies are 
described in chapters 6, 9 and 10. The NIRO 300 records data onto its own computer, 
however unlike the NIRO 500 it does not allow addition of any additional signals eg 
simultaneous Sa02. For the first validation study we connected the analogue output to 
the polysomnography system and used the digital data recorded on the NIRO without 
simultaneous Sa02. For the second validation study we fed all data onto an ADC 
analyzer on loan from Addenbrookes. For the prospective study with overnight rather 
than daytime sleep studies we used the free channel on the polysomnography system, 
and also set up a simple ADC to record simultaneous Sa02.
There were no side effects from probe use during daytime studies. We were expecting 
to see some erythema associated with the emission probe site in overnight studies, but in 
fact only observed very occasional mild reactions. I have subsequently become aware 
that continuous NIRO monitoring, for example following head injury is taking place for 
several consecutive days on neurosurgical ITUs without ill effects. There is a 
theoretical risk of retinal injury from the laser source if it is switched on without the 
probe in position, but in practice this is impossible to do. Hence we showed NIRO300 
to be a reasonably side-effect-free and easy-to-use addition to full polysomnography in 
subjects with obstructive sleep apnoea.
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5. PRINCIPLES OF DATA ANALYSIS
The output from the NIRO 300 presented several problems for data analysis. Output 
consisted of measurements of concentration changes in oxidized cytochrome oxidase 
and oxyhaemoglobin, and an absolute tissue saturation, the tissue oxygenation index or 
TOI. There was a lack of previous literature on the relation between oxygen saturation 
and TOI, as validation work had been performed in neurosurgical theatres where Sa02 
was kept constant under anaesthetic. In this setting it was possible to define a TOI 
change and then group subjects as to whether TOI changed or not, basically an all or 
none phenomenon. This technique could not be applied in OSA where arterial 
saturation changes defined the condition. Another problem was comparison of values 
between subjects, where baseline values were known to vary quite significantly between 
subjects. The sheer volume of data produced posed other problems, as unlike in other 
clinical monitoring systems (eg polysomnography, ECG monitoring etc) automated 
processing to identify noise, artifact and periods of interest have not yet been developed, 
and it was basically down to us to try and identify what the periods of interest were.
Our medical physics and physiology collaborators were accustomed to an experimental 
set up where a stimulus is applied and responses in other parameters are recorded, and 
then replicate stimuli are performed and responses averaged to give results to an 
experimental question. The study of sleep apnoea in adults is essentially observational, 
in that the subject initiates the stimulus (upper airway obstruction) and then this initiates 
changes in various physiological parameters which can be recorded. We are lucky in 
that multiple episodes naturally occur, and that these are similar in a subject, however 
the repetitive episodes are not identical and vary in duration and severity. Hence it is 
not particularly useful to model the “wiggly lines” as though they were a regular 
waveform with superimposed noise.
My main aim in the validation study was to quantify changes in the various parameters 
and to see whether they were related to changes in other parameters which occurred
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during apnoea (as if they were it implied that the changes we were measuring were real, 
rather than just being noise). At best I could define an association between the 
parameters. I might suggest causation as an explanation of these associations because 
of biological plausibility (eg association of cerebral blood flow and cerebral 
oxygenation) however our experimental setup did not allow us to prove causation 
because it was observational and I was not able to manipulate variables.
Possible ways of comparing the traces included direct comparison of the digital wave 
forms using techniques of time series analysis and lagged correlation, two point 
comparisons and cumulative averaging of changes during apnoea.
5.1 COMPARISON OF WAVE FORMS
Some attempts were made to compare the traces using lagged correlation. However 
because of the intermittent nature of the apnoeas, their non-identical nature, and our 
lack of the necessary mathematical knowledge, this did not seem to be a useful way of 
comparing subjects, or reaching conclusions on the combined data. We were able to 
obtain the lag of maximum correlation and the maximum correlation coefficient 
between two parameters for short periods of repetitive apnoeas. It was unclear how to 
select the data to use for this analysis or how to use the results. This analysis technique 
was therefore not used further. The following figure (Figure 16) illustrates correlations 
at different time lags between TOI and cytox for raw data illustrated in Table 3, 
showing maximum correlation of approximately 0.5 at a cytox lag of 4s behind TOI.
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Figure 16. Lagged correlations between cytox and TOI for subject 1 during consecutive apnoeas
This shows correlations of the ctox and TOI traces for lags between -20 and +20s, for a 200s period 
during a run o f apnoeas. Ctox = cytochrome oxidase; TOI = tissue oxygenation index.
1.00 1.00
0.75 0.75o
oa
0.50 0.50co
X
o
o 0.25 0.25
o
U)
0.00 0.00co
CO
CD - 0.25 - 0.25
oo
- 0.50 - 0.50CO
coO
- 0.75 - 0.75
- 1.00 - 1.00
-20 -10 0 10 20
L a g
C r o ss -co r re lo g r a m
5.2 TWO POINT CORRELATIONS
This technique involves defining an episode of interest (apnoea) and then recording the 
maximum and minimum values of defined parameters associated with the apnoea. The 
change in each parameter for that apnoea is then calculated. These changes can be 
compared between different parameters for individual apnoeas, and also averaged for 
each subject. The polysomnography software uses an algorithm to define the oxygen 
saturation dip associated with an apnoea. We used this value in analysis, and also 
manually calculated dips (or rises) in most of the recorded parameters in the different 
validation studies. We were able to do this on the polysomnography TOI trace by 
visually identifying the pre-apnoea maximum and post-apnoea minimum on the TOI 
trace. Clicking on the trace with the computer cursor at these points enabled us to read 
off the TOI values which were recorded in a table. By the time we came to do the 
prospective study using full night polysomnography, we were able to use the Sa0 2
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analysis algorithm to calculate TOI dips for us. For the other traces not on the 
polysomnography system (cytox, total haemoglobin, and CBFV, ABP) we illustrated 
the data series graphically in Excel® (Microsoft Office 95, Microsoft Corporation, 
USA) defined apnoea, and again read off consecutive maxima and minima by clicking 
on the visually identified points which resulted in the value appearing in a text box. The 
data was illustrated sequentially in sections of 200-300 observations for each subject. 
The maxima and minima read off were than tabulated in a further excel® file and then 
combined in a stata dataset for manipulation.
The following table (Table 3) illustrates the data as obtained from the NIRO300.
Table 3. Data obtained each second during apnoeas from one subject
(elpsec = elapsed seconds, 02Hb = oxyhaemoglobin, HHb = deoxyhaemoglobin, Ctox = cytochrome 
oxidase, ctoxlO = multiplied by 10, TOI = tissue oxygenation index. THb = 02Hb + HHb = total 
haemoglobin. Units for the chromophores 02Hb, HHb, Ctox and THb are pM from an arbitrary baseline, 
and for TOI are % saturation)
elpsec 02Hb HHb Ctox TOI THb CtoxlO
4401 1.97 10.87 1.38 67 12.84 13.8
4402 4.99 10.35 1.64 66 15.34 16.4
4403 6.14 13.52 0.6 66 19.66 6
4404 5.83 13.64 0.87 66 19.47 8.7
4405 2.96 14.17 0.28 65 17.13 2.8
4406 -3.34 13.43 0.98 65 10.09 9.8
4407 -3.85 13.41 1.32 64 9.56 13.2
4408 -2.39 16.63 0.79 64 14.24 7.9
4409 -0.18 18.38 0.77 63 18.2 7.7
4410 0.14 19.89 0.51 64 20.03 5.1
4411 -0.73 21.96 1.17 63 21.23 11.7
4412 -3.38 21.18 1.82 63 17.8 18.2
4413 -7 22.38 0.87 62 15.38 8.7
4414 -5.31 23.09 0.88 63 17.78 8.8
4415 -2.61 25.47 0.05 62 22.86 0.5
4416 -2.15 26.78 1.12 63 24.63 11.2
4417 -0.57 28.64 0.33 62 28.07 3.3
4418 -3.55 27.51 1.39 61 23.96 13.9
4419 -3.57 26.49 0.54 62 22.92 5.4
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4420 -2.25 27.84 -0.34 62 25.59 -3.4
4421 -1.12 30.28 -0.23 62 29.16 -2.3
4422 1.49 28.05 0.84 62 29.54 8.4
4423 -1.65 27.7 0.26 62 26.05 2.6
4424 -4.81 24.78 0.93 62 19.97 9.3
4425 -5.31 24.7 1.3 61 19.39 13
4426 -1.33 26.14 0.87 62 24.81 8.7
4427 -1.04 25.99 1.21 63 24.95 12.1
4428 -1.77 25.67 -0.18 62 23.9 -1.8
4429 -6.39 22.57 1.08 62 16.18 10.8
4430 -7.79 24.26 1.1 63 16.47 11
4431 -3.91 25.8 1.08 62 21.89 10.8
4432 -4.79 28.42 0.88 62 23.63 8.8
4433 -4.51 28.6 0.81 61 24.09 8.1
4434 -12.87 25.9 2.09 61 13.03 20.9
4435 -14.35 27.57 0.87 60 13.22 8.7
4436 -12.77 31.05 1.28 61 18.28 12.8
4437 -9.25 33.53 0.52 60 24.28 5.2
4438 -9.11 36.22 -0.18 58 27.11 -1.8
4439 -10.56 36.86 1.05 59 26.3 10.5
This data was illustrated in Excel® in order to read off maxima and minima from each 
trace.
Figure 17 shows the data from table 3 shown as traces on an Excel® graph. It should be 
noted that it was necessary to multiply the cytox trace by a factor of 10.
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Figure 17. Data from table 3 graphically illustrated in format used to read off maxima and 
minima
The data is consecutive observations obtained each second from one subject during apnoeas. 02Hb = 
oxyhaemoglobin, HHb = deoxyhaemoglobin, Ctox = cytochrome oxidase, ctoxlO = multiplied by 10, 
TOI = tissue oxygenation index. THb = 02Hb + HHb = total haemoglobin. Units for the chromophores 
02Hb, HHb, Ctox and THb are pM from an arbitrary baseline, and for TOI are % saturation)
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When the cursor is placed over a trace in Excel® a box appears with the value of the 
points making up the trace. Minima and maxima may be identified by looking at the 
trace and the values confirmed using the cursor in this way. Values for TOI were 
identified first as shown in the figure (Figure 18). A maximum and consecutive 
minimum defined an apnoea.
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Figure 18. TOI trace with consecutive maxima and minima marked
(Units for TOI on the y axis are % saturation and for observations on the x axis are seconds. TOI = 
tissue oxygenation index, toimax = maximum TOI for that apnoea, toimin = minimum TOI for that 
apnoea).
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The corresponding cytochrome oxidase maxima and minima were similarly read from 
the Excel® trace (See Figure 19). In order to visualise the correct values it was 
necessary to illustrate the trace multiplied by a factor of 10.
73
Figure 19. TOI and cytochrome oxidase traces with cytochrome oxidase maxima and minima 
corresponding to TOI maxima and minima marked.
(TOI = tissue oxygenation index, ctoxlO = cytochrome oxidase multiplied by 10, ctoxmax is maximum ctoxlO
for that apnoea, and ctoxmin = minimum ctoxlO for that apnoea. Corresponding maxima and minima for TOI
are also marked. Units on the y axis are %saturation for TOI and pM from an arbitrary baseline for ctoxlO, and
units on the x axis are seconds.)
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A similar technique was used to read off THb maxima and minima (Figure 20). As 
studies of cerebral haemodynamics in OSA show that there is an initial fall in cerebral 
blood flow followed by a surge at the end of apnoea, it was assumed that the THb 
minimum preceded the maximum for each apnoea.
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Figure 20. THb mimima and maxima corresponding to TOI maxima and minima
(TOI = tissue oxygenation index,THb = sum of oxygenated and deoxygenated haemoglobin, THbmax is 
maximum THb for that apnoea, and THbmin = minimum THb for that apnoea. Corresponding maxima and 
minima for TOI are also marked. Units on the y axis are %saturation for TOI and pM from an arbitrary baseline 
for THb, and units on the x axis are seconds.)
0 fmniiiniiiiiiiiiiiiiiiiiiiiiiiiiiiiirRiiniiiiiiiiiriiiCTiTiiiiiiiiiiiiiiiiiiriiTiTiiiiiiiiiiiifiiirii'iiiiiiiiiiiiiiiiiiiiiii
observations
Ohbratio was calculated as the change in Ohb which occurred during the THb surge, 
expressed as a fraction of the THb change. In order to calculate it it was necessary to 
subtract the Ohb value when THb was minimum from the Ohb value when THb was 
maximum. These values were actually obtained from lists of the raw data once the 
values and timepoints for THb max and THb min had been read off as shown in the 
preceding figure (Figure 20). The next figure (Figure 21) shows how the THb values 
are obtained from the sum of the Ohb and HHb values at that time point so that Thbmax 
= ohbthbmax + hhbthbmax.
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Figure 21. Example of values of Ohb and HHb at the timepoints of maximum and minimum THb
(OHb = oxygenated haemoglobin, HHb = deoxygenated haemoglobin, THb = sum of OHb and HHb, THbmax = 
maximum THb for that apnoea, and THbmin = minimum THb for that apnoea. Units on the y axis are pM from 
an arbitrary baseline for OHb, HHb and THb, and units on the x axis are seconds.)
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Maxima and minima read off from the traces as illustrated in the figures (Figures 18 -  
21) were tabulated as shown in table 4.
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Table 4. Minima and maxima data obtained from eg figure 17.
(TOI = tissue oxygenation index, ctox = cytochrome oxidase, toimax and toimin = maximum and 
minimum TOI for that apnoea, ctox max and ctox min = maximum and minimum ctox for that apnoea, 
THb = total haemoglobin, THbmax and THb min are maximum and minimum THb for that apnoea. Ctox 
is multiplied by 10. OHbTHbmax etc is the absolute value of OHb when THb is maximum and is used in 
the calculation of Ohbratio. Units fro chromophores are |iM from an arbitrary baseline.)
Ctox THb THb
Toimax Toi Ctox min/pM max min OHbTHb HHbTHb OHbTHb HHbTHt
% min/% max/pM /pM /pM max/pM max/pM min/pM min/pM
68 59 23.6 -11.5 40.08 5.93 1.88 38.2 5.92 0.01
68 63 19.6 -1.7 29.24 6.34 11.47 17.77 9.56 -3.22
67 61 26.8 -7.2 38.88 3.94 10.43 28.45 -6.35 10.29
68 64 16.6 -1 31.46 5.44 13 18.46 6.82 -1.38
67 58 18.6 -11.2 35.75 9.66 17.17 18.58 -1.04 10.7
71 63 23.4 -4.8 43.35 15.78 16.18 27.17 -9.26 1.91
70 59 20.8 -8.4 43.94 11.22 0.29 43.65 16.22 -5
69 59 22 -14.9 41.96 9.65 11.34 30.62 12.03 -2.38
69 65 23.6 -5.5 32.14 12.32 24.58 7.56 15.2 -2.88
70 55 23.7 -11.7 43.48 3.81 -1.41 44.89 14.11 -8.21
71 56 18.3 -6.6 60.3 18.06 3.33 56.97 24.17 -6.11
71 56 26.6 -2.1 51.62 12.18 -1.55 53.17 18.1 -5.92
70 56 25.5 1.1 53.24 11.8 1.49 51.75 19.21 -7.41
70 61 24.2 -1.4 30.85 13.5 4.68 26.17 18.22 -4.72
70 53 25.8 -4.2 45.25 1.42 8.96 36.29 -3.41 4.83
70 56 26.9 -1.9 40.32 8.88 6.55 33.77 16.46 -7.58
69 56 29.2 -1.3 50.5 7.02 11.5 39 10.74 -3.72
71 60 35.6 6 41.62 9.45 11.58 30.04 21.53 -12.08
71 56 29.1 5.8 54.63 6.66 10.65 43.98 19.36 -12.7
These tables were entered into a database. Changes in the parameters during each 
apnoea (eg TOImax -  TOImin) were calculated within the database and used in 
analysis. The choice of statistical analysis used is discussed in section 5.5.
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5.3 CUMULATIVE AVERAGING
Cumulative averaging is an analysis technique derived from the idea that sequential 
apnoeas may be viewed as a repeated “experiment” in which replications are averaged 
to give the usual response. It differs from 2 point analysis in that sequences of raw data 
are used, but because those sequences are selected as runs of similar consecutive 
apnoeas less information is lost in averaging than in, for example, lagged correlations. 
The technique involves identifying for a subject a run of consecutive apnoeas of similar 
length, usually between 8 and 15. Taking TOI or if available Sa02 as the defining 
variable, individual apnoeas between consecutive TOI minima are separated and “lined 
up” together on an Excel® spread sheet. Because of the saw tooth shape of the 
saturation traces it is much easier to define the precise minimum as an end point than 
the maximum -  however this does lead to an unconventional representation of an 
apnoea.
For example a TOI trace illustrated in Fig 22 may be “lined up” as consecutive apnoeas 
as shown in Table 5, and graphically in Figure 23.
Figure 22. TOI trace during consecutive apnoeas in one subject
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Table §. 13 consecutive apnoeas 
“lined up” together, each 
vertical column 
represents consecutive 
(every s) TOI readings (in 
% saturation) for a single 
apnoea as shown in figure 
22
1 2 3 4 5 6 7 8 9 10 11 12 13
56 56 53 56 56 60 57 57 56 59 58 58 55
56 58 55 57 60 61 59 59 57 59 59 60 57
57 59 56 59 64 63 57 61 58 60 59 61 59
56 60 59 60 64 64 59 64 60 61 60 64 62
56 63 61 63 66 67 60 65 62 62 63 63 65
56 65 62 65 68 67 63 67 64 66 64 67 66
57 67 65 66 69 68 66 69 66 66 66 66 67
61 67 66 67 70 69 66 70 67 67 67 68 68
64 67 66 67 69 69 67 70 68 67 68 68 69
65 69 68 69 70 70 69 70 68 68 68 68 69
67 69 67 69 70 70 69 71 68 69 68 68 69
68 70 67 67 71 69 69 70 70 69 68 68 69
71 69 69 69 69 70 69 69 70 70 69 69 69
70 69 67 68 71 69 70 70 69 69 69 69 69
69 70 69 67 71 70 70 70 70 68 69 69 70
69 69 70 68 70 70 71 70 69 70 69 68 70
69 69 68 69 70 69 70 70 70 70 68 69 71
69 69 69 68 70 71 69 70 68 69 69 68 70
70 68 68 68 70 71 70 70 70 69 68 68 69
69 69 68 69 71 69 70 71 68 70 69 69 69
69 69 69 68 70 70 69 70 69 68 69 69 70
68 69 68 67 70 70 69 70 69 70 69 70 70
71 69 69 67 71 69 70 70 69 69 69 69 70
69 68 68 69 70 69 69 71 69 69 70 70 70
68 68 69 67 69 70 71 71 69 70 70 69 70
70 68 68 67 70 69 70 70 70 69 70 69 70
70 68 67 67 70 69 68 70 70 70 70 70 70
71 68 69 68 70 68 69 70 71 69 71 69 70
70 68 69 66 69 69 68 69 70 70 71 70 69
70 67 67 67 69 68 68 70 70 69 70 70 70
71 68 68 66 69 67 69 70 70 69 69 71 70
69 67 67 65 69 68 69 69 70 69 69 69 69
70 66 67 65 69 67 68 68 70 68 70 70 68
69 66 66 65 68 68 67 69 70 69 69 70 69
69 66 64 64 68 66 67 68 71 68 69 70 68
69 65 64 65 67 65 66 68 71 67 68 69 68
69 65 64 63 67 66 66 68 70 66 68 69 67
68 66 63 63 67 64 66 67 69 66 67 69 67
68 65 63 63 66 64 64 67 69 66 66 69 67
67 64 62 63 65 63 65 66 70 66 67 69 65
67 62 63 61 65 64 64 65 69 65 67 68 65
67 62 61 61 64 63 64 65 69 65 66 69 65
67 62 61 61 64 63 62 64 68 65 65 67 66
66 61 61 61 64 61 61 63 68 64 65 67 65
65 61 58 60 62 61 60 64 67 62 65 68 64
65 61 59 60 62 60 61 63 68 63 65 68 62
65 58 58 59 63 60 61 62 67 63 63 67 63
63 61 57 57 62 59 59 61 68 63 63 65 62
63 59 57 57 62 60 59 60 68 62 62 65 63
63 57 58 57 61 58 59 60 66 62 61 64 62
62 58 57 57 60 56 59 60 66 60 61 65 60
62 56 57 61 59 58 60 67 61 60 64 60
62 57 57 60 57 58 59 67 61 60 64 61
60 58 56 57 58 66 59 61 63 59
61 57 56 57 58 65 59 61 64 59
60 57 56 58 58 65 59 60 63 58
60 56 56 57 57 65 59 60 62 58
59 57 64 58 58 61 59
58 57 63 60 62 59
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59 58 63 58 61 57
60 56 62 59 60 57
56 61 58 60 57
56 62 58 59 55
57 62 59 55
56 60 58 54
56 61 59 53
61 58 55
60 57 53
Figure 23. Table 5 illustrated graphically, showing TOI readings for 13 apnoeas on a single graph, 
each data series represents an apnoea.
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The 13 values are then averaged at each time point to give the TOI trace for an average 
apnoea. This is repeated for the other parameters. In order to get the changes 
synchronized, the observation number at the beginning and end of each section of the TOI 
data as shown in table 5 is recorded, and the sections of data for other parameters are 
defined by these times irrespective of the trace appearance. For example the following 
graph (Figure 24) illustrates cytochrome oxidase changes for the same data stretch. Once 
all the sections of data have been averaged they can then be combined on a graph to show 
average changes in these parameters in a particular subject (Figure 25). Clearly not all 
subjects have a series of consecutive apnoeas appropriate for this analysis, as it cannot be 
used for isolated apnoeas because changes in the parameters other than the defining one 
(TOI or Sa02) would be difficult to interpret.
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Figure 24. Cytochrome oxidase changes during consecutive apnoeas, defined by TOI dip.
Each data series is taken from a different apnoea, using the TOI minimum timepoint as the initial 
timepoint. TOI = tissue oxygenation index, Ctox = cytochrome oxidase, units for ctox are (iM from an 
arbitrary baseline.
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Figure 25. Cumulative average of changes during 13 apnoeas in one subject
(Initial timepoint is defined by TOI minimum, Hbdiff = OHb-HHb, Total HB = OHb + HHb, cytox = 
cytochrome oxidase, HHb = deoxyhaemoglobin, HbO = oxyhaemoglobin, TOI = tissue oxygenation index, 
units on th y axis are pM from an arbitrary baseline for the chromophores and %saturation for TOI)
Average changes during apnoea
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5.4 OVERNIGHT SUMMARY MEASURES FOR TOI
The previous data analysis was based on analysis at the level of individual apnoeas in order 
to fully characterize the information available from the NIRO300. The aim of this pilot 
work was to validate the use of the NIRO300 as a measure of cerebral oxygenation in OSA 
so that it could be used in a prospective study looking at the relationship between 
neuropsychological function and cerebral oxygenation in subjects with OSA before and 
after treatment.
5.4.1 Summary measures from pulse oximetry
In order for the NIRO300 to be used in this study summary measures needed to be 
developed from overnight recordings that could be compared between subjects. This is a 
similar problem to the analysis of overnight pulse oximetry readouts for sleep studies, and
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summary measures are computed by sleep study systems to allow meaningful comparison. 
For example the visilab system computes diprates, time spent below a specified saturation, 
mean saturation, absolute minimum saturation, and mean minimum saturation, all from a 
record of serial oxygen saturation against time. It is not clear which of these values is most 
useful in studies of neuropsychological function in OSA as it will depend not only on the 
mechanism of neuropsychological dysfunction (a dip rate includes more information about 
sleep fragmentation than a T90), but also on the sensitivity and specificity of the measures 
for OSA (T90 will pick up desaturation due to any cause including artifact, overlap 
syndrome, obesity hypoventilation.) The bigger neuropsychological studies in OSA have 
included several different measures of hypoxaemia, for example the Edinburgh group 
routinely use 2%, 3%, 4% dip rates and minimum saturation, as well as AI and AHI (64, 
68).
Relationship between desaturation dip rates and A H I
Because historically oximetry based systems have been developed as a cheap alternative to 
full polysomnography, validation of dip rates have been performed against AHI as a gold 
standard rather than against physiological outcomes. In one study of 98 subjects (133) a 
2% oxygen desaturation dip rate of 15 per hour identified subjects with an AHI of 15 per 
hour with sensitivity 65% and specificity 74%, a 3% dip rate of 15 had sensitivity 51% and 
specificity 90%, and a 4% dip rate had sensitivity 40% and specificity 98%. The British 
Thoracic Society therefore chose to specify a 4% dip rate of 15 dips per hour with baseline 
SaC>2 >90 as diagnostic of OSA requiring treatment and this has been validated in 69 
subjects against polysomnography with a sensitivity of 31% and specificity 100% (134). I 
quote these papers just to emphasize that the selection of clinically useful dip rates for 
Sa02 is based only on comparison with a different sleep study measure (AHI) which is 
currently used to define OSA, and so it is difficult to derive from this what dip rates to use 
for TOI.
Other measures o f  desaturation
The degree of desaturation associated with an apnea or hypopnea is highly variable and 
depends on lung volume, obesity, age, associated lung disease, chemoreceptor sensitivity, 
sleepstage etc. Apnoea at low lung volumes is associated with severe Sa02 desaturation in 
normal awake subjects (135). The rate of oxyhaemoglobin desaturation is greater in
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obstructive than non-obstructive apnoeas in animals and this may be due to increased 
tissue oxygen consumption (136). Apnoea duration can be lengthened by administration of 
oxygen or shortened by administration of carbon dioxide suggesting a role for 
chemoreceptors in apnoea termination (137). Because of these variations in oxygen 
desaturation during an apnoea, measures of OSA severity based on oxygen saturation do 
not necessarily correlate with AHI. If arousals are the main determinant of altered daytime 
functioning in OSA, then basing severity on AHI alone is appropriate, however many 
studies of neuropsychological dysfunction show an independent effect of hypoxaemia.
The most sensitive measure of oxygen desaturation would be an “area under the curve” 
integration of the oximetry trace from a baseline. Chesson et al (138) developed a 
saturation impairment time (SIT) on the principle of integrating duration and severity 
below varying threshold saturations. They compared SIT indices in a group of subjects 
with OSA and a group of normals and found a significant difference. However they found 
considerable variation in SIT index in subjects with similar RDIs and vice versa. They did 
not proceed to look at the relationship between this new measure and any outcome measure 
like neuropsychological function to reinforce their conclusion that this new measure may 
provide complementary information in assessing the severity of OSA.
5.4.2 Possible TOI derivatives to be used in study analysis
Three main methods are used to measure oxygen desaturation in sleep studies, and 
potentially can be adapted for use with TOI tissue saturation:
Absolute values These include absolute minimum saturation and average saturation. 
Because of the variation between subjects in baseline TOI, these are less useful in TOI 
measurements than saturation. Also the absolute minimum is susceptible to artifactual 
errors due to transient loss of contact.
Dip rates These record the rate at which a specified desaturation occurs (usually 
calculated by algorithm acting on serial saturation data assuming this desaturation due to 
apnoea/hypopnoea).
Measures o f  desaturation severity These include T90 (time spent below a specified 
saturation) or AUC measures (time multiplied by extent of desaturation).
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5.4.3 TOI Dip rate calculation
Theoretical considerations
One example of an algorithm to calculate a dip rate is quoted below -  “The algorithm 
sequentially scanned each recorded oxygen saturation value (1Hz). Whenever a drop in a 
sampled oxygen saturation value was detected the programme assigned an event marker to 
that reading. When an increase in oxygen saturation was detected, the programme 
determined if at least 3 consecutive event markers -  that is, three consecutive falls in 
oxygen saturation -  were present prior to this rise. If this criterion was met and one of the 
event markers was associated with an oxygen saturation value > or = 4% lower than the 
baseline oxygen saturation, then a (dip) was designated. Baseline oxygen saturation was 
calculated as a moving time average (the mean of the top fifth percentile of oxygen 
saturation values over the five minutes preceding the event)” (139).
We initially planned to use a similar algorithm to carry out TOI dip rate analysis. Because 
of the amount of noise inherent in the TOI trace, (and the lack of previous experience of 
use of the NIRO for this purpose along with minimal computer programming experience in 
the main investigators) it was not easy to develop a simple computer programme to provide 
a useful dip rate from the digital output, despite attempts by two people with programming 
experience. Hence the decision was made to use the pre-existing polysomnography 
analysis software which enables calculation of an apnoea-associated dip rate of a 
percentage which is specified by the operator. Although the dip-rates produced by sleep 
study oximetry systems like the visilab are not apnoea-associated but are calculated using 
an algorithm that will pick up any fall in saturation of the specified amount whether or not 
it is associated with an apnoea/hypopnoea, an apnoea/hypopnoea associated dip rate is a 
purer physiological concept for comparison.
Conventionally when respiratory analysis is carried out on the Compumedics® system the 
user specifies a time lag for the SaC>2 trace (30s by default), and the program scans from 
the (end of the apnoea + lag) back to the (beginning of apnoea + lag) to look for the 
minimum saturation for that apnea (ie the computer programme adds 30s to the timepoint 
at the end of the apnea and then scans back from this timepoint to find the minimum 
saturation, stopping scanning at the timepoint 30s after the beginning of the apnea, so that 
the time scanned is the same as the apnea duration at a time lag of 30s). The user also 
inputs the SaC>2 percentage drops to be used for definitions of apnoea and hypopnoea
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respectively, currently set at 1% and 4%. Also of relevance is the minimum duration of an 
event which is internationally accepted as 10s (invariable within the program). If the 
names of the SaC>2 and TOI channels are transposed and respiratory analysis is repeated the 
program will calculate minimum TOI and TOI dip for each events, but will not produce a 
report from the altered data. A dip rate can be produced by manually scanning through the 
study and recording the dips for computer scored apnoeas. To provide a comparable result 
for the Sa0 2  trace the same technique was used for that as well, ie without later manual 
scoring, and ignoring “unsure” events.
Choice o f  lag for SaO2 and TOI
Lags from our validation study are published as follows: “The cTOI and Sa02 nadir 
occurred at 9.5 (± 2.8) sec and 28.7 (± 5.0) sec (range 6.9 - 15.9 vs. 24.7 - 38.7 sec; p < 
0.001) after the end of an apnoea/hypopnoea.” (1). For this paper nadirs were measured 
manually by visual inspection. As expected the difference between TOI and Sa02 is about 
20s, the circulation time. Bearing in mind that the program scans back from the (end of 
apnoea + lag) to the (beginning of apnoea + lag) to reach the minimum and that the 
minimum apnoea duration is 10s, the use of lags of 35s for Sa02 and 15s for TOI will 
obtain the maximum correct nadirs without resorting to varying the lags for each subject 
(because the computer will scan back from 35 s after the apnoea to at least 25s after the 
apnoea for Sa02, and from 15s to 5s for TOI, thus encompassing most of the range).
Figure 26 illustrates the way the lags are used on the polysomnography trace to obtain 
minimumum values for TOI and Sa02.
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Figure 26. Figure showing lags used to calculate minimum TOI and Sa02 for dip rates
This is part o f an annotated polysomnography trace with Sa02 = oxygen saturation by pulse oximetry and 
cTOI = tissue oxygenation index. Minsat = minimum S a02 for that apnoea and minTOI = minimum TOI 
for that apnoea. The annotation shows that for apnoea 1 the computer scans from the end o f the apnoea plus 
35s back to the beginning o f the apnoea plus 35s (time period A in the diagram) on the S a02 trace to find 
minimum saturation 1, and from the end of the apnoea plus 15s back to the beginning of the apnoea plus 
15s (time period B in the diagram) on the TOI trace to find minimum TOI 1.
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For SaC>2 the 4% dip rate is supported by the literature as correlating best with AHI (133), 
and is also conventionally accepted.
For TOI there is no precedent. Again from our previous paper '‘Mean event related dips in 
TOI ranged from 1.4 to 6.85%, where mean oxygen desaturation dips ranged from 3.8 to 
22.3% in the 13 subjects”, ie TOI dips were less than Sa02 dips (1)(109). We calculated 
event related 2% and 4% dip rates for this data (1036 apnoeas), published only in abstract 
form (140), omitted from the published paper because of reviewers’ objection to the 
arbitrary selection of 2% and 4%. To quote from an early draft “2% cTOI dip rates ranged 
from 3.5 to 94, and 4% from 0 to 77, where corresponding AHI ranged from 14.6 to 97.6.
A significant relationship was observed between the number of apnoea- associated 2% TOI 
dips per hour and the AHI (c = 0.95, p < 0.01). The 4% TOI diprate/hr also correlated with 
the AHI (c = 0.84, p < 0.01), and correlated better than AHI with the mean min. Sa02 (c =
0.71, p < 0.01) and the % sleep time spent below 91% Sa02 (c = 0.775, p < 0.01), and 
below 86% Sa02 (c=0.61, p<0.05).” Correlations with AHI (apnoea hypopnoea index) are
87
to be expected because these dip rates are apnoea associated by definition. We calculated 
both 2% and 4% apnoea associated TOI dips for the prospective study as we had no 
evidence that one was any more relevant than the other.
Practical protocol
This protocol explains exactly the commands used in the compumedics® software to 
calculate TOI and Sa02 dip rates in an equivalent and reproducible manner. It should be 
read in conjunction with the Compumedics® analysis manual(see appendix).
1.Files were restored to hard disc.
2.Only baseline studies prior to CPAP treatment(n=58) were used (as on CPAP, automated 
analysis is less accurate as loss of mask contact is interpreted as apnoea and is normally 
manually deleted; also apnoea associated dips form a smaller proportion of saturation 
variation).
3.Initially, in analysis option, lag was set to 35s, apnoea defining sat change to 4%, 
hypopnoea defining sat change to 4%, “apply sat criteria” was ticked.
(a) Automatic respiratory analysis was performed
(b) 5min screens were scanned through starting at epoch 1
( c) A 5min screen was omitted if loss of contact of either SaC>2 probe or TOI probe for 
>10s
(d) Sleep stage at start of screen was recorded
(e) Each apnoea/hypopnoea was “clicked on” and sleep stage, minimum saturation and 
saturation dip were recorded. Unsures were ignored.
(f) Dip rate was obtained by dividing total number of events by time asleep. Mean 
minimum sat and mean dip were calculated.
5.“Config poly” option was entered and Sa02 channel was renamed TOI and vice versa.
In analysis option lag was set to 15s, apnoea defining sat change to 2%, hypopnoea defining 
sat change to 2%, “apply sat criteria” was ticked.
Steps (a) to (f) were repeated.
5. 4% dip rates were obtained from 2% dip rate data.
6. Copy file was deleted.
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5.4.4 Calculation of area under the curve measures
Data used was the digital output to computer file of TOI or Sa02. Initially a simple plot of 
TOI over time was examined to ensure there were no gaps or major baseline shift.
For a series of saturation values, summing consecutive values is the same as multiplying 
the average value by the number of values. We need to sum the difference between the 
maximum value and each value. Area under the curve was therefore calculated by 
subtracting mean TOI from maximum TOI and multiplying by the number of seconds (for 
output every s) (See Figure 27). AUC per minute was then computed by dividing by the 
number of seconds and multiplying by 60. This calculation was performed for AUC from 
maximum TOI and then from max -  2, max -  4 and max - 10, restricting the data set to 
include values up to the specified maximum each time.
TOI max was defined as the lowest value that 99% of recorded values were less than or 
equal to, so that single outlying values did not have a big effect on the resulting AUC. 
Values of Sa02 <50% and TOI < 40% were assumed to be artifactual (loss of contact) and 
omitted from analysis.
No attempt was made to distinguish sleep time, sleep stages or apnoea time.
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Figure 27. Simple calculation of area under the curve
Ymax = maximum value o f y, y l,y2 etc are consecutive points on the y axis, n are consecutive timepoints on the 
x axis, AUC is area under the curve as shown.
5.5 STATISTICAL METHODS
5.5.1 Introduction and definitions
Statistics is the science of collecting, summarising, presenting and interpreting data, and of 
using them to estimate the magnitude of associations and test hypotheses (141). Methods 
of data collection have been described. The data collected in any investigation consists of 
measurements taken on individuals. The number of individuals is called the sample size. 
Any aspect of an individual that is measured or recorded is called a variable. Numerical 
variables may be either continuous or discrete and the statistical methods applied for 
analysis differ.
The raw data obtained from OSA patients analysed in this thesis falls into two parts. In the 
first sections the “individuals” were apnoeas and many different variables were measured 
per apnoea. Particular statistical methods needed to be applied because we used data from 
more than one apnoea per patient in a combined data set, which resulted in clustering of
AUC. = (v *  < *J -
  . h
~  Co
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the data because of variation between subjects. In the subsequent analysis for the 
prospective study we obtained single summary readings for each subject and so the 
“individuals” were different subjects. Statistical analysis in this section is therefore more 
straightforward.
5.5.2 Discussion of distribution of data including the use of parametric and non- 
parametric tests
Distribution o f  data
The appropriateness of a particular statistical test for a set of data depends on both sample 
size and frequency distribution. The normal distribution is a good empirical description of 
the distribution of many variables. We are interested in how closely the sample mean 
approximates the population mean (the generalisability of the results). Even when 
individual observations are not normally distributed, the sampling distribution of the mean 
is normal, provided that the sample size is not too small (141). A sample size of 15 or 
more is generally enough for this assumption. This forms the basis of the calculation of 
confidence intervals as used in this thesis. Most of the variables were distributed as a 
normal or skewed normal distribution as shown in Figures 28 and 29. The positively 
skewed normal distribution is also the typical distribution of measures of sleep apnoea 
severity in a population for example AHI (142). The exception shown is minimum TOI in 
Figure 30 where there is substantial variation between subjects resulting in non-normality 
in the combined dataset resulting in need for statistical techniques to adjust for between 
subject variation as described below.
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Figure 28. Example of distribution of TOIdiff in 1036 apnoeas overlaid with an appropriately 
scaled normal distribution with same mean and standard deviation as the data.
The data approximates to a normal distribution, however the apnoeas within the positive skew are
almost all from a subset of 3 or 4 of the subjects. Analysis o f the whole dataset therefore adjusted for
this clustering of the data by subject. TOIdiff is change in tissue oxygenation index for each apnoea
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Figure 29. Example of distribution of ctoxdiff in 303 apnoeas overlaid with an appropriately scaled 
normal distribution with same mean and standard deviation as the data.
The data approximates to a skewed normal distribution. Analysis o f the whole dataset adjusted for
clustering of the data by subject. Ctoxdiff is change in cytochrome oxidase for each apnoea
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Figure 30. Example of distribution of TOImin in 1036 apnoeas overlaid with an appropriately 
scaled normal distribution with same mean and standard deviation as the data.
The data in non-normally distributed and appears bimodal because o f clustering o f absolute TOI
values by subject. Analysis of the whole dataset therefore adjusted for between subject variation as
described below. TOImin is minimum tissue oxygenation index for each apnoea
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R egression  a n d  correlation
The strength of the association between two numerical variables is conventionally assessed 
using regression or correlation. The equation of the regression line for dependent variable 
y against independent variable x is y = ax +b, where a is the regression coefficient. . The 
statistical package produces a p value testing the null hypothesis that the regression 
coefficient is equal to zero.
Two assumptions underline linear regression. The first is that, for any value of x, y is 
normally distributed. The second is that the magnitude of the scatter of the points about 
the line is the same throughout the length of the line. For each linear regression a scatter 
plot is first drawn to ensure the relationship is approximately linear (141). Correlation 
coefficients examine the strength of the linear association between outcome and exposure 
variables. Correlation coefficients vary from -1 to +1 and equal zero if the variables are
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not associated. The significance of a particular correlation coefficient depends on sample 
size and can be obtained from tables (eg Biometrika Tables for Statisticians (143)).
Comparison o f means.
When both groups are large, methods for comparing means are based on the normal 
distribution. For smaller samples methods based on the t distribution are used. These 
require that the population means are normal but are robust against departures from this 
assumption. They require that the sample standard deviations are similar. The t test is 
appropriate for sample sizes under 15, but can be used for larger samples.
Non-parametric tests
All tests based on the normal distribution are known as parametric tests. Non parametric 
tests are used to analyse a numerical outcome variable without assuming that it is 
approximately normally distributed. Each value of the outcome variable is replaced by its 
rank. As the sampling distribution of a mean tends to be normally distributed even if the 
underlying distribution is non normal (central limit theorem), these techniques are only 
used for sample sizes less than 15. Non-parametric methods are less powerful than 
parametric tests (more likely to miss genuine differences), but more robust (less sensitive 
to outlying values). They have disadvantages in that they lack techniques for deriving 
confidence intervals, they can never produce small p-values if sample sizes are extremely 
small, and they are not easily extended to situations where it is necessary to take into 
account the effect of more than one variable on the outcome (141). They were therefore 
not appropriate in most of the statistical analysis in this thesis. Sample sizes for apnoea 
analysis were 1036 apnoeas in chapter 7 (15-160 per patient); 303 apnoeas in chapter 8 
(29-40 per patient); and 287 apnoeas in chapter 9 (6-59 per patient). In the latter analysis 
a single patient had less than 15 apnoeas for analysis. In chapter 11 the number of subjects 
for comparison was 56. Most of the COPD analysis (chapter 13) was comparing changes 
on multiple observations within subject rather than between subject.
Statistical methods for repeated observations
In our analysis it was necessary to combine repeated apnoeas from single subjects in a 
single dataset. Because of intrasubject correlation it is misleading to analyse this sort of
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data by combining repeated observations from several subjects and then calculating the 
correlation coefficient as if the data were a simple sample (144). The choice of analysis 
depends on the question asked. If we want to see if subjects with high values of ATOI also 
tend to have high values of ASaC>2, we are interested in whether the average ATOI for a 
subject is related to the subject’s average ASa02- An appropriate test for this comparison 
would be the correlation between the subject means (145). In our analysis we were more 
interested in whether increasing ATOI within the individual was associated with an 
increase in A Sa02. We therefore wanted to remove the differences between subjects and 
look only at changes within (144). We were recommended by the department of statistics 
at UCL to use a two level regression, with subject at one level. This was achieved using 
the “xtgee” command of Stata (146) which enabled two level multiple regression, 
specifying the variable “subject id” to group the data at one level. The initial dataset was 
examined by the statisticians who confirmed that this analysis was appropriate for the 
variables which mainly approximated to skewed normal distributions. They confirmed that 
logarithmic transformation was not required.
Analysis of variance of ATOI in this dataset confirmed that 20-30% of variance was 
between subject and 70-80% was within subject. The contribution of between subject 
variation was greater for absolute values of TOI than changes.
5.5.3 Calculation of sample size for the studies
Sample size calculations are conventionally carried out prior to commencement of a study 
comparing two groups of subjects. For our study of neuropsychological function in OSA, 
the background to which is presented in this thesis, the sample size was calculated to detect 
a specified difference in neuropsychological outcome. Simple snorers were used as 
controls in the neuropsychological tests and power calculation was performed assuming 
patients with OSA and snorers form a continuous distribution of AHI (142). This power 
calculation indicated that 92 subjects would be required to give a median effect at the 0.05 
level. Neuropsychological results are not presented in this thesis but we completed a total 
of 104 people (59 OSA subjects and 45 snorers).
Most of the analysis involved comparison of two continuous variables in a single group of 
individuals (apnoeas or subjects), rather than comparison of two groups of individuals.
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There are no readily available formulae for sample size calculation in this situation 
(although tables for calculating significance of the correlation coefficient depend on 
sample size(143)). A form of sample size calculation can be made by grouping a 
continuous variable into two groups, below and above the median value, and then 
considering the mean value of a second variable separately for those two groups. One can 
then use the formula for comparison of 2 means.
This formula is (u + v )2 ( g i2 +  an2)
(M i -  Mo)2
where u is the one-sided percentage point of the normal distribution corresponding to 
100% - the power (u = 1.28 for a power of 90%); v is the percentage point of the normal 
distribution corresponding to the (two sided) significance level (v = 1.96 for a significance 
level of 5%), pi -  po is the difference between the means and oi, Go are the standard 
deviations of each group (141).
Sample size calculations for the dataset from validation study 1
Using the relationship between ATOI and A Sa02 and the current dataset as no other 
similar data was available at the time, the median ATOI was calculated for each subject. A 
Sa02 was grouped into two equal groups for ATOI above and below the median value and 
mean A Sa02 and standard deviation of these two groups were obtained. The standard 
deviations thus obtained were entered into the equation with a value of difference between 
means of 4% which was thought to be a clinically significant difference. This then gave 
sample size values for the different subjects as follows (see Table 6), and a mean required 
sample size of 22.6 for power of 90% and significance of 5%. Actual analysis will obtain 
greater power by considering exposure quantitatively, but lose some by controlling for 
confounding.
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Table 6. Calculated and actual sample sizes for 13 subjects in first validation study
Sample sizes calculated by grouping ATOI in two groups about the median and calculating mean and 
standard deviation for A Sa02 in each of these groups according to the formula for sample size calculation for 
comparison of two means as given above (141). Sample size is calculated to detect a difference of 4% Sa02 
with significance level 0.05 and power of 90%. Sample sizes vary for different subjects because of variation 
in standard deviations in Sa02 in different subjects.
Subject id Calculated sample size Acti
1 29 130
2 45 160
3 9 48
4 20 90
5 81 17
6 49 110
7 3 15
8 10 27
9 5 32
10 8 71
13 9 108
15 14 125
16 12 103
Mean 22.6
Calculation o f  sample size for cytochrome oxidase and CBV calculations
Using an estimated standard deviation for cytox of 0.1 pM the above formula gives a 
required sample size of 5.25 apnoeas per subject for an estimated significant difference 
between groups of 0.2pM, for power of 90% and significance of 5% and 7.5 apnoeas per 
subject for significance of 1%.
Using an estimated standard deviation for CBV of O.lml/lOOg the above formula gives a 
required sample size of 9.3 apnoeas per subject for an estimated significant difference 
between groups of 0.15 ml/lOOg, for power of 90% and significance of 5% and 13.3 
apnoeas per subject for significance of 1%.
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We aimed to study 40 consecutive apnoeas per subject and achieved 40 in 6 subjects, 29 
and 32 in the remaining 2 subjects.
Calculation o f sample size for cbfv calculations
Using an estimated standard deviation for TOI of 1.2 the above formula gives a required 
sample size of 7.6 apnoeas per subject for an estimated significant difference between 
groups of 2% for power of 90% and significance of 5%; and 16.9 apnoeas per subject for 
significance of 1%. All apnoeas during the study naps were analysed and the number 
studied in 7 individuals were 6,16, 46, 49, 54, 57, 59, so the minimum sample size was 
achieved in all but 1 subject.
5.5.4 Correction for multiple comparisons
Even if there is no association between variables one in twenty comparisons will be 
statistically significant at the 5% level by definition. This is a particular problem when the 
effect of many different variables on eg ATOI are examined, and interpretation of 
significant findings should be cautious if the analysis has not been guided by an a priori 
hypothesis. The problem may be avoided if only comparisons specified in the hypothesis 
are examined. If data are subjected to “dredging” where all possible variables are 
compared, there is a risk that comparisons which arose by chance are reported as 
significant (141). Where the hypothesis involves multiple factors, a higher threshold for 
significance of eg 0.01 is recommended.
There are some statistical techniques to minimise the chance of this happening, for 
example the Newman-Keuls procedure based on the distribution of the studentised range 
and the Scheffe procedure which indicates significance much less readily than the t-test 
(147). We performed 3 comparisons for the dataset in chapter 7, 3 for the cytochrome 
data, 3 for CBV data, 7 in chapter 9, and 4 in the COPD analysis (chapter 13). All 
comparisons made were reported and so there is no misleading selective reporting. We did 
not feel that correction for multiple comparisons was indicated in these analyses. 
Correction for multiple comparisons could be applied to the data in chapter 11 where 
multiple possible TOI summary measures are compared with similarly derived saturation 
variables and with conventional polysomnography variables. However all measures of 
sleep apnoea severity are heavily intercorrelated and so the interpretation applied to
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significant p values is minimal. In fact the results in this chapter where no correlation 
occurs are the more interesting.
5.5.5 Other methods of comparing data in validation studies
The studies reported are called validation studies, but are not true validation studies in the 
conventional sense of the description. A validation study should compare a new way of 
measuring a variable with the accepted way of measuring it. The new and old methods 
should produce similar absolute values -  it is not enough that they correlate. There are 
specific statistical techniques for this situation as described below. As there is no accepted 
way of measuring cerebral tissue oxygenation, TOI cannot be validated in this way. It can 
only be validated indirectly, by showing what factors affect it. Our analyses showed that, 
for example, CBFV and A Sa02 changes correlated with TOI changes, but were measured 
in different units in the case of CBFV and would not be predicted to be identical in the case 
of A Sa02. The methods for assessing agreement between two methods of clinical 
measurement are therefore not appropriate to the TOI validation studies reported here. 
These methods include the Bland-Altman plot where the difference between the two 
methods of measurement is plotted against their mean (148). An alternative method where 
a gold standard is available is to plot Receiver Operating Characteristic curves. This 
would be appropriate if a particular TOI cut off was used to diagnose a clinical condition 
or a significant degree of cerebral hypoxia measured by another technique with an already 
validated cut-off. Two by two tables of true and false positive and negatives at different 
TOI cut-offs can be combined in a graph of specificity against sensitivity to see which TOI 
cut off has maximum sensitivity and specificity in relation to the accepted technique. This 
plot is know as the receiver operating characteristic curve and is very useful in validation 
of diagnostic tests (147).
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5.6 RELIABILITY AND REPEATABILITY OF MEASUREMENTS
5.6.1 Blinding and bias in techniques of analysis used
Statistical methods provide techniques for describing the effects of random error in 
analysis, bias is systematic error and can be minimised by study design. Bias is defined in 
Last’s Dictionary of Epidemiology as any trend in the collection, analysis, interpretation or 
publication or review of data that can lead to conclusions that are systematically different 
from the truth. In a randomised control trial it is very important that the people making the 
observations are blind to the outcome and treatment allocation of the study. If they are not 
there is a potential source of bias in the study. In the neuropsychological study the 
neuropsychologists were blind to the diagnosis (OSA or simple snorer) and also to any 
polysomnography results. The polysomnography scorers were blind to the 
neuropsychological results. There two datasets were not combined, and no analysis was 
performed until all study visits had been completed. Bias introduced by the observer 
making the measurements in a study may be non-random, because the observer 
(deliberately or unknowingly) systematically selects data to obtain a positive result. 
Observer bias may be minimised by blinding observers to the hypothesis under 
consideration (less of an issue in a predominantly observational study), training observers 
and use of standard protocols, or replacing human judgement by automated procedure.
5.6.2 Manual vs automated scoring of eg respiratory events, and implications for 
observer bias
Polysomnography scoring was performed by 4 operators using the Compumedics® 
automated analysis, manually checked.according to a standardized sheet of staging and 
event scoring criteria according to accepted definitions in 1998. Repeated scoring by a 
single or different operators was not performed because of time constraints. Sleep staging 
and manual event scoring in the studies was peripheral to the main analysis, and therefore
101
unlikely to be a source of bias. TOI scoring for chapter 7 was perfomed by AV and AM, 
for chapter 8 by AM alone, and for chapter 9 by AM, with a separate analysis on the same 
dataset carried out by P A-R.
All TOI scoring in the validation studies was performed manually, as no automated option 
was available. Identification of events was automated using the Compumedics® software 
in chapter 7, and manual according to a predefined definition in chapters 8 and 9. These 
definitions were a TOI drop of 2 lasting 4s or more in a run of 2 or more for chapter 8, and 
cessation of airflow for 10s from the capnogram trace for chapter 9. Manual reading off of 
values from the traces was performed on the compumedics® software for chapter 7 and in 
Excel® for chapters 8 and 9. In all cases the cursor was placed over the trace and the 
maximum or minimum visually identified was read off. Several adjacent points were 
clicked on to check that the correct maximum had been identified. As values were read off 
and not measured, all recorded values must have been part of the trace, and there was little 
possibility of systematically over-estimating values. Where there were runs of consecutive 
apnoeas the changes corresponding to each one were more easily defined, and for this 
reason, subjects with severe sleep apnoea were invited to participate where possible, and 
the need for consecutive changes formed part of the definition in chapter 8. Detailed 
manual analysis took many hours for each subject, and for this reason repeated analysis 
was not undertaken by the same or a different observer. Attempts were made to minimise 
bias by using strict protocols as above.
Aware of the problems of manual scoring, methods of summarising TOI overnight by 
AUC or dip rate were developed independent of manual scoring. The AUC calculations 
used the continuous data set without removing awake time or regions of noise. This 
minimised potential bias and made the analysis reproducible, but would make our results 
less likely to detect a true difference. For the dip rate analysis the Compumedics® 
software was used, entering parameters appropriately for the analysis, and swapping the 
channel names so that the TOI channel was analysed automatically. Only machine 
identified events were used, and where the machine flagged up “unsure”, and manual 
checking would usually have been performed, these unsure events were ignored in order to 
make the analysis entirely reproducible from the protocol listed earlier in chapter 5. Again 
because of time constraints, no double reporting of studies by different observers was 
performed.
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It is common practice for sleep studies to be either part or entirely manually scored, as this 
is considered to be more accurate than automated systems because of the complexity of the 
datasets. It is also common, particularly in oximetry systems, for sections of data that are 
noisy and therefore probably awake time, to be removed by eye. This is because many of 
the algorithms for oximetry trace analysis are relatively simple and do not differentiate 
dips from other saturation variation. Generally manual polysomnography systems are 
more accurate than automated ones, and are reproducible with protocols and training, but 
are time-consuming as data is analysed in 20-3Os epochs over a full night study (149). 
Automated systems are more reproducible, less accurate, may not be quicker and are more 
expensive (150). A combination of an automated poly system with manual checking has 
been recommended (149) with the proviso that automated analysis should only be 
performed by those able to perform a visual analysis. For the newer limited sleep studies, 
manual analysis has been shown to be more accurate when compared to polysomnography 
than automated analysis software (151). Automated analysis programmes even when 
provided by the manufacturer may then be inferior to visual analysis because of the 
multiple simultaneous recordings. The NIRO had not been previously used much in sleep 
studies and no automated analysis was available. Because of perceived problems with 
reproducibility because of manual selection of data for analysis in the validation studies, an 
automated technique without manual correction was used for dip rate analysis in the 
prospective study, using the software for Sa02 dip rate analysis. The absence of manual 
checking meant that some apnoeas labelled as “unsure” were not analysed, so accuracy 
was traded against reproducibility.
5.6.3 Method of performing reproducibility measures that would have enhanced 
the validity of the technique.
There are theoretical reasons why baseline TOI varies in the same patient on different 
occasions. Even pulse oximetry saturation varies from day to day in a subject over a small 
range. TOI also depends on cerebral blood flow and local oxygen consumption and so will 
be sensitive to changes in blood pressure and local cerebral activation. Reproducibility of 
baseline values was therefore not performed in awake subjects on different occasions. 
Variability of baseline traces was performed using the coefficient of variation, which is the 
standard deviation of a series of values as a proportion of the mean.
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Error in the recordings will arise both from variation in the actual measurements (which is 
impossible to distinguish from true variation because of the absence of a gold standard) 
and from error in reading of the measurements by the individual operator. This error can 
be quantified by having the same data scored by multiple operators or by the same operator 
on different occasions. A measure of the reproducibility of the set of rules used for data 
collection can then be obtained. For categoric variables the kappa measure of agreement 
used. Kappa is defined as the difference between observed and expected agreement 
expressed as a fraction of the maximum difference (147). This approach could have 
usefully employed to the classification of events if all potential events could be flagged up 
and presented to 2 operators for classification as apnoea or non-apnoea. The 
polysomnography software used for chapter 7 does flag up all potential events and this 
method of data analysis could have been checked in this way. The raw data used in 
chapters 8 and 9 provided a continuous data set and an algorithm would need to be derived 
to flag up potential events, subsequently manually checked by 2 observers. In both cases 
the necessary algorithm was missing, and so although 2 observers could have picked 
events for analysis, it would be difficult to define events not picked in the continuous data 
series to compute this statistic.
Once events were picked, the reproducibility of the values of variables read off the Excel® 
graphs could also have been computed. As these are continuous variables, the appropriate 
statistical test is the intra-class correlation coefficient. This is a measure of the correlation 
between the values obtained by two different observers within the same individual 
(apnoea). Formulae for its calculation are available (147). Measurement of the intraclass 
correlation coefficient for variables read off by two different observers would have 
enhanced the validity of the analysis techniques used, but unfortunately the time required 
for this was not available (as manual analysis of each dataset took many hours, and no 
second observer was available on this timescale).
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6. SUBJECTS AND PROTOCOLS FOR FIRST
VALIDATION STUDY IN OSA SUBJECTS
6.1 OVERALL HYPOTHESIS
Measurement of cerebral oxygenation using near-infra red spectroscopy gives more valid 
information than measurement of arterial oxygen saturation alone
6.2 SUMMARY
The first validation study was on 16 patients with previously diagnosed moderate or severe 
OSA measuring cerebral oxygenation using the NIRO 300 during daytime naps with 
simultaneous full polysomnography. This was performed between June 1999 and March 
2000.
The work was performed by myself and Dr Arschang Valipour, Research Associate from 
Vienna, Austria, under the supervision of Professor S Spiro and Dr H Makker, Department 
of Thoracic Medicine, University College London Hospitals. Work was carried out in the 
Sleep Unit at the Middlesex Hospital.
6.2.1 Subjects
16 patients agreed to participate in the study, however the recording was technically 
unsatisfactory in 3 patients. They were invited to participate if they had moderate or 
severe sleep apnoea diagnosed on a screening sleep study (Visilab, Stowood Scientific 
Instruments, Oxford, UK). They were all patients of the Middlesex Hospital sleep clinic, a 
clinic receiving referrals from GP’s, ENT surgeons and other tertiary referrals of subjects
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with obstructive sleep apnoea. The first 8 subjects were invited to attend for study during 
the initial loan of the equipment. These subjects were already established on treatment 
although at least 2 were known to be non-compliant with treatment (on the basis of their 
own reports). They were asked to stop treatment for at least 2 nights prior to the study.
The remaining 8 subjects were consecutive new diagnoses of moderate or severe OSA who 
consented to attend for the daytime study, prior to commencement of CPAP treatment. 
Three of the recordings were technically unsatisfactory. Characteristics of the remaining 
13 subjects are given in Tables 7 and 8, with dip rate quoted from preliminary Visilab 
sleep study.
Table 7. Characteristics of 13 subjects in first validation study
Pat. ID Age/yrs Gender BMI
kg/m2
Ethnicity
G I1 55 M 33.4 White other
DP 2 35 M 32.6 Black Asian
DS 3 57 M 31.5 White UK
CM 4 56 M 33.8 Black Asian
VP 5 47 M 35.5 Black Asian
SM 6 39 M 39.1 Black
Afrocaribbean
MA 7 59 M 29.4 Black Asian
TD 8 61 M 34.3 White UK
WC 9 39 M 35.0 Black Asian
GD 10 44 M 36.8 Black
Afrocaribbean
BD 13 55 F 35.0 White UK
PH 15 33 M 36.6 White UK
DK 16 40 M 47.3 White UK
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Table 8. Additional descriptive data for 13 subjects. Haemoglobin measurements 
were made in the subjects included in the cytochrome oxidase and total 
haemoglobin analysis
Pat. ID ESS Dip rate/ 
per hour
Baseline
oxygen
saturation
/%>
Baseline
Hbg/l
GI 1 20 42.9 100 13.2
DP 2 20 60.0 100 16.1
DS 3 15 40.0 99 15.3
CM 4 19 88.8 100 13.8
VP 5 10 65.5 100
SM 6 21 95.3 100 15.4
MA 7 11 38.0 99
TD 8 11 27.1 100
WC 9 14 25.6 98 14.9
GD 10 14 73.9 100 16.4
BD 13 15 29.6 97 13.6
PH 15 19 87.1 96 15.4
DK 16 20 91.5 100 14.8
None of the patients had a history of lung disorders, or cerebral or myocardial infarction. 
Subject 2 was undergoing venesection for polycythaemia, and subject 4 was on treatment 
for type 2 diabetes and hypertension.
Ethical approval was granted by the relevant ethics committee, and all subjects gave verbal 
consent. Written consent is not currently accepted policy for the clinical use of medical 
monitoring instruments.
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6.2.2 Protocol
The polysomnography electrodes were connected in a standard manner. The pulse 
oximeter probe was applied to a finger because of problems with signal stability on the ear 
lobe.
The NIRS optodes were placed in a black plastic holder and attached to the left forehead 
using a self-adhesive pad as described in chapter 4.
Care was taken to avoid air sinuses and the temporalis muscle and the optodes were placed 
on as flat a part of the head as possible. The optodes were bandaged in place using a crepe 
bandage. Once all the apparatus was attached the outputs were tested and the patient was 
then allowed to sleep in a darkened room for up to 2 hours.
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7. ANALYSIS OF TOI CHANGES IN
ASSOCIATION WITH THE 
POLYSOMNOGRAPHY TRACE FROM 
FIRST VALIDATION STUDY
7.1 OVERALL HYPOTHESIS
7.1.1 Measurement of cerebral oxygenation using near-infra red spectroscopy 
gives additional valid information compared to measurement of arterial 
oxygen saturation alone.
7.2 HYPOTHESES UNDERLYING ANALYSIS IN THIS CHAPTER
7.2.1 Characteristics of TOI differ from characteristics of arterial oxygen 
saturation.
7.2.2 TOI changes during apnoeas cannot be predicted from arterial oxygen 
saturation alone.
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7.3 SUMMARY.
This chapter describes the analysis of the TOI trace and polysomnography trace during 
daytime sleep for 13 subjects from the first validation study. Results include absolute 
values of TOI and Sa02 observed, the relationships between TOI and Sa02, and other 
factors affecting the changes in TOI during apnoea including apnoea duration and REM 
sleep stage. Finally a multiple regression looking at predictors of the amplitude of the TOI 
dip during apnoea is given.
7.4 DATA ANALYSIS
13 subjects with moderate or severe OSA undertook daytime naps with polysomnography 
and NIRO monitoring. The TOI channel o f the NIRO300 was fed into a spare channel on 
the polysomnography computer. Analysis was carried out manually using the graphical 
display and software o f the Compumedics® polysomnography system. For each 
obstructive apnoea/hypopnoea, the lowest Sa0 2  value (min. Sa0 2 ), the Sa0 2  difference 
from baseline (ASa0 2 ) and apnoea duration were obtained from the analysis function of the 
polysomnography software. The computer scans from the end of the apnoea plus a 
specified time lag (set at 30s for a finger oximeter probe) back to the beginning of the 
apnoea plus the time lag, to obtain the saturation minimum (see fig 31). The difference 
between the maximum baseline TOI value preceding each apnoea/hypopnoea and the TOI 
nadir obtained during each apnoea/hypopnoea related oxygen desaturation was recorded 
for every event (A TOI). This was performed manually using a cursor on the screen.
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Figure 31. Figure showing how TOI results were read off the polysomnography trace
This is part of an annotated polysomnography trace with S a0 2 = oxygen saturation by pulse oximetry and cTOI 
= tissue oxygenation index. Minsat = minimum S a02 for that apnoea and maxTOI and minTOI = maximum and 
minimum TOI for that apnoea. Sa02 and TOI readings were obtained as follows. For apnoea 1 the 
polysomnography software scanned from the end o f the apnoea plus 30s back to the beginning of the apnoea 
plus 30s (marked as time period A) on the S a02 trace to obtain the minimum saturation 1. Minimum and 
maximum TOI corresponding to apnoea 1 were identified visually and the cursor was then placed over the point 
of interest causing a text box to appear which allowed identification of the values max TOI 1 and min TOI 1. 
This process was repeated for subsequent apnoeas.
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All apnoeas for which the recording was technically satisfactory were recorded, so that the 
total number of events recorded varied from 15 to 160 in different subjects.
7.5 STATISTICAL ANALYSIS
Absolute maximum and minimum values of TOI and Sa02 were described and compared 
using scatter plots and regression analysis for the 13 subjects.
Changes in various parameters during each apnoea were described for each subject using 
mean and standard deviation.
Initial analysis consisted of comparing the TOI and saturation dips in each subject 
individually. Scatter plots were drawn for each relationship to check they were 
approximately linear. Linear regression analysis was then used. Acceptable level of 
significance was taken as p<0.05.
Apnoea characteristics in REM and non-REM sleep were compared using a two-tailed t 
test.
When the data was combined it was necessary to choose an analysis technique suitable for 
repeated measures, and the xtgee command of stata6 (146) was recommended to us by our 
statistical advisers at UCL (152). This was a two level analysis where subject identity (id) 
comprised one of the two levels, and did not provide an R value because of its 2 level
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nature. It allowed measurements from repeated apneas in different subjects to be 
combined in a single analysis. Acceptable level o f significance was taken as p<0.05.
7.6 POLYSOMNOGRAPHY RESULTS
13 subjects with moderate or severe OSA undertook daytime naps with polysomnography 
and NIRO monitoring. Recordings were obtained during a mean sleep period of 89.9 min 
(SD 24.4) with a mean sleep latency o f 2.1 min (SD 3.2). Slow wave sleep was observed in 
eleven o f the subjects and rapid eye movement (REM) sleep in four. Eleven subjects had 
an AHI greater than 30 during the daytime polysomnography. After connecting up the 
apparatus there was a time interval o f <5 minutes before the polysomnography computer 
was turned on, so the quoted sleep latencies are an underestimate. See tables 9 and 10 for 
staging and respiratory event characteristics o f the polysomnographies.
Table 9. Sleep latency, total sleep time and sleep staging data for 13 subjects.
Pat. ID Sleep
latency
/min
Sleep
time/min
Stage 1 
min
Stage 2 
min
Stage 3 
min
Stage 4 
min
REM/
min
G I 1 0 n/a
DP 2 0 101 5.7 41 48 0.7 5.6
DS 3 7 30 7 23 0.3 0 0
CM 4 0 95 8.7 78 7 0 1.3
VP 5 n/a 120 4 97 12 0 7
SM 6 1.3 77.7 5.3 55.7 6.7 0 10
MA 7 0.7 36.7 10.7 22.7 3.3 0 0
TD 8 n/a 57.3 2.3 44.3 4.3 0 6.4
WC 9 10 18.7 1.3 16.7 0.7 0 0
GD 10 0 89 12 28 27 9 13
BD 11 0.7 76.3 3.3 61.7 5.3 0 6
PH 12 0 80 7 50 22 0 0
DK 13 2 61 6.7 37 16.3 1 0
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Table 10. Respiratory analysis from polysomnography in 13 subjects.
All indices are per hour.
Pat. ID Apnoea
index
central
Apnoea
index
obstructive
Apnoea 
index mixed
Hypopnoea
index
AHI
GI 1 0 58.8 0 9.4 69.8
DP 2 0.6 84.1 5.9 3.6 94.2
DS 3 0 74 0 2 76
CM 4 0 56.5 0 2.5 59
VP 5 8.5 24.4 4 3.5 40.4
SM 6 1.5 75.5 9.9 9.2 96.1
MA 7 0 0 1.6 13 14.6
TD 8 0 5 0 20.9 25.9
WC 9 3.2 37.9 6.3 9.3 56.7
GD 10 0 40.7 0.7 2.7 44.1
BD 11 0 28.3 0.8 55.8 79.7
PH 12 0 55 0 40 95
DK 13 0 39.7 4.8 55.2 99.7
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7.7 THE TOI TRACE
Figure 32 gives an example of the polysomnography and TOI trace obtained in one subject 
(subject 1) during a period of repetitive apnoeas.
Figure 32. Polysomnography trace in subject 1 during OSA
Sa02 = oxygen saturation, cTOI = tissue oxygenation index, AcTOI is the TOI change for that apnoea, ASa02 is 
the S a02 change for the corresponding apnoea.
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It illustrates that repetitive drops in TOI were observed during successive 
apnoeas/hypopnoeas. There was a time lag of approximately 20s between the Sa02 
(measured from a pulse oximeter using a finger probe) and TOI dips. The TOI and Sa02 
nadir occurred at 9.5 (± 2.8) sec and 28.7 (± 5.0) sec (range 6.9 - 15.9 vs. 24.7 - 38.7 sec; p 
< 0.001) after the end of an apnoea/hypopnoea.
Baseline TOI varied from 50.2 -  75.0%, where awake baseline Sa02 was 94% or above in 
all subjects. No shifts in the TOI baseline were detected during periods of relaxed 
wakefulness or sleep stage transitions in Non-REM sleep. In 3 subjects the TOI baseline 
was affected by major body movements. The median coefficient of variation of the TOI 
immediately preceding each apnoea was 2.4% (range 1.2 to 8.1%) in all subjects; median 
2% (range 1.2 to 3.5%) in 10 subjects without baseline shift.
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7.7.1 Initial observations on TOI in 13 subjects
There is very limited data on the relationship between TOI and arterial saturation in 
different subjects, as so much validation work has been performed in neurosurgical 
patients with Sa02 fixed. Otherwise fit sleep apnea patients tend to have very similar 
baseline Sa02 values (>95%), but variable minimum Sa02 values depending on apnea 
duration and other factors. We wondered if the same were true for TOI values. 
Absolute maximum and minimum TOI and arterial saturation from the dataset obtained 
from apnoea analysis were compared in 13 subjects. There was more variability in 
maximum TOI values than maximum saturation values, and no correlation between the 
two (p=0.6) (Fig 33).
Figure 33. Graph of maximum saturation against maximum TOI in 13 subjects
These are absolute maximum values from the data o f each subject, with units % saturation.
Maxsat -  absolute maximum arterial oxygen saturation, max toi = absolute maximum tissue 
oxygenation index, both in %
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However there was some relation between absolute minimum arterial saturation and TOI, 
reflecting severity of OSA (Figure 34).
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Figure 34. Relationship between absolute minimum S a02 and TOI. R2 = 0.54 Coeff = 0.59 p=0.004
These are absolute minimum values from the data o f each subject, with units % saturation. Mlnsat = absolute 
minimum arterial oxygen saturation, mintoi = absolute minimum tissue oxygenation index, both in %
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There was no relation between maximum arterial oxygen saturation and absolute minimum 
saturation (p=0.126) (Figure 35).
Figure 35. Relationship between maximum and minimum S a0 2 in 13 subjects.
These are the absolute maximum and minimum values from the data of each subject, with units % saturation. 
Maxsat and minsat = absolute maximum and minimum arterial oxygen saturation, both in %
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However TOI minimum was related to TOI maximum quite strongly (Figure 36). This 
suggests that individual factors influence TOI measurements and need to be taken into 
account when subjects are compared. However TOI is marketed as an absolute saturation
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measurement, and the relation between absolute minima TOI and Sa02 suggest that this is 
legitimate.
Figure 36. Relationship between maximum and minimum TOI. R2=0.47, p=0.01
These are the absolute maximum and minimum values from the data of each subject, with units % saturation. 
Maxtoi and mintoi = absolute maximum and minimum tissue oxygenation index, both in %
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The main decision to be made when analyzing TOI values was whether to bother with 
absolute values or whether to stick to measures of change as had always been conventional 
in previous NIR models, because of the degree of intercorrelation within the TOI values of 
an individual. In multiple regression both TOI maximum and arterial saturation minimum 
significantly predict TOI minimum, and together they explain 80% of the variance (Table 
11). We proceeded on the basis of these initial observations to look at both TOI dip and 
TOI minimum in analysis but to use a statistical method that corrected for the fact that 
observations within an individual were more similar than observations between 
individuals.
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Table 11. Regression analysis showing predictors of minimum TOI during sleep 
apnoea
This illustrates the statistical output from the program Stata(146). minTOI = absolute minimum TOI, 
maxTOI = absolute maximum TOI, minsat = absolute minimum Sa02
regress mintoi maxtoi minsat 
Source | SS df MS Number of obs = 13
 +  F( 2, 10) = 20.81
Model | 1082.53436 2 541.26718 Prob > F = 0.0003
Residual | 260.125577 10 26.0125577 R-squared = 0.8063
----------+--------------------------------- Adj R-squared = 0.7675
Total | 1342.65994 12 111.888328 Root MSE = 5.1003
mintoi I Coef. Std. Err. t P>|tI [95% Conf. Interval]
 +-------------------------------------------------------------------------------------------------
maxtoi | .7792175 .2105048 3.702 0.004 .3101836 1.248251
minsat | .4784729 .1150118 4.160 0.002 .2222106 .7347352
cons | -34.3595 14.75388 -2.329 0.042 -67.23318 -1.485812
7.7.2 Mean values of SaC>2 and TOI variables during apnoea
Mean values for each patient of Sa02 and TOI variables during apnoea are shown in 
Table 12. These values are averages of changes in TOI and Sa02 and of minimum values 
for individual apnoeas. The number of apnoeas averaged per patient varied from 15 to 
160. Mean minimum saturation varied from 76.7 to 93.8 and mean minimum TOI varied 
from 47.6 to 70.5. The average change in TOI during apnoea (ATOI) varied from 1.4 to 
6.9, and in arterial saturation (ASa02) from 3.8 to 21.8. As discussed above there was a 
wider variation in baseline TOI than baseline saturation, and so there was a bigger range of 
mean minimum TOI, despite the changes during apnoea being smaller.
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Table 12. Mean values for SaC>2 and TOI variables for 13 patients with OSA during 
daytime sleep.
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, ATOI = mean TOI change during 
apnoeas, ASa02 = mean Sa02 change during apnoeas, mean minimum TOI = mean of minimum TOI reached 
during each apnoea, mean minimum Sa02 = mean of minimum Sa02 reached during each apnoea, duration = 
mean apnoea duration.
id Number of events ATOI1% A Sa02% Mean min TOI
%
Mean min S a0 2 
%
Duration/s
1 130 6.6 (4.4) 14.7 (6.8) 63.1 (4.5) 81.8(5.9) 30.4(13.6)
2 160 5.7 (2.6) 21.8(6.9) 51.7 (3.5) 76.7(7.1) 25.7 (7.8)
3 48 4.3 (1.5) 12.4 (3.3) 64.0(1.4) 85.0 (3.0) 32.8 (9.8)
4 90 2.5 (1.1) 10.1 (4.4) 47.6(1.2) 87.7 (4.4) 25.9(10.1)
5 17 6.9 (1.9) 11.6 (9.2) 53.9 (3.3) 85.0 (8.8) 33.4 (8.8)
6 110 5.2 (3.1) 17.0 (6.4) 53.0 (7.0) 81.0 (6.8) 19.8(8.1)
7 15 1.4 (0.6) 3.8 (1.4) 70.5(1.0) 92.5(1.4) 15.4 (3.5)
8 27 1.8 (0.7) 4.9 (2.9) 66.2(1.0) 93.8(2.7) 20.9 (12.2)
9 32 3.7 (1.8) 8.8 (2.4) 63.5 (2.4) 90.4 (2.2) 17.8(5.0)
10 71 6.3 (1.7) 10.8(3.1) 61.8(2.3) 86.7 (4.5) 27.7 (8.3)
11 108 3.5 (1.3) 6.2 (2.6) 53.0 (2.1) 89.9 (2.4) 14.1 (4.4)
12 125 4.0 (1.3) 7.5 (3.3) 69.1 (1.6) 86.4 (3.5) 17.1 (5.0)
13 103 4.9 (1.4) 9.4 (3.1) 66.3 (2.5) 87.7 (2.9) 20.0 (5.7)
7.7.3 Relationships between parameters in individual subjects
The relationships between pairs of recorded parameters were first examined in individual 
subjects, using simple regression (Tables 13-15). Because of the problems in combining 
data between subjects it was important to first establish any relationships that existed in 
individual subjects.
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Table 13. Relation between ATOI and ASa02.
TOI = tissue oxygenation index, Sa02 = arterial oxygen saturation, ATOI and ASa02 are change in TOI and 
corresponding change in Sa02 during each apnoea. Statistical analysis is uses simple regression, coefficient 
is regression coefficient.
id coefficien
t
R
squared
P Number of 
events
1 0.57 0.78 <0.001 130
2 0.33 0.74 <0.001 160
3 0.38 0.71 <0.001 48
4 0.14 0.30 <0.001 90
5 0.15 0.53 0.001 17
6 0.22 0.20 <0.001 110
7 0.23 0.26 0.05 15
8 0.13 0.29 0.004 27
9 0.52 0.47 <0.001 32
10 0.34 0.39 <0.001 71
11 0.15 0.08 0.002 108
12 0.20 0.24 <0.001 125
13 0.22 0.24 <0.001 103
ATOI and A Sa02 were significantly related in all subjects (Table 13), however the 
regression coefficient varied, ie the change in TOI per unit change in Sa02 varied between 
subjects.
Mean minimum TOI was related significantly to mean minimum saturation in 8 out of 13 
subjects (Table 14). This did not seem to be just a problem of power as some subjects with 
over a hundred apnoeas did not have a significant relationship. It is more likely that the 
contribution of individual factors to TOI measurement varied between individuals.
TOI change was significantly related to apnoea duration in 10 out of 13 subjects (Table 
15). The number of apnoeas was small in two out of three subjects where the relationship 
was non-significant. Clearly arterial desaturation will be greater during longer apnoeas, 
and so multiple regression was necessary to find out if the effect of apnoea duration on 
TOI change added anything to the effect of desaturation.
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Table 14. Relationship between minimum TOI and minimum Sa02 during each 
apnoea
TOI = tissue oxygenation index, Sa02 = arterial oxygen saturation, minimum TOI and minimum Sa02 are 
corresponding minima during each apnoea. Statistical analysis is uses simple regression, coefficient is 
regression coefficient.
id coefficient R squared p Number
of
events
1 0.55 0.51 <0.001 130
2 0.45 0 .82 <0.001 160
3 0.37 0 .62 <0.001 48
4 0.12 0 .20 <0.001 90
5 0.29 0 .59 <0.001 17
6 0.57 0 .30 <0.001 110
7 0 .087 15
8 0.068 27
9 0.72 0 .43 <0.001 32
10 0.35 71
11 0.68 108
12 0.08 125
13 0.47 0 .30 <0.001 103
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Table 15. Relationship between ATOI and apnoea duration
TOI = tissue oxygenation index, ATOI is the change in TOI during each apnoea, here compared to 
corresponding apnoea duration. Statistical analysis is uses simple regression, coefficient is regression 
coefficient.
Id coefficient R squared p Number of events
1 0.27 0.70 0.000 130
2 0.24 0.53 0 .000 160
3 0.11 0.51 0.000 48
4 0.53 0.25 0.000 90
5 0.13 0 .37 0 .009 17
6 0.30 0.60 0.000 110
7 0.04 0.04 0.451 15
8 0.02 0.13 0.062 27
9 0.28 0 .57 0.000 32
10 0.07 0.13 0.002 71
11 0.08 0.08 0.004 108
12 0.07 0 .08 0.002 125
13 0.03 0 .02 0.198 103
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1.1 A Effect of REM sleep stage
Four subjects had apnoeic episodes during REM sleep during daytime naps, and apnoea 
characteristics were compared in REM and non-REM sleep in these subjects using a 2- 
tailed t test (Tables 16-19). Changes in TOI, Sa(>2 and apnoea duration during REM sleep 
were significantly greater than in Non-REM sleep in 3 of the 4 subjects. The fourth 
subject had mean minimum saturations of around 90% both in REM and non-REM sleep 
and these values were much higher than the other subjects who had REM sleep during the 
daytime naps, however it is not clear why differences in REM and non-REM sleep were 
not observed.
Table 16. Differences in parameters in REM and nonREM sleep in Subject 1
REM = rapid eye movement, Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, ASa02 = 
change in Sa02 during apnoea, min Sa02 = minimum Sa02 during apnoea, duration = apnoea duration, min 
TOI = minimum TOI during apnoea, ATOI = change in TOI during apnoea.
REM Non-REM P
observations 14 116
Mean ASa02(%) 24.4 13.6 0.000
Mean min Sa02 
(%)
73.6 82.8 0.000
Mean duration (s) 49 28.2 0.000
Mean min TOI (%) 57.6 63.7 0.000
Mean ATOI (%) 13.9 5.7 0.000
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Table 17. Differences in parameters in REM and nonREM sleep in Subject 2.
REM = rapid eye movement, Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, A Sa02 -  
change in Sa02 during apnoea, min Sa02 = minimum Sa02 during apnoea, duration = apnoea duration, min 
TOI = minimum TOI during apnoea, ATOI = change in TOI during apnoea.
REM Non-REM P
observations 10 150
Mean A Sa(>2 (%) 38.6 20.7 0.000
Mean min Sa02(%) 59.3 77.9 0.000
Mean duration (s) 41.3 24.6 0.000
Mean min TOI (%) 40.9 52.4 0.000
Mean ATOI (%) 13.2 5.2 0.000
Table 18. Differences in parameters in REM and nonREM sleep in Subject 6.
REM = rapid eye movement, Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, ASa02 = 
change in Sa02 during apnoea, min Sa02 = minimum Sa02 during apnoea, duration = apnoea duration, min 
TOI = minimum TOI during apnoea, ATOI = change in TOI during apnoea.
REM Non-REM P
observations 12 98
Mean A SaC>2 (%) 21.7 16.4 0.007
Mean min Sa02 74.8 81.7 0.001
(%)
Mean duration(s) 33.3 18.2 0.000
Mean min TOI (%) 41.0 54.5 0.000
Mean ATOI (%) 10.2 4.6 0.000
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Table 19. Differences in parameters in REM and nonREM sleep in Subject 13.
REM = rapid eye movement, Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, ASa02 = 
change in Sa02 during apnoea, min Sa02 = minimum Sa02 during apnoea, duration = apnoea duration, min 
TOI = minimum TOI during apnoea, ATOI = change in TOI during apnoea.
REM Non-REM P
observations 11 97
Mean A Sa02 (%) 5.64 6.30 0.43
Mean Min Sa02(%) 90.2 89.9 0.66
Mean duration (s) 13.5 14.2 0.63
Mean min TOI (%) 53.7 52.9 0.27
Mean ATOI (%) 3.65 3.43 0.61
7.7.5 Combined analysis of 1036 apnoeas/hypopnoeas
We had shown that change in SaC^, apnoea duration and REM sleep stage affect the size 
of the TOI drop during apnoea in most subjects, however changes in Sa02 are increased in 
long apnoeas and during REM sleep, so it was still not clear whether the TOI measurement 
provided additional information to pulse oximetry. We therefore used regression analysis 
to see whether the effects of apnoea duration and REM sleep were independent of Sa02.
In a two level regression analysis including all apnoeas the following factors were 
significantly associated with the magnitude of the fall in cerebral oxygen saturation 
associated with an apnoea, corrected for interpatient differences: min Sa02, Sa(>2 
difference, apnoea duration and REM sleep stage (Table 20). The minimum TOI reached 
during an apnoea was significantly predicted by min Sa02 and REM sleep stage, with 
apnoea duration being borderline significant.
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Table 20. Factors affecting apnoea-associated TOI drops and TOI minimum. Two 
level regression analysis, adjusting for interpatient differences.
Cl = confidence intervals, REM = rapid eye movement, Sa02 = arterial oxygen saturation, TOI = tissue
oxygenation index, A Sa02 = change in Sa02 during apnoea, min Sa02 = minimum Sa02 during apnoea,
TOI minimum = minimum TOI during apnoea, ATOI = change in TOI during apnoea. Statistical analysis
was performed using the xtgee command of stata6 (146).
Factors affecting ATOI Factors affecting TOI minimum
Factor Regression 95% Cl* P Regression 95% Cl* P
Coefficient coefficient
ASa02 0.105 0.023 -0.187 0.012 0.069 -0.224 - 0.361 0.644
Minimum -0.107 -0.128-0.086 0.000 0.328 0.046-0.611 0.023
Sa02
Apnoea 0.092 0.036-0.149 0.001 -0.090 -0.180-0.001 0.052
Duration
REM sleep 2.405 1.134-3.676 0.000 -3.970 -7.828-0.112 0.044
7.7.6 Conclusions
7.7.7 Characteristics of TOI differ from characteristics of arterial oxygen 
saturation.
In this chapter we have looked at the initial findings when TOI changes were compared to 
saturation changes during obstructive sleep apnoea. At the time when we performed this 
work there was very little data on baseline TOI values in human subjects. We started by 
looking at maximum and minimum values of TOI and arterial saturation. We were not 
surprised to find baseline Sa02 values all between 95 and 100% in otherwise well subjects 
with OSA. However the baseline TOI values were lower and more variable than Sa02 
values as they depended on the relative proportion of arterial and venous blood under the 
probe. There was no correlation between Sa02 and TOI maximum values which is perhaps 
as expected given that maximum Sa02 is relatively fixed. There is a correlation between 
the minimum TOI and Sa02 values, suggesting that severe apnoea is associated with bigger
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changes in both SaC>2 and TOI. Minimum Sa02 does not correlate with baseline maximum 
Sa02, suggesting that minimum saturation is dependent on other factors. There is however 
a close correlation between an individual’s maximum and minimum TOI suggesting that 
individual factors have a greater influence on TOI values than Sa02. This description of 
the characteristics of TOI compared to Sa02 is important so that more complicated analysis 
of TOI can be performed and interpreted correctly.
7.7.8 TOI changes during apnoeas cannot be predicted from arterial oxygen 
saturation alone.
The other important fact established by this early analysis was that TOI changes did occur 
during apnoea and could not be predicted by arterial saturation changes alone. It has been 
postulated that cerebral autoregulation might keep cerebral oxygenation constant during 
peripheral desaturation, and demonstration of any TOI changes during OS A show that this 
is not the case. Additionally it has also been suggested that any changes in cerebral 
saturation during apnoea may occur secondary to Sa02 changes, so that TOI changes can 
be predicted from and add nothing to Sa02 changes. Again our results demonstrate that 
this is not the case and that TOI changes also depend on sleep stage and apnoea duration 
independently of Sa02- Cerebral oxygenation will also be affected by cerebral blood flow 
changes which are greater in REM sleep. We moved on to attempt to characterise the 
changes in cerebral oxygenation occurring during OS A more fully in later validation 
studies. We were able to look at total haemoglobin and cytochrome oxidase oxidation 
state from the NIRO output and this is described in chapter 8, as well as simultaneous 
CBFV measurement summarised in chapter 9.
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8. ANALYSIS OF CYTOCHROME OXIDASE, 
CEREBRAL BLOOD VOLUME AND TOI 
CHANGES FROM VALIDATION STUDY 1.
8.1 OVERALL HYPOTHESIS
8.1.1 Measurement of cerebral oxygenation using near-infra red spectroscopy 
gives additional valid information compared to measurement of arterial 
oxygen saturation alone
8.2 HYPOTHESES UNDERLYING ANALYSIS IN THIS CHAPTER
8.2.1 Changes in intracellular redox state measured using cytochrome oxidase 
redox state are seen during obstructive sleep apnoea.
8.2.2 There is a fixed temporal relationship between changes in total haemoglobin 
and measures of oxygenated haemoglobin during obstructive sleep apnoea
8.3 INTRODUCTION.
The NIRO300 measures cerebral tissue saturation (TOI) using spatially resolved
spectroscopy but also gives the basis chromophore concentration changes: OHb, HHb and
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cytochrome oxidase. Before tissue saturation measurements were available, chromophore 
concentration changes used to be extensively analysed to give as much information as 
possible. The most used haemoglobin derivatives were the Hb difference (OHb -  HHb) 
which gives an idea of the redox state of the haemoglobin and has been superceded by 
TOI, and total haemoglobin (OHb + THb) a value which can be equated to relative blood 
volume, and gives limited information about whole blood movement within the tissue. 
Changes in total haemoglobin occurring during apnoea were observed previously by 
Hayakawa (Hayakawa) and used to support the view that cerebral blood flow changes do 
not completely compensate for arterial hypoxaemia during apnoea. In their paper they 
only illustrated data from one patient, and did not suggest that the temporal relationship of 
the changes differed between patients. Clearly if the degree of compensation differs 
between patients this supports our basic hypothesis that the measurement of cerebral 
oxygenation directly will give more information than measuring arterial saturation alone. 
We approached this question by looking at total haemoglobin changes in relation to 
changes in the basic chromophores during individual apnoeas.
Changes in concentration of oxidized cytochrome oxidase can also be calculated to look at 
intracellular redox state. When the NIRO300 is used clinically the chromophore readings 
are often ignored and TOI used alone. There are various reasons for this; TOI is an 
absolute saturation measurement and has been validated as independent of extracranial 
contamination, unlike the simple chromophore measurements. We chose however to 
spend some time analyzing total haemoglobin and cytochrome oxidase changes in OSA 
because of the additional haemodynamic and metabolic information available, and then 
comparing these changes to cerebral saturation changes measured with TOI.
This chapter presents findings relating to changes in cytochrome oxidase and cerebral 
blood volume occurring during OSA measured by NIRS in the first validation study in 
which 13 subjects underwent polysomnography and simultaneous cerebral oxygenation 
monitoring using the NIRO300 during daytime naps. Changes in cytochrome oxidase and 
cerebral blood volume were quantified and then correlated to changes in TOI, and TOI dip 
duration. The temporal relationship between changes in these parameters was examined 
using cumulative averaging. An attempt was made to explain two different observed 
temporal patterns.
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8.4 DATA ANALYSIS
8.4.1 Subject selection
Of the 13 subjects included in analysis of polysomnography traces (chapter 7), five were 
eliminated from further analysis because their recordings were technically poor, or because 
they did not have sufficient runs of consecutive apnoeas during the recording period. The 
five eliminated were subjects 4,5,7,8 and 9. Analysis of cytochrome oxidase and CBV 
changes was carried out on the 8 patients who had several runs of at least 3 consecutive 
apnoeas during these daytime naps and were the most severe among the group (subjects 
1,2,3,6,10,11,12,13). Three subjects did not sleep during the daytime recording period and 
were not included in either analysis.
8.4.2 Quantification
Fig 37 shows an example of the raw data from one patient during a run of consecutive 
apnoeas illustrated graphically. It can be seen that there are repetitive changes in TOI, 
OHb, HHb, total HB and cytochrome oxidase occurring during apnoeas.
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Figure 37. Raw NIRO data from one subject (subject 1) during repetitive apnoeas
TOI = tissue oxygenation index, Cytox = cytochrome oxidase, OHb = oxygenated haemoglobin, 
HHb = deoxygenated haemoglobin, THb = total haemoglobin (OHb + HHb), all chromophores 
measured in pM from arbitrary baseline, TOI measured in %saturation.
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This raw data did not include Sa(>2 or airflow so a standard method of defining apnoea was 
not available to us. We instead chose to use a prespecified definition of TOI dip and look 
at the relationship of CBV change and cytox change with this. TOI dips were selected as 
being >= 2% and >= 4sec, in runs of at least 2 consecutive dips. In the validation paper for 
the TOI and NIRO300 (80) after accounting for baseline variation in TOI, a ATOI of >2% 
was considered significant, and our previous work using the analogue output of TOI to the
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polysomnography system has shown consistent TOI dips occurring in association with 
apnoeas with a correlation coefficient of 0.94 between 2% dip rate and AHI. The first 40 
successive TOI dips fitting the prespecified criteria were selected for each patient (303 dips 
in total) and maximum and minimum TOI were recorded. For each selected TOI dip the 
maximum and minimum values of cytochrome oxidase and total haemoglobin occurring 
during the TOI dip were recorded, as well as the times at which these occurred. The 
method by which this was done is explained more fully in chapter 5. The duration of the 
TOI dip from preceding maximum to end minimum was also recorded. Mean TOI dip 
duration in session 1 correlated with mean apnoea duration from the polysomnography 
(c=0.94). An adjustment of the NIRS Hb and cytochrome oxidase output is required in 
order to calculate concentrations and this differential pathlength factor was assumed to be 
6.26 in all analysis (96). Cerebral blood volume was calculated from total haemoglobin, 
using corrections for cerebral large to small vessel haematocrit ratio, cerebral tissue density 
and subject haemoglobin concentration as previously described (93). We assumed that 
CBV change was related to change in cerebral blood flow and as such might be a 
determinant of cerebral oxygenation measured as TOI, that changes in cerebral saturation 
might affect cytochrome oxidase oxidation state, and that TOI dip duration could be used 
as a measure of apnoea duration in the absence of a better alternative. The following 
relationships within an apnoea were therefore studied using linear regression: the effect of 
CBV change on TOI, the effect of TOI change and CBV change on cytochrome oxidase 
change, and the effect of TOI dip duration on both cytochrome oxidase and CBV changes. 
This analysis was carried out initially in each subject separately and then two level 
multiple regression was used to combine the results to correct for intersubject differences 
(152).
8.4.3 Cumulative average of changes
Visual inspection of the data revealed two different time relationships between THb 
changes and TOI changes. To illustrate these two relationships the longest run of 
consecutive apnoeas of similar length was selected for each of the two patterns. The length 
of this run happened to number thirteen apnoeas. A cumulative average of OHb, HHb,
THb, cytox and TOI was calculated over 13 apnoeas. The method is described fully in 
chapter 5. Graphs were plotted to illustrate average changes during apnoea for these 2 
patterns.
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8.4.4 Redox changes in Hb oxidation during CBV increase (OHb ratio)
Total haemoglobin is the sum of OHb and HHb. There is a fixed relation between THb 
change and CBV change. Whether or not a particular apnoea was of one pattern or the 
other depended on the relative changes in OHb and HHb during the CBV increase. The 
change in OHb which occurred during the rise in total haemoglobin was calculated from 
the OHb values at the minimum and maximum of the THb change for each of the 303 
apnoeas. This was signed to distinguish between a rise and fall of OHb and expressed as a 
fraction of the THb rise (OHbratio). Cerebral oxygenation would increase when total 
haemoglobin increased if the increase was mainly due to oxygenated haemoglobin.
Cerebral oxygenation would decrease when total Hb increased if the increase in THb was 
mainly due to deoxygenated haemoglobin.
The OHbratio gives an estimate of the redox change during the THb change, and is a 
useful measurement if THb change is used as a proxy for CBV change to give some idea of 
the oxygenation of the incoming blood.
8.4.5 Statistics
Baseline variation of the cytochrome signal was described using standard deviation. As 
the trace starts from an arbitrary zero, coefficient of variation could not be used.
Changes were quantified using mean and standard deviation.
Changes were compared in individual subjects using scatter plots with simple regression 
analysis. Changes in different subjects were combined using a two level multiple 
regression, with subject id at one level as described previously.
Confidence intervals were calculated for each point of each parameter of the cumulative 
averages, but are not presented graphically here.
Acceptable level of significance was taken as p<0.05.
8.5 RESULTS
8.5.1 Baseline variables
We looked first of all at the baseline variability in the cytox trace. Figure 38 shows an
example of baseline variability in the TOI and cytochrome oxidase traces at sleep onset in
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subject 1. Median baseline TOI was 70.5, (range 58 -  78) for the 8 selected subjects in 
session 1. The median standard deviation of the cytox signal during 2 minutes (120 
observations) of non-obstructed breathing in 6 subjects was 0.034 jjM  (range 0.023 to 
0.055). The median cytox standard deviation over a similar period in the 5 subjects without 
significant OSA was 0.034 jiM (range 0.020 to 0.053).
Figure 38. Baseline variability at sleep onset
TOI = tissue oxygenation index measured in % saturation, Acytox = change in cytochrome oxidase in pM from 
arbitrary baseline.
Sleep Onset
80 n
75 -
n O  
0s
2T 70  ^
O
65 -
60 - 
0.6 i
V
r_JRl
0.4 -
X
O
>.
O<
0.2
0.0 -
- 0.2
1 2
Time (minutes)
134
8.5.2 Quantification of cytox changes
We wanted to look at how big the changes in oxidised cytochrome oxidase were during 
apnea, to see if they were physiologically relevant. Quantification of cytochrome oxidase 
changes ranged from mean (+SD) 0.48 ± 0.08 to 0.13 ± 0.05pM in the 8 patients ( see table 
21), where absolute cytochrome oxidase concentration in adult brain is <5.5pM (153).
Table 21. Mean changes in cytochrome oxidase redox state during apnoea for 8 
patients (29- 40 apnoeas/patient).
TOI = tissue oxygenation index, cytox = cytochrome oxidase, changes are during apnoea defined as TOI dip.
Patients are numbered in order of mean TOI change, with ID number from validation study 1 in brackets.
Patient Mean TOI change Mean cytox change
+/- SD +/- SD (pM)
%
K D 12.22+/-4.09 0.48 +/- 0.08
2(6) 7.76 +/- 2.82 0.28+/- 0.13
3(2) 6.93+/-3.14 0.40+/-0.16
4(10) 5.48 +/- 2.03 0.23+/- 0.11
5(12) 5.43 +/- 1.62 0.23+/- 0.10
6(13) 5.30 +/- 0.99 0.29 +/- 0.08
7(11) 4.33+/- 1.07 0.13+/- 0.05
8(3) 4.05 +/- 0.85 0.29 +/- 0.06
8.5.3 Quantitative correlations of cytox changes
We also examined how cytox changes were related to TOI changes, to see if cerebral tissue 
oxygenation changes were related to intracellular redox state. We considered that if the 
small changes in ctox correlated with TOI changes they were more likely to be real. 
Correlations between cytox changes and TOI changes in individual subjects are shown in 
Table 22.
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Table 22. Regression analysis between TOI parameters during apnoea and changes in 
cytochrome oxidase redox state during apnoea, for individual subjects.
TOI = tissue oxygenation index, cytox = cytochrome oxidase, ATOI and Acytox are changes in TOI and 
cytox during apnoea defined as TOI dip, duration is duration of TOI dip, coeff is regression coefficient from 
simple linear regression.
id ATOI/Acytox TOI minimum/Acytox Duration/Acytox
coeff r2 P coeff r2 P coeff r2 P
1 16.96 0.13 0.04 -14.96 0.15 0.03 52.43 0.18 0.02
2 6.66 0.11 0.08 -17.81 0.14 0.05 17.35 0.08 0.12
3 6.90 0.14 0.01 -9.40 0.14 0.01 18.44 0.07 0.08
4 10.06 0.31 0.00 -10.20 0.14 0.02 94.33 0.36 0.00
5 1.45 0.01 0.56 -0.86 0.00 0.67 -1.81 0.00 0.87
6 2.87 0.06 0.13 -5.03 0.21 0.00 -4.85 0.01 0.63
7 5.27 0.07 0.1 -4.43 0.02 0.44 0.14 0.00 0.99
8 5.52 0.18 0.01 -6.77 0.18 0.01 59.51 0.1 0.04
The change in cytochrome oxidase oxidation during apnoea was significantly related to 
ATOI in half the subjects, to TOI minimum in 6 out of 8 subjects and to dip duration in 3 
out of 8 subjects. Significant correlations were seen between the magnitude of cytochrome 
oxidase change and TOI difference, minimum TOI and duration of TOI drop in the group 
of 303 apnoeas corrected for interpatient differences (Table 23).
Table 23. Two level multiple regression for effects on cytox difference.
TOI = tissue oxygenation index, cytox = cytochrome oxidase, ATOI and Acytox are changes in TOI and 
cytox during apnoea defined as TOI dip, TOImin is minimum TOI during apnoea, duration is duration of TOI 
dip. Coeff= regression coefficient. Regression was performed using the xtgee command of stata6 (146).
Effect Coeff 95% Cl P
TOI min on Acytox -0.010 -0.013,-0.006 <0.001
ATOI on Acytox 0.016 0.010, 0.022 <0.001
Duration on Acytox 0.003 0.002, 0.004 <0.001
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8.5.4 Quantification of CBV
We looked at the size of cerebral blood volume shifts during apnoea, and compared them 
to measured absolute cerebral blood volume from previous NIRS studies. Quantification 
of changes in CBV during apnoea showed mean (± SD) CBV changes ranging from 0.41 ± 
0.13 to 0.09 ± 0.07 ml/lOOg in the 8 patients (see table 24). The value of absolute blood 
volume in the normal adult brain using NIRS techniques ranges from 1.1 -  2.85 ml/lOOg 
(154, 155), so at most this would equate to a shift of about a third of the blood volume.
Table 24. Mean changes in CBV during apnoea for 8 patients (29- 40 apnoeas/patient).
TOI = tissue oxygenation index, CBV = cerebral blood volume, changes are during apnoea defined as TOI 
dip. Patients are numbered in order of mean TOI change, with ID number from validation study 1 in 
brackets.
Patient Mean TOI 
change 
+/-SD (%)
Mean CBV change +/- SD 
(ml/lOOg)
i ( i ) 12.22+/-4.09 0.41 +/- 0.13
2(6) 7.76 +/- 2.82 0.21 +/- 0.10
3(2) 6.93+/-3.14 0.18+/- 0.09
4(10) 5.48 +/- 2.03 0.27 +/- 0.22
5(12) 5.43 +/- 1.62 0.11 +/- 0.05
6(13) 5.30 +/- 0.99 0.10+/- 0.06
7(11) 4.33+/- 1.07 0.09 +/- 0.07
8(3) 4.05 +/- 0.85 0.16+/-0.04
8.5.5 Quantitative correlations of CBV changes.
CBV changes can be used as a proxy for cerebral blood flow changes under some 
conditions. We looked at how cerebral blood volume changes were related to cerebral 
oxygenation measured as TOI as it would be predicted that changes in cerebral blood 
volume would affect cerebral oxygenation. We were also interested in whether CBV 
changes were affected by apnoea duration. The following table shows CBV correlations 
with TOI changes during each apnoea for individual subjects (Table 25).
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Table 25. Regression analysis between change in cerebral blood volume during apnoea 
and TOI parameters for individual subjects.
TOI = tissue oxygenation index, CBV = cerebral blood volume, ATOI and ACBV are changes in TOI and
CBV during apnoea defined as TOI dip, duration is duration of TOI dip, coeff is regression coefficient from
simple linear regression.
id ATOI/ACBV TOI minimum/ACBV Duration/ACBV
coeff r2 P coeff r2 P coeff r P
1 26.5 0.60 0.000 -22.2 0.62 0.000 58.33 0.41 0.000
2 10.29 0.13 0.05 68.97 0.06 0.22 174.1 0.09 0.11
3 16.5 0.26 0.001 -20 0.21 0.002 51.01 0.18 0.005
4 6.07 0.46 0.000 -3.22 0.06 0.13 53.34 0.47 0.000
5 -10.7 0.13 0.02 3.44 0.02 0.39 28.42 0.05 0.18
6 -1.91 0.01 0.49 0.44 0.00 0.87 -23 0.07 0.11
7 2.37 0.02 0.34 -5.11 0.04 0.24 6.29 0.01 0.64
8 5.73 0.08 0.07 -10.6 0.19 0.006 114.0 0.16 0.01
Changes in CBV correlate significantly with ATOI in 5 out of 8 subjects, with minimum 
TOI in 2 out of 8 subjects and with dip duration in half the subjects.
Significant correlations were also seen between CBV change and TOI change, minimum 
TOI and duration, in the whole group (Table 26).
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Table 26. Regression coefficients for effect of CBV difference on TOI minimum,
difference and duration of drop for 303 apnoeas corrected for interpatient 
differences.
TOI = tissue oxygenation index, CBV = cerebral blood volume, cytox = cytochrome oxidase, ATOI, Acytox, 
and ACBV are changes in TOI, cytox and CBV during apnoea defined as TOI dip, TOImin is minimum TOI 
during apnoea, duration is duration of TOI dip. Coeff = regression coefficient. Regression was performed 
using the xtgee command of stata6 (146).
Effect Coeff 95% Cl P
ACBV on Acytox 0.373 0.108, 0.638 0.006
ACBV on TOI min -8.58 -16.13,-1.04 0.026
ACBV on ATOI 9.84 2.95, 16.73 0.005
ACBV on duration 49.07 39.03,59.11 <0.001
8.5.6 Temporal relationship
We wanted to assess how CBV change was temporally associated with TOI change. An 
increase in CBV would not necessarily increase oxygenation as it would depend on the 
saturation of the incoming blood. There are rapid swings in saturation during apnoea so it 
would be possible for incoming blood to increase or decrease overall oxygenation 
depending when during the apnea an increase in cerebral blood flow occurred. Figure 37 
shows an example of one temporal relationship between CBV change and TOI change 
where the two traces are approximately 180 degrees out of phase. Figure 39, from a 
different subject, illustrates the second observed relationship, where CBV change is 
approximately in phase with TOI change.
Figures 40 and 41 show the result of cumulative averaging over consecutive apnoeas of the 
data shown in Figures 37 and 39. This illustrates the two different time relationships; in 
Figure 40 THb maximum occurs close to HHb maximum and TOI minimum; and in 
Figure 41 THb maximum coincides with OHb maximum as well as TOI maximum. 
Cytochrome oxidase changes in both cases are approximately in phase with TOI. The 
average TOI change over these 13 apnoeas is 12.8 in Fig 37 and 3.7 in Fig 39.
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Figure 39. Raw NIRO data from subject 8
TOI = tissue oxygenation index, Cytox = cytochrome oxidase, OHb = oxygenated haemoglobin, HHb = 
deoxygenated haemoglobin, THb = total haemoglobin (OHb + HHb), all chromophores measured in pM from 
arbitrary baseline, TOI measured in %saturation.
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Figure 40. Cumulative average over consecutive apnoeas in subject 1 (See figure 34 for raw data)
TOI = tissue oxygenation index, Cytox = cytochrome oxidase, OHb = oxygenated haemoglobin, HHb = 
deoxygenated haemoglobin, THb = total haemoglobin (OHb + HHb), all chromophores measured in pM from 
arbitrary baseline, TOI measured in %saturation. Cytox enlarged by a factor of 5.
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Figure 41. Cumulative average over consecutive apnoeas in subject 8 (See figure 36 for raw 
data).
TOI = tissue oxygenation index, Cytox = cytochrome oxidase, OHb = oxygenated haemoglobin, 
HHb = deoxygenated haemoglobin, THb = total haemoglobin (OHb + HHb), all chromophores 
measured in pM from arbitrary baseline, TOI measured in %saturation. Cytox enlarged by a factor 
of 5.
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8.5.7 Redox changes in haemoglobin oxidation during CBV increase (OHbratio)
A measure of the distribution of the two patterns in the 303 apnoeas is given by the OHb 
ratio. OHb ratio is the ratio of the change in OHb occurring during the THb rise to the 
change in THB (or how much of the THb rise is oxygenated). In 86 apnoeas the OHbratio 
was less than 0, ie the OHb fell during the total haemoglobin rise, similar to Figure 40. In 
67 apnoeas the OHbratio was >1 ie the HHb fell during the total haemoglobin rise, similar 
to Figure 41. In the remainder both OHb and HHb rose during the THb rise. The mean 
OHb ratio ranged from -0.15 (subject 1 illustrated in Figs 37 and 40) to 0.96 (subject 8, 
illustrated in Figs 39 and 41). The other subjects had a mixture of the two patterns, with 
mean OHbratios of 0.24 -  0.76 (Table 27).
Table 27. Average OHbratio in 8 subjects
OHb = oxygenated haemoglobin, THb = total haemoglobin, OHbratio is the ratio of OHb to THb in the THb 
change during apnoea. ATOI = change in tissue oxygenation index during apnoea
Id Mean
OHbratio
Mean
ATOI
1 -0.15 12.22
5 0.24 5.43
3 0.43 6.93
2 0.47 7.76
7 0.54 4.33
4 0.73 5.48
6 0.76 5.3
8 0.96 4.05
There is a non-significant tendency for a higher mean OHbratio to be associated with a 
lower mean TOI drop in these 8 patients. When the apnoeas were divided into two groups 
above and below mean OHbratio, the effect of CBV change on TOI change was 
significantly greater in the group with low OHbratio (Table 28).
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Table 28. Relationship between change in CBV and TOI change with apnoeas split 
into 2 groups by OHbratio.
CBV = cerebral blood volume, TOI = tissue oxygenation index, OHb = oxygenated haemoglobin, THb =
total haemoglobin, OHbratio is the ratio of OHb to THb in the THb change during apnoea. ATOI and ACBV
= changes in TOI and CBV during apnoea defined as TOI dip. Coeff = regression coefficient from simple
regression.
Effect Coeff 95% Cl P
ACBV diff on ATOI diff (OHbratio > 5.83 3.51,8.16 <0.001
mean)
ACBV diff on ATOI diff (OHbratio < 18.44 11.59, 25.29 <0.001
mean)
If the incoming blood is well oxygenated it may partially compensate for the drop in 
cerebral oxygenation due to fall in SaC>2 . If however the incoming blood is poorly 
oxygenated (because the CBF increase occurs at the end of the apnoea when in some 
subjects Sa0 2  is very low) then it may exacerbate the cerebral hypoxia due to reduced 
SaC>2 . This early pilot work suggests that the CBF increase could both compensate and 
exacerbate hypoxia during apnoeas and that some patients had predominantly 
compensation, some exacerbation and some a mixture. However this work was based on 
tHb as a proxy for CBF and there are theoretical problems with this, principally 
extracranial contamination of the signal. We therefore went on to look at the effect of CBF 
change on TOI in more detail in a further validation study (Chapter 9).
8.6 SUMMARY
8.6.1 Changes in intracellular redox state measured using cytochrome oxidase 
redox state are seen during obstructive sleep apnoea.
In this chapter we demonstrated changes in cytochrome oxidase oxidation state that occur 
during apnoea and correlate with changes in cerebral oxygenation measured as TOI. These 
changes were small (0.13 -  0.48 micromolar) but are interesting as a demonstration of 
changes in intracellular metabolism during OSA.
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8.6.2 There is not a fixed temporal relationship between changes in total
haemoglobin and measures of oxygenated haemoglobin during obstructive 
sleep apnoea
Using the haemoglobin signals from NIRS it is possible to derive a total haemoglobin 
measurement (OHb + HHb). Changes in THb in the field studied can be assumed to be 
due to changes in cerebral blood volume. If cerebral blood flow is not being measured, 
these CBV changes can be used as a proxy for CBF changes. We described changes in 
CBV during apnoea of 0.41-0.09 ml/lOOg and showed an overall correlation between CBV 
changes and TOI changes. We explain this by postulating that changes in CBF will affect 
cerebral oxygenation. We also showed that the proportion of Ohb in the THb change 
varies in different apnoeas, and quantified this proportion as Ohbratio. This variation 
occurs because there are cyclical changes in both Sa02 and CBF during repetitive apnoeas, 
and the extent of desaturation varies between different subjects. We showed that a 
negative Ohbratio was associated with a bigger TOI dip, and this is consistent with the 
suggestion that in some apnoeas haemodynamic changes exacerbate rather than 
compensate for hypoxia. This reinforces the idea that these CBF changes are largely 
passive rather than autoregulatory and that they do not necessarily even partially protect 
the brain from hypoxia.
We also used the technique of cumulative averaging to illustrate two different patterns of 
TOI change and THb change during apnoea, showing by another method that in some 
apnoeas the THb change occurs at maximum TOI (and may compensate for hypoxia) and 
in others it occurs at minimum TOI (and may exacerbate hypoxia). The initial hypothesis 
was therefore shown to be false. This finding adds to the evidence supporting the fact that 
measuring cerebral oxygenation during OSA provides more information than pulse 
oximetry alone.
This is a large amount of very detailed analysis on the raw NIRO data. In order to proceed 
further in investigating the importance of cerebral blood flow changes in cerebral 
oxygenation in OSA it was necessary to measure cerebral blood flow more directly. The 
relationship between pulse oximetry, NIRO and Doppler cerebral blood flow velocity is 
described in the next chapter.
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9. PROTOCOL AND RESULTS OF SECOND
VALIDATION STUDY USING NIRS IN OSA 
WITH SIMULTANEOUS MEASUREMENT 
OF DOPPLER CEREBRAL BLOOD FLOW
VELOCITY.
9.1 OVERALL HYPOTHESIS
9.1.1 Measurement of cerebral oxygenation using near-infra red spectroscopy 
gives additional valid information compared to measurement of arterial 
oxygen saturation alone
9.2 INTRODUCTION
This chapter contains a description of underlying hypotheses, protocols, data analysis and 
results of the second validation study which aimed to validate the NIRO 300 as a measure 
of intracerebral oxygenation in OSA using Doppler cerebral blood flow velocity 
measurements (CBFV). 8 subjects underwent NIR cerebral oxygen monitoring with 
simultaneous measurement of pulse oximetry, CBFV using Doppler, laser Doppler flow, 
arterial blood pressure and airflow during daytime naps.
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9.3 HYPOTHESES UNDERLYING ANALYSIS.
9.3.1 Background.
The second validation study was carried out with two main aims. Our neurosurgical 
collaborators were interested in validation of the NIRO300 in a physiological system other 
than carotid endarterectomy. In their previous validation studies in neurosurgery both 
Sa02 and ABP were constant and controlled (111). Validation was based on showing the 
TOI to be affected by changes in intracranial circulation (CBFV) and not by changes in 
extracranial circulation (measured as cutaneous circulation using laser Doppler flow). 
CBFV is affected by ABP changes, although it also depends on autoregulatory changes, 
whereas cutaneous flow is passively dependent on ABP. We would therefore predict that 
TOI would be more closely related to CBFV than to ABP in sleep apnoea, and that LDF 
measurements would be related to ABP. Validation of the NIRO300 will depend on these 
relationships and also on the temporal relationships between the changes of these 
parameters. As researchers into sleep apnoea physiology, our aim was to see if the CBFV 
changes which are known to occur in sleep apnoea are associated with cerebral 
oxygenation changes, and if so whether they compensated for or exacerbated the effects of 
arterial hypoxaemia on cerebral oxygenation. The analysis required to achieve both these 
aims was very similar; they are, in a way, two ways of interpreting the same results.
9.3.2 TOI changes are affected by changes both in cerebral blood flow and in 
arterial saturation.
This was investigated by examining the relationship between TOI, CBFV and Sa02. 
Theoretically cerebral oxygenation depends on both arterial saturation and cerebral blood 
flow. This analysis has the dual aim of demonstrating this relationship for the first time 
during the dynamic changes that occur in OSA and validating the NIRO300 TOI as a 
measure of cerebral oxygenation.
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9.3.3 TOI changes are not affected by extracranial changes
This was investigated by examining the interrelationships of ABP, LDF, CBFV and TOI, 
to see if TOI is obviously affected by extracranial changes. This was done both by looking 
at absolute changes in parameters during apnoea, and also looking at the temporal 
relationships using cumulative averaging as described below. We were also able to look at 
the effects of etC02 on TOI and CBFV.
9.3.4 THB (relative cerebral blood volume) can be used as a proxy for changes in 
CBFV, (as used in chapter 8).
We were able to check using the CBFV readings whether the assumption that THb could 
be used as a proxy for cerebral blood flow was valid. We were also interested in checking 
the validity at OHbratio,a measure of the redox status of the change in total haemoglobin 
which occurs during apnoea, which was postulated to influence the effect of the increased 
cerebral blood flow on cerebral oxygenation during apnoea (see chapter 8).
9.3.5 Changes in cytochrome oxidase redox state during obstructive sleep apnoea 
are related to cerebral oxygenation measured independently of NIRS
We related changes in cytochrome oxidase redox state to changes in CBFV and in SaC>2 
during apnoea. We had shown in chapter 8 relationships between cerebral oxygenation as 
TOI and changes in cytox redox state during OSA. As both were measured using NIRS, 
we wished in this second validation study to relate cytox to components of cerebral 
oxygenation (Sa02 and CBFV) measured independently of NIRS.
9.4 COLLABORATION
This study was carried out in collaboration with Mr P Kirkpatrick and the University 
Department of Neurosurgery, Addenbrooke’s Hospital. The study was performed by 
myself and Pippa Al-Rawi, Research Associate from the Department of Neurosurgery, 
Addenbrooke’s, under the supervision of Mr Kirkpatrick (Cambridge) and Professor S 
Spiro and Dr H Makker (UCLH). Work was carried out in the Sleep Unit at the Middlesex 
Hospital over a period of 2 weeks in October 2000.
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9.5 SUBJECTS
8 men with significant OS A (mean 4% oxygen desaturation dip rate 71 +/- 19) and no 
known cerebrovascular disease problems were recruited from our sleep clinic population. 
One subject with mild OS A also participated at short notice. Suitable subjects with severe 
OSA were informed of the opportunity to participate in the study by letter and telephone. 
An attempt was made to contact the people who had participated in the previous study of 
whom 5 agreed to participate. Seven stopped using their therapeutic CPAP 2 nights prior 
to the study, two were not on current treatment. Venous blood was drawn for full blood 
count at the time of the study. Characteristics and comorbidities of the subjects are shown 
in table 29 and 30.
Ethical approval was granted by the relevant ethics committee and all subjects gave written 
consent.
Table 29. Subjects who took part in second validation study.
Subjects who also took part in the first validation study are marked with an asterisk. All were men.
ID Age
/yrs
BMI
kg/m2
Dip rate 
/hr
ESS Hb/
g/dl
CPAP
l.CM* 57 33.8 66 19 13.1 Y
2.DH 48 47.7 66 15 14.7 Y
3.DS* 57 31.5 40 15 15.7 Y
4.GD* 44 36.8 74 14 15.7 Y
5.JP 56 43.9 45 8 15.3 N
6.PH* 32 36.6 87 19 15.4 Y
7.SM* 40 39.1 95 21 15.3 Y
8.SZ 56 16 13.6 N
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Table 30. Comorbidity of subjects
ID Cerebrovascular
disease
Ischaemic
heart
disease
hypertension
CM 1 n y n
DH 2 n n n
DS 3 n n n
GD 4 n n n
JP 5 n n y
PH 6 n n n
SM 7 n n n
SZ 8 n y y
9.6 PROTOCOL FOR RECORDING AND ANALYSIS
9.6.1 Recording protocol
The following monitoring devices were used as described in chapters 3 and 4:
(a) NIRO 300, recording oxygenated and deoxygenated haemoglobin, cytochrome oxidase 
and TOI signals every 2 seconds into a data acquisition system.
(b) Pulseox 7 (Minolta, now Anandic Medical Systems, Diessenhofen, Switzerland) 
pulse oximeter using both finger and ear probes.
(c) Middle cerebral artery flow velocity using a transcranial doppler probe (PCDop 842, 
Scimed, Bristol, UK) over the middle cerebral artery, held in place by a custom-made 
head-band.
(d) Scalp blood flow using laser doppler flowmetry (MBF3D monitor and modified P3 
probe, Moor Instrument Ltd, Axminster, Devon, UK), with the probe placed in the 
immediate vicinity of the NIR optodes.
(e) Blood pressure was monitored continuously using a non-invasive Finapres BP monitor 
(Ohmeda 2300, Boulder Colorado USA).
(f) End tidal carbon dioxide monitoring, using Capnosleep, (Weinmann, Germany).
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(g) Sleep staging, using EEG, EOG, EMG (S Series Sleep System, Compumedics®, 
Melbourne, Victoria, Australia)
The monitoring equipment was connected and subjects were asked to lie down in a 
darkened side room and allowed to sleep for up to 2 hours. The Doppler probe was sited 
by an experienced operator and continuously observed throughout the recording period.
All the parameters were simultaneously recorded onto a data acquisition system, except for 
the EEG, EOG and EMG which were recorded on to the polysomnography computer.
9.6.2 Methods for analysis
Sleep was staged using standard criteria. Data from one subject was unusable for technical 
reasons. One subject (Subject 8) did not demonstrate any obstructive events during 52 
minutes of sleep and his data were analysed separately. Apnoeas were defined as cessation 
of airflow for 10s from the capnogram trace. For the remaining 7 subjects, baseline values 
of Sa02, cerebral blood flow velocity (CBFV), mean arterial blood pressure (ABP), and 
tissue oxygenation index (TOI) were obtained by averaging values over 10 seconds from 
the initial part of the recording while the subjects were awake. Maximum and minimum 
values of Sa02, CBFV, ABP, TOI, cytochrome oxidase and total haemoglobin were 
recorded for each apnoea that occurred during sleep in these 7 subjects (287 apnoeas in 
total, 6-59 per subject). EtC02 was recorded before and after each apnoea. Absolute 
changes in each parameter were then calculated for each apnoea and averaged for each 
subject. The relationship between changes in TOI and changes in CBFV, ABP, Sa02 and 
total haemoglobin, were examined, initially using a single independent variable and then 
multiple variables, using two level regression adjusting for subject (111). Relationships 
between etC02 and both CBFV and TOI were also examined. The relationships between 
changes in CBFV, ABP and total haemoglobin were examined, as were those between 
changes in CBFV, Sa02 and cytochrome oxidase.
OHbratio was calculated as described in chapter 5 as the change in OHb which occurred 
during the THb rise, expressed as a fraction of the THb rise and signed to distinguish 
between a rise and a fall in OHb.
In 5 subjects who all showed runs of consecutive apnoeas, a cumulative average of 
readings of CBFV, ABP, TOI, Sa02 and laser Doppler flow from the raw data was
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calculated over a run of consecutive apnoeas (9-18 apnoeas). This cumulative average was 
then plotted to illustrate the time relationship between the changes.
Twenty-six episodes of repetitive change in CBFV were analysed for the subject who did 
not demonstrate oxygen saturation changes (subject 8). For each of these episodes, 
maximum and minimum SaC>2, TOI, CBFV and ABP were recorded, and changes in these 
parameters were compared using regression analysis as above.
9.6.3 Statistics
Baseline variability was assessed using coefficient of variability.
Changes in parameters and mean minimum and mean preapnoea values of TOI were 
expressed as mean plus SD.
Changes in parameters were analysed separately in each subject using scatterplots to check 
the relationships were approximately linear followed by simple regression analysis. 
Apnoeas were then combined as described previously in a two level regression adjusting 
for subject.
Cumulative averaging was used for illustrative purposes only and significance testing was 
not performed.
Acceptable level of significance was taken as p<0.05.
9.7 RESULTS
9.7.1 Descriptive sleep data
Descriptive sleep data was available for 7 of the 8 subjects whose data were analysed 
(Table 31). They slept for an average of 57 minutes (range 12 to 83). One subject had a 
sleep latency of 45 minutes, in the remainder sleep latency was < 5 minutes. No subjects 
demonstrated REM sleep during these daytime naps. Mean AHI during the recording was 
66 (range 34 -  118). Respiratory event data is given in Table 32.
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Table 31. Descriptive sleep data for subjects.
The staging polysomnography was technically inadequate for subject 7. REM = rapid eye movement, n/a = 
not available.
ID Sleep
latency/min
Total
sleep/min
Stage 1 
min
Stage2
min
Stage 3 
min
Stage4
min
REM
min
CM 1 0.3 82.7 41.7 41 0 0 0
DH 2 2.3 53.7 7.0 27.0 19.7 0 0
DS 3 0 12.0 11.7 0.3 0 0 0
GD 4 0.3 74.7 19.0 54.7 1.0 0 0
JP 5 1.3 49.3 6.3 30.3 12.3 0.3 0
PH 6 0.3 70.0 1.3 33.3 35.3 0 0
7 n/a
SZ 8 0 52.3 8.0 18.3 26 0 0
Table 32. Respiratory event data for 7 of 8 subjects.
Mean min sat = mean minimum Sa02 during apnoea, av desat = average Sa02 desaturation during apnoea.
ID Apnoea Hypopnoea AHI Mean Av Mean
index index /hour min sat desat apnoea
/hour /hour duration/s
1 49.4 8.7 58.1 88.1 7.2 21
2 33.3 43.3 76.7 84 9.5 14.5
3 20.0 15.0 35.0 89 3 12.9
4 71.5 6.4 77.9 84 9.5 17.6
5 29.2 4.9 34.1 86.3 5.7 15.9
6 95.1 23.1 118.3 85 4.5 16.8
7
8 0 0 0 90.6 0 0
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9.7.2 Baseline measurements, variability and changes during apnoea (TOI, Sa02, 
CBFV, ABP)
Baseline mean arterial blood pressure ranged from 75.7-106.6 mmHg (Table 33) and the 
changes during apnoea ranged from 17.5+/- 6.1 to 30.6+/-7.5 mmHg (Table 34). The 
range of baseline CBFV was 30.2 - 78.6m/s, where changes during apnoea (ACBFV) 
ranged from 12.5 +/- 3.4 to 30.2 +/- 6.0m/s. The maximum drop in CBFV as a fraction of 
baseline ranged from 32 to 50% for the 7 subjects, with a mean drop of 8 to 40%. Baseline 
Sa02 values were all above 94% (range 94.8-99.6) where baseline TOI values ranged from 
60.8-84.0. The range of mean Sa02 drops (A Sa02) during apnoea was 1.7 +/- 0.4 to 12.1 
+/- 3.8; that of mean TOI drops (ATOI) was 2.3+/-0.5 to 5.0+/- 2.0 (Table 34).
There was no correlation between values of Sa02 and TOI preceding apnoea, however 
minimum TOI correlated with minimum Sa02 during an apnoea after adjusting for 
interpatient differences (p<0.001, regression coefficient 0.215, 95%CI 0.132-0.298). 
Median coefficient of variation of TOI over 100 observations in 6 subjects was 1.22% 
(range 0.58 -  1.35). The mean coefficient of variation of CBFV in 6 subjects over 100 
observations during unobstructed breathing was 6.7% (range 4.22 -  10.5%).
Table 33. Baseline awake values for measured parameters
ABP = arterial blood pressure, CBFV = cerebral blood flow velocity, Sa02 = arterial oxygen saturation, TOI 
= tissue oxygenation index.
ID ABP mmHg CBFV m/s Sa02 % TOI %
1 75.7 53.2 97.3 67.8
2 87.4 69.2 94.8 72.4
3 82.3 38.1 99.6 82.7
4 87.4 49.7 96.7 73.5
5 102 30.2 95.6 84
6 106.6 78.6 96.5 71.4
7 87 59.8 96.7 60.8
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Table 34. Mean minimum SaC>2 and TOI, mean TOI preceding apnoea, and mean 
changes in ABP, CBFV, Sa02 and TOI during apnoea.
ABP = arterial blood pressure, CBFV = cerebral blood flow velocity, Sa02 = arterial oxygen saturation, TOI
= tissue oxygenation index. Mean min Sa02 and TOI are mean of minimum value for each apnoea, mean
baseline TOI is maximum value preceding each apnoea. AABP, ACBFV, A Sa02 and ATOI are changes
during apnoea, duration is apnoea duration from capnogram.
ID No. of 
apnoeas
Mean min 
Sa02 %
Mean baseline 
TOI %
Mean min 
TOI %
1 54 88.5 +/- 4.7 67.2 +/- 2.5 62.9 +/- 2.6
2 46 87.9 +/- 2.8 68.6 +/- 1.3 64.2 +/-1.7
3 6 96 +/- 0.4 83.3+/-1.7 81 +/- 2.0
4 57 84.8+/- 3.5 76.8 +/- 3.0 71.9+/-2.8
5 16 89.1+/-3.2 81.5+/- 2.9 77.4+/-3.1
6 59 92.2+/- 3.1 71.9+/- 1.2 69.6 +/-1.4
7 49 82.7 +/- 3.9 59.6+/-1.0 56.4+/-1.5
ID No. of 
apnoeas
Mean
AABPmmH
g
Mean
ACBFV
m/s
Mean 
ASa02 %
Mean ATOI 
%
Mean 
duration s
1 54 25.9 +/- 4.9 18.0+/- 4.3 9.1 +/- 4.8 4.3+/- 1.6 25 +/- 8.8
2 46 20.1 +/- 5 23.0+/-3.9 10.6+/- 1.9 4.4+/-1.2 16+/-4.2
3 6 17.5+/-6.1 15.6+/- 4.8 1.7+/- 0.4 2.4 +/- 0.8 11 +/- 3.2
4 57 24.1 +/- 8.7 26.0 +/- 7.3 10.3+/-3.5 5.0 +/- 2.0 16.2+/-5.6
5 16 24.6 +/- 4.2 12.5 +/- 3.4 8.4 +/- 3.3 4.1 +/- 1.4 16.8+/-5.4
6 59 27.6+/-5.5 30.2 +/- 6.0 7.1 +/-3.1 2.3 +/- 0.5 16.6+/- 4.6
7 49 30.6 +/- 7.5 25.5+/-8.1 12.1 +/- 3.8 3.2+/- 1.0 16.8+/- 5.2
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9.7.3 Relationships between changes in TOI and changes in other measured 
parameters
When data was analysed separately for each subject, the relationship between ATOI and 
ACBFV and the relationship between ATOI and A Sa02 were significantly positive in 5 of 
the 7 subjects. The relationship between ATOI and A ABP was significant in 2 subjects. 
Combining all 287 apnoeas using simple regression adjusting for interpatient differences 
the magnitude of ATOI during an apnoea correlated with the magnitude of A SaC>2, 
ACBFV, AABP and duration of apnoea (p<0.001 in all cases; Table 35).
Table 35. Relationships between changes in TOI and changes in other measured 
parameters
ABP = arterial blood pressure, CBFV = cerebral blood flow velocity, Sa02 = arterial oxygen saturation, TOI 
= tissue oxygenation index. Sa02min is minimum value of Sa02 for each apnoea. AABP, ACBFV, A Sa02 
and ATOI are changes during apnoea, duration is apnoea duration from capnogram. OHb = oxygenated 
haemoglobin, THb = total haemoglobin, OHbratio is the ratio of OHb to THb in the THb change during 
apnoea. Pairs of parameters during apnoeas in different subjects were combined in a two level simple 
regression using the xtgee command of stata6(146). Coeff = regression coefficient.
Dependent variable Independent variable Coeff 95% Cl P
ATOI ASa02 0.176 0.112,0.241 <0.001
ATOI ACBFV 0.063 0.043, 0.083 <0.001
ATOI AABP 0.058 0.034,0.081 <0.001
ATOI duration 0.204 0.116,0.293 <0.001
ATOI OHbratio -0.271 -0.734,0.191 0.25
ATOI Sa02min -0.189 -0.245,-0.133 <0.001
As mentioned before, trying to separate intracranial and extracranial contributions to TOI 
changes is complicated by the changes in ABP and Sa02 during apnoea which are 
associated with/cause change in CBFV (Table 36).
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Table 36. Relationships between changes in CBFV and changes in other measured 
parameters.
ABP = arterial blood pressure, CBFV = cerebral blood flow velocity. Sa02min is minimum value of Sa02 
for each apnoea. AABP, ACBFV are changes during apnoea, duration is apnoea duration from capnogram. 
Pairs of parameters during apnoeas in different subjects were combined in a two level simple regression 
using the xtgee command of stata6(146). Coeff = regression coefficient.
Dependent variable Independent variable Coeff 95% Cl P
ACBFV AABP 0.379 0.308,0.450 <0.001
ACBFV duration 0.618 0.078,1.16 0.03
ACBFV Sa02min -0.515 -0.857,-0.174 0.003
Using multiple regression including duration, ACBFV and A SaCh as independent 
variables, these 3 factors retained a significant effect on ATOI difference (Table 32).
Table 37. Two level regression models showing effect of ACBFV, duration and ASaC>2 
on ATOI
CBFV = cerebral blood flow velocity, Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index. 
Parameters during apnoeas in different subjects were combined in a two level multiple regression using the 
xtgee command of stata6(146). Coeff = regression coefficient.
Independent Coeff 95%CI P
variable
Duration 0.137 0.055,0.219 0.001
ACBFV 0.015 0.003,0.014 0.012
A SaC>2 0.129 0.053,0.206 0.001
9.7.4 Cytochrome oxidase and THb measurements
Cytochrome oxidase measurement started from an arbitrary baseline of 0 at the beginning 
of each recording. Concentration changes in cytochrome oxidase ranged from 0.18±0.08 
to 0.08±0.03pM (Table 38). The median standard deviation of the cytox signal during 2
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minutes (120 observations) of non-obstructed breathing in 6 subjects was 0.046 pM (range 
0.021 to 0.076). Changes in THb ranged from 1.0 +/- 0.78 to 2.9 +/-1.5jjM.
Table 38. Measured changes in cytox and THb during apnoea.
Cytox = cytochrome oxidase, ThB = total haemoglobin, TOI = tissue oxygenation index. Acytox, ATHb and 
ATOI are changes occurring during apnoea defined by capnogram trace.
ID No. of Mean Acytox Mean Mean ATOI
apnoeas pM ATHb
pM
1 54 0.08 +/- 0.03 1.0+/- 0.78 4.3 +/-1.6
2 46 0.14+/-0.06 1.1 +/-0.3 4.4+/- 1.2
3 6 0.11 +/-0.06 1.5+/- 0.4 2.4 +/- 0.8
4 57 0.17+/- 0.08 2.2+/- 1.0 5.0 +/- 2.0
5 16 0.17+/- 0.1 2.8+/- 1.6 4.1 +/-1.4
6 59 0.14+/- 0.08 2.9+/- 1.5 2.3 +/- 0.5
7 49 0.19+/- 0.08 2.2 +/- 0.9 3.2+/-1.0
Changes in THb were much better correlated with changes in ABP than with changes in 
CBFV. Cytox changes correlated with changes in TOI, CBFV and Sa02 (p<0.01) and with 
ABP (p<0.05) (Table 39).
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Table 39. Relationships between changes in cytox and THb and other measured 
changes.
ABP = arterial blood pressure, CBFV = cerebral blood flow velocity, Sa02 = arterial oxygen saturation, TOI 
= tissue oxygenation index, cytox = cytochrome oxidase, THb = total haemoglobin. AABP, ACBFV, A 
Sa02, ATOI, Acytox and ATHb are changes during apnoea, duration is apnoea duration from capnogram. 
Pairs of parameters during apnoeas in different subjects were combined in a two level simple regression 
using the xtgee command of stata6(146). Coeff = regression coefficient.
Dependent variable Independent variable Coeff 95% Cl P
ATHb ACBFV 0.275 0.007,0.542 0.044
ATHb AABP 0.352 0.150,0.555 0.001
ATOI ATHb 0.028 -0.013,0.068 0.18
Acytox ATOI 0.432 0.160,0.704 0.002
Acytox ACBFV 0.083 0.035,0.130 0.001
Acytox ASa02 0.189 0.105,0.272 <0.001
Acytox duration 0.125 -0.114,0.363 0.3
Acytox AABP 0.076 0.007,0.146 0.03
9.7.5 OHbratio
Unlike in the previous validation study, OHbratio did not predict the steepness of the 
relationship between ATOI and either ATHb or ACBFV.
9.7.6 End tidal CO2
The etC02 immediately preceding apnoea correlated with the maximum CBFV during 
apnoea (regression coefficient 0.156 (0.031-0.281) p=0.015), but there were no significant 
correlations with the etC02 following apnoea, or between TOI and etC02 variables. A 
possible correlation between etC0 2  at the start of apnoea and change in cytochrome redox 
state was found (regression coefficient -0.068, 95% Cl -0.137 - 0.001, p=0.053),but no 
relationship between etC0 2  at the end of apnoea and cytochrome changes.
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9.7.7 Cumulative average
The use of 2 point correlations to compare changes in different parameters is a simplified 
method for analysis, as changes in Sa02 and CBFV occur at different times during the 
apnoea and may be separately reflected in the TOI trace. One subject shows a biphasic 
waveform for TOI particularly clearly (subject 2, Fig 42). A cumulative average of these 
apnoeas is shown in Fig 43. Fig 43 also shows ABP and LDF averaged traces, and 
illustrates graphically that the ABP and LDF traces lag behind the CBFV and TOI traces.
In Fig 43 Sa02 maximum occurs at timepoint 3, TOI and CBFV maxima at time point 11, 
and ABP and LDF maxima at time point 15. In 4 other subjects who showed consecutive 
apnoeas, the lag between the CBFV and ABP traces is less obvious, but in 3 subjects 
(subjects l,Fig 44; 4, Fig 45; 7,Fig 46) the TOI trace can be seen to rise during the initial 
part of the CBFV rise and then fall as CBFV and ABP reach a maximum. In the 4th 
subject (subject 6, Figure 47) the CBFV peak is reached early during the Sa02 desaturation 
and there is minimum alteration in the averaged TOI trace. Subjects 3 and 5 had only 6 
and 16 apnoeas respectively and did not demonstrate any runs of consecutive events.
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Figure 42. Raw data from subject 2
This illustrates the raw data output recorded every 2s. Abp = (mean) arterial blood pressure, fv = cerebral blood 
flow velocity, Sa02 = arterial oxygen saturation, toi = tissue oxygenation index. Units on the y axis are mmHg 
for abp, m/s for fV, % for Sa02 and % for TOI.
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Figure 43. Cumulative average for subject 2 (16 apnoeas)
16 apnoeas averaged every 2s with minimum Sa02 at time 0 to illustrate the temporal relationship of changes in 
different parameters. Sat = arterial oxygen saturation, toi = tissue oxygenation index, cbfv = cerebral blood 
flow velocity, abp = (mean) arterial blood pressure, ldf = laser doppler flow. Units on the y axis are % for 
Sa02and % for TOI, m/s for cbfv, mmHg for abp, and arbitrary units for ldf.
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Figure 44. Cumulative average from subject 1 (10 apnoeas)
10 apnoeas averaged every 2s with minimum Sa02 at time 0 to illustrate the temporal relationship of changes in 
different parameters. Sa02 = arterial oxygen saturation, toi = tissue oxygenation index, cb f= cerebral blood 
flow velocity, abp = (mean) arterial blood pressure, ldf = laser doppler flow. Units on the y axis are % for Sa02 
and % for TOI, m/s for cbf, mmHg for abp, and arbitrary units for ldf.
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Figure 45. Cumulative average from subject 4 (9apnoeas)
9 apnoeas averaged every 2s with minimum Sa02 at time 0 to illustrate the temporal relationship of changes in 
different parameters. Sa02 = arterial oxygen saturation, toi = tissue oxygenation index, fv = cerebral blood 
flow velocity, abp = (mean) arterial blood pressure, ldf = laser doppler flow. Units on the y axis are % for Sa02 
and % for TOI, m/s for fv, mmHg for abp, and arbitrary units for ldf.
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Figure 46. Cumulative average for subject 7 (16 apnoeas)
16 apnoeas averaged every 2s with minimum SaC>2 at time 0 to illustrate the temporal relationship of changes in 
different parameters. Satshift = arterial oxygen saturation, toi = tissue oxygenation index, fv = cerebral blood 
flow velocity, abp = (mean) arterial blood pressure, ldf = laser doppler flow. Units on the y axis are % for 
satshiftand % for TOI, m/s for fV, mmHg for abp, and arbitrary units for ldf. A finger oximeter was used in this 
subject because of poor recordings from the ear oximeter so saturation has been corrected for 20s timelag 
between finger and ear oximeter.
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Figure 47. Cumulative average for subject 6 (15 apnoeas)
15 apnoeas averaged every 2s with minimum Sa02 at time 0 to illustrate the temporal relationship o f changes in 
different parameters. Sat = arterial oxygen saturation, toi = tissue oxygenation index, fv = cerebral blood flow 
velocity, abp = (mean) arterial blood pressure, ldf = laser doppler flow. Units on the y axis are % for sat and % 
for TOI, m/s for fv, mmHg for abp, and arbitrary units for ldf.
no -—
100
0 •  10 11 12 13 1* 10 16 17 1665 72 3 41
9.7.8 Subject 8 (CBFV changes without Sa02 changes)
Data from subject 8 who had changes in CBFV without saturation changes were analysed 
separately. His raw data is shown in Fig 48. In 26 events the average change in ABP was 
15.6+/- 3.6; in CBFV was 9.5 +/- 2.7, in Sa02 was 0.8 +/- 0.7 and in TOI was 2.7 +/- 0.9.
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Correlations between TOI difference and differences in Sa02 and ABP were not 
significant; however correlation between magnitude of change in CBF and in TOI was 
significant (p=0.005, regression coefficient 1.52, 95%CI 0.51-2.54). Cumulative average 
is shown in Figure 49.
Figure 48. Raw data from subject 8 during period of repetitive change in CBFV
This illustrates the raw data output recorded every 2s. Abp = (mean) arterial blood pressure, fv = cerebral blood 
flow velocity, Sa02 = arterial oxygen saturation, toi = tissue oxygenation index. Units on the y axis are mmHg 
for abp, m/s for fv, % for Sa02 and % for TOI.
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Figure 49. Cumulative average from subject 8 (15 episodes CBFV change)
15 episodes of CBFV (cerebral blood flow velocity) change averaged every 2s with minimum fv at time 0 to 
illustrate the temporal relationship of changes in different parameters. Abp = (mean) arterial blood pressure, fV 
= cerebral blood flow velocity, sat = arterial oxygen saturation, toi = tissue oxygenation index, ldf = laser 
Doppler flow. Units on the y axis are mmHg for abp, m/s for fv, % for Sa02, % for TOI and arbitrary units for 
ldf.
100
90
80
70
60
50
4 0
t im e /2 s
fv
abp
sat
toi
ldf
168
9.8 CONCLUSIONS FROM THESE RESULTS
9.8.1 TOI changes are affected by changes both in cerebral blood flow and in 
arterial saturation.
TOI depends on both CBFV and Sa02. We showed this in multiple regression in 7 
subjects (287 apnoeas), and also in subject 8 where Sa02 was effectively constant, changes 
in CBFV were associated with changes in TOI.
9.8.2 TOI changes are not affected by extracranial changes
Changes in arterial blood pressure will affect the extracranial circulation which can be 
assessed using laser Doppler flowmetry. Changes in cerebral blood flow should affect the 
intracranial circulation and it may be possible to assess this using TOI. The association 
between CBFV and ABP changes and the occurrence of both changes during apnoea 
means that it is difficult to demonstrate changes in TOI due to changes in CBFV 
independent of changes in ABP using crude measurements of maximum change during 
apnoea. Cumulative averaging suggests a closer temporal relationship between TOI 
changes and CBFV changes than ABP changes. In subject 8 correlations between TOI 
changes and ABP changes were not significant. There was no relation between LDF 
measurements and TOI measurements in subject 2. Our results do not rule out the high 
specificity of the NIRO 300 for intracranial changes previously found.
9.8.3 THB (relative cerebral blood volume) can not be used as a proxy for changes 
in CBFV, (as used in chapter 8).
These results suggest that the NIRO THb measurements are closely related to ABP 
measurements and so may reflect extracranial blood flow changes more than TOI does.
The OHbratio measurement did not appear useful in explaining the physiology in this 
group. It aims to describe what fraction of the incoming blood during the CBF surge 
towards the end of apnoea is oxygenated, however it depends on the assumption that the 
change in THb comes from a change in CBF, which may not be the case. Also in the 
previous validation very low OHb ratios were reached by two subjects during REM sleep 
so the range was much higher.
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9.8.4 Changes in cytochrome oxidase redox state during obstructive sleep apnoea 
are related to cerebral oxygenation measured independently of NIRS
Cytox measurements made in this validation study are similar to those made in the 
previous validation study. The associations found here between cytox changes and 
changes in CBFV and in SaCh, support a real rather than artefactual explanation of the 
observed changes.
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10. SUBJECTS AND PROTOCOLS FOR
STUDY COMBINING NOCTURNAL NIRS 
MEASUREMENTS WITH OBJECTIVE 
NEUROPSYCHOLOGICAL TESTING
10.1 OVERALL HYPOTHESIS
Measurement of cerebral oxygenation using near-infra red spectroscopy gives more valid 
information than measurement of arterial oxygen saturation alone.
The hypothesis underlying the prospective trial protocol was that measurement of cerebral 
oxygenation using NIRS would be a better predictor of neuropsychological function than 
arterial saturation, but the neuropsychological results are not presented in this thesis.
10.2 INTRODUCTION
This thesis includes details of how the NIRO300 output was used to compare cerebral 
oxygenation between patients in a prospective study also using neuropsychological testing. 
Neuropsychological results are not included in this thesis. An outline of the study protocol 
is given here. The prospective study was entitled “Impact of obstructive sleep apnoea on 
cerebral oxygenation, measured by near-infrared spectroscopy, and the consequences for 
neuropsychological function” and the protocol was designed in collaboration with Prof S 
Newman and the Unit of Health Psychology at UCL between 1999 and 2000, while 
validation studies were taking place. This study assessed neuropsychological function, 
objective sleepiness, conventional polysomnographic measures of OS A severity, and
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cerebral oxygenation using near infrared spectroscopy, in a group of patients with OSA 
before and after CPAP therapy, using a group of snorers as a comparison group for the 
neuropsychological tests.
10.2.1 Subject selection
Consecutive referrals to a sleep new patient clinic for possible obstructive sleep apnoea 
were recruited to the study, prior to any overnight sleep investigations. Inclusion criteria 
were all consenting subjects who were undergoing a screening sleep study for possible 
OSA because of snoring or daytime symptoms, irrespective of Epworth sleepiness score or 
reported snoring or witnessed apnoea. Referrals came for GPs, or other hospital 
specialties, mainly ENT or endocrinology. Exclusion criteria were cerebrovascular disease 
with residual disability, significant heart failure, significant chronic obstructive pulmonary 
disease, metabolic encephalopathy, untreated psychiatric disorder, insufficient command of 
the English language to perform the neuropsychiatric tests (which require literacy and 
verbal fluency), insufficient hearing or visual acuity for the neuropsychological tests.
10.2.2 Study visits
Visit 1 (DAYTIME)
All patients referred with suspected sleep apnoea were invited to attend a research 
clinic on a Thursday morning. At this clinic, following a routine history and examination, 
they were given information about the study, and were invited to consent to participate. 
Initial investigations (full blood count, thyroid function tests, spirometry, 
electrocardiogram, blood pressure) were performed at this stage.
Visit 2 (DAYTIME)
A neuropsychological assessment, using specially selected tests, were performed by 
a psychologist on all subjects, taking about 40minutes. Following this the subject had an 
Osier maintenance of wakefulness test performed supervised by the research fellow. They 
were asked to complete an Epworth Sleepiness Scale.
Visit 3 (OVERNIGHT)
A Visilab sleep study was carried out, in sleep study rooms at the Middlesex 
Hospital. This sleep study was analysed in the context of the clinical features to diagnose 
if the subject had obstructive sleep apnoea or was a simple snorer. Diagnosis of OSA was 
based on a dip rate >10, with confirmed apnoeas on video, and daytime symptoms. OSA
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patients had a repeat visilab study on CPAP the following night to determine the 
effectiveness of CPAP in abolishing apnoeas.
Visit 4 (OVERNIGHT) (OSA ONLY)
Subjects with OSA were invited for an overnight polysomnography study with 
simultaneous NIRS (near infra red spectroscopy) measurements. The following morning 
each subject was shown how to use CPAP and loaned a CPAP machine, fitted with 
compliance monitoring.
Subjects were contacted weekly by telephone to check compliance, mask problems,etc. 
Visit 5 (DAYTIME)
After 4 weeks OSA patients and snorers as a comparison group underwent repeat 
neuropsychological assessment, Osier maintenance of wakefulness test and Epworth 
Sleepiness Scale.
Visit 6 (OVERNIGHT) (OSA ONLY)
After 4 weeks of treatment subjects with OSA had a repeat polysomnography and 
NIRS measurements performed while using CPAP. CPAP compliance was recorded.
10.2.3 Osier Maintenance of Wakefulness test.
The Oxford sleep resistance test (Osier test, Stowood Scientific Instruments, 
Oxford, UK) (35) was chosen as the objective test for assessment of wakefulness in this 
study. It is a behavioural test, rather than being based on polysomnographic criteria of 
sleep onset, and is therefore simpler to administer and less operator dependent. The 
standard instructions are the same as a conventional maintenance of wakefulness test: the 
subject is asked to lie semirecumbent in a dark room and asked to remain awake. They are 
asked to press a switch (touch sensitive) in response to a small regularly illuminated light 
emitting diode lit for Is every 3 s. If there is no response for 7 illuminations (21s), the 
computer beeps and the test is ended. The test is terminated at 40mins if not asleep. 
Subjective sleepiness was also assessed using the Epworth Sleepiness score (36).
10.2.4 Neuropsychological testing
A battery of tests were selected by the Unit of Health Psychology, University College, 
London. Particular tests were selected because they examine the domains previously 
shown to be affected in OSA. I was not involved in the test selection or administration as
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they were all administered by a trained psychologist from the Unit of Health Psychology, 
UCL.
10.2.5 CPAP machines
Pressure titration was performed manually followed by an in-patient night on CPAP with 
oximetry or visilab monitoring to ensure diprate correction. The machine used was the 
ResMed CPAP S6 which monitors compliance with a pressure sensor (mask on time), 
rather than just recording the hours the machine is switched on. Compliance was read on 
the day of the repeat neuropsychological tests to give total days of loan, average use in 
total, percentage of total days when machine used, and average use on usage days.
10.2.6 Analysis
Summary cerebral oxygenation measures were derived from the overnight recordings for 
use in regression analysis. Regression analysis was used to predict neuropsychological 
score pre treatment using age, education, sleepiness, AHI and cerebral oxygenation. 
Regression analysis was also employed to predict neuropsychological outcome post 
intervention using sleepiness, AHI and cerebral oxygenation as predictors. The derivation 
of summary measures is described in this thesis, but the results of neuropsychological 
testing are not.
The following tables (Tables 40-44) give descriptive data for each subject with OSA who 
was offered polysomnography with NIRO monitoring, including demographic and clinical 
data, sleepiness data, polysomnography data and compliance data.
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Table 40. Demographic and descriptive data for subjects with OSA in prospective study
BMI = body mass index, f  = female, all other subjects male.
Id
number
Age/yr Smoke/day Alcohol
Units/week
Coffee
Cups/day
Height 
hn
Weight
/kg
BMI
kg/m2
Collar size 
cm
Blood
pressure
mmHg
1 59 3 50 1 1.8 81 25 - 140/92
2 54 Ex 3 0 1.66 87 31 17.5 120/70
3 55 Never 16 1 1.82 93 28 16.5 -
4 54 Ex 56 1 1.8 123 37 - 140/75
6 f 51 3 15 1 1.73 85 27 - 140/85
7 28 Never - 0 1.75 135 44 - 140/95
8 43 Ex 0 8 1.79 86 42 17.5 130/80
14 31 Ex 1 0 1.84 109 32 - 140/90
16 44 Never 10 5 1.83 90 27 - 120/80
20 59 Never 0 2 1.69 85 30 16.5 120/80
21 48 Never 40 0 1.65 140 52 18.5 140/90
23 47 40 0 6 1.82 106 32 17 174/98
28 53 1 32 1 1.75 71 23 - 156/100
31 45 Never 0 3 1.73 114 38 18.5 132/89
35 f 51 17 0 0 1.57 81 33 16 138/78
38 f 55 Never 1 3 1.64 67 25 13 180/120
39 39 Ex 3 2 1.78 97 30 15.5 140/90
42 53 Ex 0 0 1.74 97 32 17 150/100
44 46 Never 1 0 1.64 72 26 16 190/130
47 43 Never 0 0 1.72 152 52 - 130/80
49 45 5 25 1 1.7 140 49 19 150/98
52 49 Never 2 0 1.72 94 32 17 130/80
54 71 Never - - 1.72 102 34 17.5 180/80
55 46 Never 14 - 1.86 127 37 18 130/100
60 41 30 0 30 1.76 86 28 15.5 120/70
63 64 Ex - 0 1.68 89 25 18 130/80
68 32 6 10 0 1.76 93 30 16.5 125/88
69 49 Never 20 0 1.82 118 35 18.5 140/85
70 43 Never 4 3 1.73 103 34 18.5 130/90
72 64 Never 20 2 1.69 73 25 16 150/70
75 51 Never 1 3 1.9 113 31 17 140/95
79 44 Ex 15 - 1.72 97 33 17 150/95
81 47 Never 7 5 1.84 114 33 16.5 140/100
84 f 48 Ex 21 0 1.64 95 35 18 140/90
86 59 Current 2 0 1.69 96 34 17.5 130/80
87 f 45 Ex 2 3 1.63 139 53 18 -
88 50 Ex 5 2 1.77 116 39 18 120/85
89 64 Ex 25 6 1.66 91 33 17.5 146/84
93 69 Never 4 - 1.76 93 30 16.5 140/90
95 50 Never 7 1 1.78 146 46 20 150/100
96 43 Never 2 0 1.96 196 51 19 140/90
97 31 Ex 35 - 1.79 110 34 17 130/80
98 40 Never - 2 1.82 146 45 19 140/85
101 60 30 0 6 1.72 121 41 17 140/88
102 56 Ex 14 4 1.83 98 29 17.5 125/85
106 45 Ex 2 1 1.78 99 33 17 130/80
111 33 20 0 0 1.78 109 34 17 -
114 65 Never 0 1 1.65 72 27 13.5 130/80
118 29 Never 6 0 1.84 119 35 - 120/84
119 39 Never 2 6 1.78 85 27 - 138/80
122 52 20 16 6 1.87 107 30 17.5 140/85
123 49 Never 8 1 1.79 115 35 17.5 130/95
125 35 Ex 2 1 1.77 120 38 17.5 160/90
126 f 52 Ex 36 0 1.68 94 33 17.5 125/85
127 65 Never 10 2 1.71 95 32 18 -
129 62 Never 4 0 1.84 103 30 17 130/80
130 47 Current 0 1 1.67 119 42 17.5 150/100
135 58 never 20 0 1.76 91 29 16 150/90
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Table 41. Presenting symptoms and comorbidities (Total n=58, all OSA subjects)
Symptom or comorbidity Number with 
symptom/comorbidity
Percentage
Snoring 57 98%
Witnessed apnoea 45 78%
Sleepiness 50 86%
Cerebrovascular disease 1
Cardiovascular disease 9 16%
Respiratory disease 8 15%
Hypertension 23 40%
Psychiatric history 9 16%
Endocrine history 4 9%
On medication 29 50%
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Table 42. Spirometry, screening dip rate and sleepiness variables pre and post CPAP for OSA 
patients in study
FEV1 = forced expiratory volume in first second, FVC = forced vital capacity, ESS = Epworth sleepiness
score. Osier = mean of 2 runs of Osier sleep resistance test.
Id
number
FEV1 / I FVC / I ESS p r e  
CPAP
O s ie r  
p r e  CPAP 
rain
S c re e n in g  
d i p  r a t e  
/h o u r
ESS
p o s t
CPAP
O s ie r
p o s t
CPAP
min
1 4.56 6.12 15 29.7 11 5 40
2 1.78 2.27 20 3.5 40 13 4.6
3 3.95 5.3 14 4.0 21.6 17 10.7
4 2.76 3.6 15 38.1 31 11 40
6 f 3.17 3.72 7 13.6 13 7 9.7
7 3.58 3.97 20 10.0 18 28.8
8 4.22 4.95 11 26.6 56 10 32.3
14 3.97 4.85 16 12.8 24 13 32.2
16 3.87 4.96 16 27.0 22 11 23.2
20 2.13 2.52 19 5.9 60 7 40
21 1.72 2.17 18 5.7 78 20 39.7
23 2.93 3.32 10 14.6 66.7 13 14.8
28 2.41 3.13 20 5.9 13 16 36.8
31 2.42 4.45 8 14.6 14 5 27.9
35 f 2.08 2.53 17 26.2 31.4 21 15.2
38 f 2.49 2.74 18 14.9 6.9 15 40
39 3.87 4.42 13 10.7 34 9 40
42 2.28 4.32 14 40 16 3 22.1
44 2.76 3.33 12 27.4 29.6 40
47 1.98 2.92 13 23.0 113 11 31.2
49 2.41 3.11 18 14.0 46.2 22
52 3.16 4.31 13 28.8 12 14 28.9
54 3.06 3.99 9 40 43.5 8 40
55 3.61 4.44 12 8.1 66.5 18 17.0
60 3.44 4.16 12 4.4 13 11 6
63 2.59 2.8 7 8.4 17 6 19.0
68 2.99 3.02 10 21.2 27 16 16.3
69 2.27 2.94 4 40 35 5 40
70 3.74 3.75 18 4.1 57.4 15 11.7
72 3.02 3.59 5 34.8 26 6 40
75 2.66 2.77 7 13.2 9 24.2
79 3.16 3.63 6 9.0 86 0 10.8
81 3.05 3.74 17 28.0 38.7 21 7.2
84 f 2.41 2.72 12 12.1 10.4 9 40
86 12 10.7 42.8 5 25.1
87 f 1.96 2.38 20 2.1 133 16 13.0
88 2 2*52 16 5.4 34.3 17 20.8
89 1.99 2.31 15 10.1 58 17 9.4
93 3.36 4.5 15 7.6 28.4 10 40
95 3.94 4.83 8 40 1.5 8 40
96 3.22 3.66 7 32.7 79.6 6 40
97 1.48 5.35 3 40 36 6 40
98 3.59 4.09 16 38.8 13 3 38.9
101 1.76 1.88 13 10.9 76.1 10
102 2.03 4.15 16 11.8 54.4 15 22.9
106 3.3 3.97 11 28.2 12.5 11 12.0
111 3.22 3.77 2 28.9 13 12 23.9
114 2.19 2.51 11 40 11.4 17 22.0
118 2.94 4.119 11 20.4 18.7 6 40
119 2.87 3.09 12 25.2 49.5 13
122 3.86 4.55 17 35.5 16.6 15 39.6
123 3.4 3.74 16 25.6 51.2 6 40
125 2.95 3.15 6 28.0 27.6 13 8.7
126 f 3.81 4.09 6 40 17 10 40
127 2.68 2.68 9 36.7 35.6 4 40
129 2.87 4.21 19 14.6 32.3 9 32.7
130 1.85 2.01 9 2.6 39.4 8 25.3
135 2.81 3.03 29.7 11.9 8 40
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Table 43. Polysomnographic data for OSA patients
CPAP= continuous positive airway pressure, AI= arousal index, AHI = apnoea hypopnoea index, REM =
rapid eye movement
imber
Pre CPAP
s l e e p t i m e
/min
Pre CPAP 
REM
d u r a t io n
/m in
Pre
cpap
AI
/ h r
Pre
CPAP
AHI
/ h r
P o s t
CPAP
s l e e p
t im e /m in s
Post CPAP 
REM
d u ra t io n /m in
P ost  
CPAP 
AI / h r
P ost
CPAP
AHI
/ h r
1 246.3 29.3 45.1 49.4 413.3 72.7 7.1 4.5
2 354 31.7 36.6 43.4 329.3 73.7 15.5 6
3 474.3 68 22.8 26.3 503.7 104 4.8 .5
4 420 43.3 21.1 26.9 191.3 41.3 13.8 6.9
6 f 417 54.3 11.1 3.7 456 97.3 5.9 .7
7 562 4.7 26.9 85 430.7 97 7.5 3.3
g 352.7 29.3 31.8 66.6
14 289.7 39.7 59.2 70 340.3 41.7 18 10.4
16 378.7 74.3 18.4 23.9
20 288.7 13 47.2 73.2 339.7 57.7 7.4 7.4
21 374.7 29.7 62.3 81 303 78.5 5.1 4.3
23 248.7 2 22.2 54 463.3 64.3 14.6 23.4
28 375 45.7 35.7 34.4 267.7 40.7 15.5 1.8
31 357 53.3 17.1 10.6
35 f 320.3 32.3 31.8 16.5 279.7 64.3 17.2 10.7
38 f 373.3 21.7 19.6 17.5
39 344.7 36.7 50.5 61.7 456.3 95 16.6 1.6
42 382.7 31 19.8 33.9 388 90.3 14.5 7.9
44 457.3 71 18.9 46.4 327.3 68.7 5.1 2.9
47 450 24 88.4 105.7 455.7 56 19.7 18.1
49 356.7 54 12.4 28.9 457.7 86 10.1 15.7
52 410.7 47.7 28.9 23.2 422 64.7 14.4 2
54 422.7 9.3 20 79.7 433.3 43.7 9.7 3.2
55 456.7 27 43.1 67 407.3 73.3 7.2 2.4
60 525.3 88.3 14.6 17.4 516.3 60.3 7.6 6.4
63 381.7 52.7 21.9 14.1 366.7 38.3 13.4 10.9
68 422 .3 45 86.3 448.3 78 23 24.5
69 349 17 59.5 54.5 344.7 38.3 29.6 5.2
70 416.7 33.7 26.2 62.2 417 38.3 9.4 8.8
72 389.7 34.3 21.6 63 355.7 61 8.5 2
75 421.3 33.3 26.1 35.2 399.7 76 4.3 1.1
79 400.7 55.7 50 82.7 438.3 88.3 7.4 2.3
81 390.7 50 21.3 79.9 529.7 108.3 6.9 8.6
84 f 297 35.3 21.4 12.1 312.7 59 13.2 3.3
86 341.7 7.7 16 15.5 337.3 36.7 6.4 1.4
87 f 418.7 9 20.2 106.4 415 121 4.2 13.6
88 275.3 5 39.2 22.4 357 44.7 6.4 1
89 473 ‘ 100.7 28.9 70.9
93 429 75 13.7 20.6 384 81.7 6.7 3.8
95 360.7 9.3 10.6 15.5
96 402.7 13 41.4 78.1 350.3 56 14.7 32.5
97 418.7 70.3 18.6 41 488.3 106.7 9.7 5.2
98 453.3 54 10.5 20.2 242.3 12 3.7 5.7
101 343.7 20.7 31.3 25.1
102 452.3 16.3 30.2 62.3 467 140 9.4 5.3
106 378.7 16 7.6 13.2 429.3 63.3 1.3 5.7
111 455.7 64 11.9 30.4 520 88 3.5 .5
114 390.7 44 6.5 4.6 356.3 1.3 4.2 0
118 263 13 21.2 35.5 462.8 58.7 8.6 5.3
119 319.7 15 46.5 46.9 347.7 93.3 3.6 5
122 388 49.3 38.2 43.3 418 68.7 15.2 2.9
123 475 39 29.8 73.8 420.3 66.7 5.1 5.9
125 413 42 29.2 42.1 459.3 103.7 3.9 9.4
126 f 468.7 5.3 36.4 41 487.7 52.7 25.6 13.4
127 368 36 16.6 30.1 513.3 106 2.3 .2
129 355 29 19.4 39.7 420 54 3 1.3
130 420 47.3 14.3 23.1 306.7 59.7 4.3 3.1
135 179 0 13.7 49.2
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Table 44. CPAP compliance data for OSA patients.
Subjects 8,31,38,87,95 and 135 refused to take CPAP following their initial trial night
Id number Days o f  
CPAP use
Median use t o t a l  
n i g h t s , min
P e rcen ta g e
usage
n ig h t s
Median use ,  
usage n i g h t s ,  
min
Use on n ig h t  
b e f o r e  p o l y ,  mins
1 69 168 68 .1 192 408
2 42 0 3 5 .7 84 0
3 38 324 8 9 .5 342 270
4 34 150 67. 6 210 228
6 f 50 180 78 234 354
7 30 519 100 519 336
8 0
14 41 96 5 1 .2 276 300
16 69 276 8 9 .9 291 402
20 47 300 100 300
21 56 225 8 9 .3 252 474
23 102 0 17 . 6 219 0
28 34 306 94 .1 315 348
31 0
35 f 29 0 10 .3 48 0
38 f 0
39 112 132 54 . 5 288 414
42 47 426 97. 9 429 384
44 40 375 80 402 420
47 55 210 98 .2 213 132
49 33 228 9 0 .9 258 138
52 41 216 61 288 342
54 49 126 69 .4 186 216
55 68 210 91 .2 228 282
60 42 195 69 282 324
63 40 0 40 210 42
68 42 303 64 .3 360 498
69 35 546 100 546 576
70 63 132 61. 9 198 0
72 37 324 73 348 354
75 36 279 100 279 132
79 39 408 94 . 9 408 342
81 44 444 6 5 .9 516 672
84 f 35 282 88. 6 288 492
86 37 276 83. 8 324 414
87 f 37
88 37 216 8 9 .2 222 0
89 35 0 17 .1 102 150
93 37 360 100 360 348
95 0
96 30 * 75 8 3 .3 90 276
97 51 0 3 7 .3 72 30
98 42 0 9 .5 120 168
101 11 474 90. 9 483 492
102 44 42 5 4 .5 159 222
106 44 0 3 1 .8 291 0
111 43 180 74 . 4 273 300
114 32 39 50 249 0
118 30 90 83.3 108 0
119 42 0 4.8 222 0
122 34 354 97.1 354 456
123 56 273 92.9 279 354
125 37 222 89.2 222 0
126 f 37 0 35.1 324 60
127 37 396 100 396 378
129 35 366 100 366 378
130 37 228 100 228 168
135 0
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11. CALCULATION OF SUMMARY TOI
MEASURES TO COMPARE SUBJECTS
11.1 OVERALL HYPOTHESIS
11.1.1 Measurement of cerebral oxygenation using near-infra red spectroscopy 
gives more valid information than measurement of arterial oxygen saturation 
alone
11.2 HYPOTHESES UNDERLYING ANALYSIS IN THIS CHAPTER
11.2.1 It is possible to use NIR cerebral oxygenation monitoring in unmanned full 
night polysomnography.
11.2.2 Summary measures from an overnight study can be calculated for TOI 
which differ from measures based on Sa0 2  and conventional 
polysomnography measures.
11.3 INTRODUCTION
We have shown that TOI can be used to measure cerebral oxygenation in subjects with
OSA, and that it adds additional information that cannot be predicted from simple arterial
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oximetry and also reflects changes in cerebral blood flow. We then wanted to 
physiologically validate this new measurement to see if it was a better predictor of daytime 
neuropsychological function than conventional polysomnography variables. In order to do 
this we had to derive a summary measure of TOI from an overnight study that could then 
be used in analysis as a predictor of neuropsychological function. The summary measures 
used were area under the curve measures and dip rates derived as described in chapter 5. 
The main findings of the neuropsychology study are not presented in this thesis. In this 
chapter we describe the TOI AUC and dip rate measures and compare them with AHI and 
Sa02 variables. We have seen how saturation and TOI are related at the level of individual 
apnoeas, but here the two are compared during overnight studies using exactly the same 
way of analyzing the two traces, to confirm whether different information is obtained.
AHI is the gold standard measure for assessing OSA severity and so any new overnight 
measure of OSA severity is conventionally “validated” against AHI. Clearly validation 
against symptoms would be more physiological, but is not conventionally used. The 
results in this chapter therefore tabulate and describe overnight summary measures for TOI 
and relate them to similarly calculated saturation measures and conventional 
polysomnography variables.
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11.4 SUBJECTS AND BASELINE CHARACTERISTICS
136 consecutive subjects were recruited from a clinic seeing referrals of subjects with 
possible obstructive sleep apnoea. Following a screening sleep study, 69 subjects (61 men) 
fulfilled criteria for polysomnography (4% oxygen desaturation dip rate >10 and 
obstructive apnoeas on video). Their mean (SD) age was 48.7yrs, (10.5), mean BMI 34.4 
(7.2) kg/m2, mean dip rate 36.2 (25)/hr, mean ESS 12.6 (4.8) and mean Osier sleep latency
20.3 (12.5) mins. 62 of 69 eligible patients underwent polysomnography, and the data 
obtained was adequate in 59 for AUC measurements, and 56 for dip rate measurements.
51 underwent repeat polysomnography after approx 1 month’s treatment. Demographic, 
clinical and polysomnography data for these subjects are given in tables 40-44 in chapter 
10.
We recorded full polysomnography with TOI monitoring onto the polysomnography 
computer, and we also recorded a digital output of TOI and Sa02 onto a separate computer. 
This enabled us to calculate dip rates and AUC measurements using the same method for 
both TOI and Sa02 as described in chapter 5. Anyone with experience of sleep medicine 
has a pretty good feel of how severe a subject is from isolated values of dip rate, AHI or 
T90, but when a new method like AUC is used, values even for Sa02 need to be first 
described, then put into context by comparison with the familiar AHI values. Similarly dip 
rate and AUC values for TOI need to be described and compared to give the investigator a 
feel for their distribution and how they differ from the Sa0 2  values.
The following tables include a description of the values obtained for TOI AUC and dip rate 
calculations, comparison of AUC values before and after treatment with CPAP, and 
relationship between these measures and the conventional poly measures: AHI, AI and 
mean minimum saturation. AUC measures include both the percentage of observations 
below a particular saturation (analogous to T90 as a fraction of total recording time) and 
the summated area below a particular saturation. The “percentage obs” measures thus 
measure fractional time spent below a particular saturation, whereas the “area under the 
curve” measures include both time and severity of desaturation.
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11.4.1 Statistics
Calculated summary measurements are described using mean and SD. They are compared 
pre and post CPAP using a paired t test. The new measurements are compared to 
conventional polysomnographic measurements using correlation coefficients, using tables 
to give the significance level for a specified number of subjects (Biometrika ref). P<0.05 
was taken as significant. Because of multiple comparisons p<0.01 is a more valid test of 
significance, and both are quoted.
11.5 AREA UNDER THE CURVE MEASUREMENTS AT BASELINE
Table 45 illustrates AUC measurements for SaC>2 and TOI at baseline. Although 
individuals may have very similar baseline maximum levels for Sa0 2 , baseline values for 
TOI are variable, and so AUC is expressed from a particular value (2%, 4% and 10% 
below baseline) rather than from an absolute saturation value. For example a subject might 
have a maximum Sa0 2  of 100% so that nearly 100% of the observations (obs) were below 
100%, 80% below 98%, 50% below 96% and 2% below 90%. This subject would have a 
“% obs 2% below maximum” of 80%, “% obs 4% below maximum” of 50%, and “% obs 
10% below maximum” of 2%. For Sa02 the “% observations 10% below maximum” is 
analogous to T90 (time below SaC>2 of 90%) divided by total time. Units for AUC are % 
per minute. If TOI and Sa02 are compared, the % obs values tend to be higher for TOI, 
but the AUC values are very similar. Total AUC averages 421.5 %/min for Sa02 and
415.5 %/min for TOI. AUC 10% below maximum averages 85.8%/min for Sa02 and 
50.8%/min for TOI.
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Table 45. Mean values obtained for SaC>2 AUC variables before CPAP treatment
(n=59).
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, AUC = area under the curve (variation 
below maximum), maximum defined as value of Sa02 or TOI that 99% of observations are below. % of 
observations, and AUC below three thresholds below maximum are quoted here. Units for AUC are %/min.
Sa02 TOI
Variable Mean SD Min Max Mean SD Min Max
%observations 2% below 
maximum
90.9 7.2 68.4 98.6 94.0 4.4 77.9 98.7
%observations 4% below 
maximum
67.3 20.8 14 95.6 76.7 17.2 23.2 97.6
%observations 10% below 
maximum
18.7 20.5 0 72.1 23.1 22.7 0 87.2
AUC below maximum 421.5 231.9 173 1202 415.5 154.0 167 775
AUC 2% below maximum 307.7 231.5 72 1070 311.6 155.5 75 672
AUC 4% below maximum 213.6 221.3 6 966 210.2 144.1 17 559
AUC 10% below maximum 85.8 153.4 0 699 50.8 69.9 0 256
11.6 AREA UNDER THE CURVE MEASUREMENTS USING CPAP
We would expect AHI values on CPAP to be reduced to below 10, especially when CPAP 
studies are performed after a month of CPAP use at home so that poorly compliant subjects 
are likely to have stopped CPAP use. We might therefore predict that AUC levels would 
be reduced to a uniform low level. Following CPAP, AUC values are reduced, but maybe 
less than might be expected due to the sensitivity of this method and the noise in the traces 
(Table 46). “Mean AUC below maximum” on CPAP was 308.5 %/min for SaC>2 and 339.4 
for TOI. “Mean AUC 10% below maximum” was 37.8 for Sa02 and 10.5 for TOI. Apart 
from the “AUC 10% below maximum” the TOI values are higher than the Sa02 values, 
suggesting that CPAP may correct Sa02 better than cerebral oxygenation. Dips in Sa02 
are known to be greater in general than TOI dips during an apnea (ie TOI ranges are 
smaller), which accounts for the reduction in the AUC 10% below maximum for TOI.
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Table 46. Mean values obtained for SaC>2 and TOI AUC variables using CPAP
treatment (n=51).
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, AUC = area under the curve (variation 
below maximum), maximum defined as value of Sa02 or TOI that 99% of observations are below. % of 
observations, and AUC below three thresholds below maximum are quoted here. Units for AUC are %/min.
Sa02 TOI
Variable Mean SD Min Max Mean SD Min Max
%observations 2% below 
maximum
86.9 12.8 46.9 97.8 93.7 4.2 81.1 98.5
%observations 4% below 
maximum
52.5 28.6 0.5 95 72.6 16.1 19.4 96.4
%observations 10% below 
maximum
8.1 14.0 0 70.1 9.8 12.4 0 68
AUC below maximum 308.5 170.2 89 944 339.4 89.7 161 675
AUC 2% below maximum 193.7 165.1 3 804 231.7 86.1 69 541
AUC 4% below maximum 114.5 148.4 0 707 134.1 78.0 19 442
AUC 10% below maximum 37.8 88.2 0 412 10.5 20.4 0 131
11.7 DIP RATE VARIABLES PRE TREATMENT
Apnea associated dip rates were calculated using the polysomnography software as 
described in chapter 5 for SaC>2 and TOI. As smaller dips were observed for TOI than for 
Sa02, both 2% and 4% dip rates were calculated for TOI.
Mean 4% Sa02 dip rate was 32.6. Mean 2% TOI dip rate was 38.1 and mean 4% TOI dip 
rate was 24, so that mean 4% Sa02 diprate was between the 2% and 4% TOI diprate.
Mean apnoea associated diprates overall and in REM were similar (Table 37). To ensure 
that dip rate calculations were objective and without bias they were calculated using the 
polysomnography software algorithm only, without subsequent manual revision and 
allocation of “unsures”. Unfortunately this meant that TOI diprates could not be calculated 
for the polysomnography on CPAP because the analysis program was not able to
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distinguish correctly between loss of mask contact and apnoea (because the airflow probe 
was attached to the CPAP mask).
Table 47. Mean and range of dip rate variables for pre-treatment polysomnography 
for SaC>2 and TOI.
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, REM =rapid eye movement sleep. Units 
for AUC are %/min. Units for dip rates are /hr.
Variable Numbe
r
Mean SD Minimum Maximum
4% Sa02 diprate 56 32.6 23.7 1.5 90.6
4% Sa02 dip rate (REM) 46 32.9 27.1 0 88.0
2% TOI dip rate 56 38.1 24.4 2.6 97.6
4% TOI dip rate 56 24.0 23.2 0.1 95.7
2% TOI dip rate (REM) 46 36.5 27.2 0 90
4% TOI dip rate (REM) 46 25.0 23.6 0 86.0
11.8 COMPARISON BETWEEN VARIABLES BEFORE AND AFTER CPAP
The following table compares values of AUC and dip rate and conventional 
polysomnography variables on and off CPAP using a Wilcoxon rank test. Apart from 
baseline TOI and sat; AUC variables for both TOI and saturation, and conventional 
polysomnography variables significantly improved on CPAP, as would be expected (Table 
48).
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Table 48. Comparison between pairs of variables with and without CPAP.
sat = arterial oxygen saturation, TOI = tissue oxygenation index, AUC = area under the curve (variation 
below maximum), maximum defined as value of Sa02 or TOI that 99% of observations are below. Mean 
values of AUC below maximum (0) and below three thresholds (2%, 4% and 10%) below maximum are 
quoted here. Ranges for these means are given in table 45. Units for AUC are %/min. CPAP = continuous 
positive airway pressure treatment. AHI = apnoea hypopnoea index, mean min Sa02 = mean of minimum 
values during apnoeas, REM = rapid eye movement. Statistical test is Wilcoxon rank sum, assuming unequal 
variances.
Variable number Pre- 
CP AP
On CPAP pvalue (Wilcoxon 
rank test)
AUC 0 toi 49 420.2 337.1 0.0014
AUC 2 toi 49 316.8 229.5 0.0008
AUC 4 toi 49 214.6 132.0 0.0005
AUC 10 toi 49 49.1 10.0 0.0001
AUC 0 sat 49 438.7 309.0 0.0000
AUC 2 sat 49 324.6 194.3 0.0000
AUC4 sat 49 229.5 114.3 0.0000
AUC 10 sat 49 99.7 37.0 0.0001
Baseline sat (%) 49 99.3 99.4 0.98
Baseline toi (%) 49 76.4 78.4 0.11
Arousal index /hr 51 29.4 10.1 0.0000
AHI/hr 51 45.7 6.5 0.0000
Mean min Sa02 % 47 88.2 93.6 0.0000
Mean dip Sa02 % 49 9.42 5.03 0.0000
REM AHI /hr 48 36.0 7.4 0.0000
11.9 RELATIONSHIP BETWEEN CONVENTIONAL POLY VARIABLES AND 
AUC VARIABLES PRE TREATMENT
New sleep study variables may be validated as measures of OSA severity by comparison 
with AHI. AUC variables for Sa02 were significantly associated with conventional
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polysomnography variables. The variable: “% obs 10% below maximum” (analogous to 
T90) and all the AUC variables were strongly related to the conventional saturation 
variables (Table 49). Relationships with AHI were less strong. This would be expected as 
AUC variables and conventional saturation variables are based on the pulse oximeter 
readout. The poorer correlations with the “% obs below maximum” than with AUC reflect 
the fact that AUC measures include the severity of desaturation as well as its duration.
Table 49. Correlation coefficients for relationship between poly variables and AUC 
variables for SaC>2 from baseline pretreatment polysomnography (n=57)
AUC = area under the curve (variation below maximum), maximum defined as value of Sa02 that 99% of
observations are below. % of observations, and AUC below three thresholds below maximum are compared
here. AHI = apnoea hypopnoea index, mean min Sa02 = mean of minimum values during apnoeas, mean sat
dip = mean of Sa02 drops during apnoea.
AHI Mean min 
Sa02
Mean sat dip
%observations 2% below maximum 0.181ns -0.421** 0.367**
%observations 4% below maximum 0.380** -0.496** 0.484**
%observations 10% below maximum 0.642** -0.814** 0.825**
AUC below maximum 0.617** -0.833** 0.856**
AUC 2% below maximum 0.620** -0.834** 0.852**
AUC 4% below maximum 0.622** -0.840** 0.861**
AUC 10% below maximum 0.582** -0.835** 0.867**
** p<0.01
TOI AUC variables were weakly correlated with AHI, but not significantly related to 
conventional oxygen measures (Table 50). This is expected as TOI variables are produced 
from a different trace to the oxygen measures, and so best correlation is with the AHI or 
event rate. This does suggest that TOI and Sa02 measure different things, but also that 
there is some relation between TOI measures and OSA severity.
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Table 50. Correlation coefficients for relationship between poly variables and AUC 
variables for TOI from baseline pretreatment polysomnography (n=57)
AUC = area under the curve (variation below maximum), maximum defined as value of TOI that 99% of
observations are below. % of observations, and AUC below three thresholds below maximum are compared
here. AHI = apnoea hypopnoea index, mean min Sa02 = mean of minimum values during apnoeas, mean
Sa02 dip = mean of Sa02 drops during apnoea.
AHI Mean min 
SaC>2
Mean Sa02 
dip
%observations 2% below maximum 0.044 0.048 -0.160
%observations 4% below maximum 0.211 -0.088 0.031
%observations 10% below maximum 0.324* -0.260 0.216
AUC below maximum 0.316* -0.251 0.193
AUC 2% below maximum 0.302* -0.223 0.174
AUC 4% below maximum 0.305* -0.235 0.186
AUC 10% below maximum 0.258 -0.259 0.205
** p<0.01 ,* p<0.05
11.10 RELATIONSHIP BETWEEN CONVENTIONAL POLY VARIABLES AND 
AUC VARIABLES POST TREATMENT
The relationships between AUC variables and polysomnography variables were also 
examined in the studies on CPAP. On CPAP the relationship between the Sa02 AUC 
variables and conventional poly variables was less strong presumably because most Sa0 2  
variation was not now caused by apnoeas or hypopnoeas (Table 51). There was no 
significant correlation with AHI, but reasonable correlations (0.396 -  0.758) with the 
saturation variables.
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Table 51. Correlation coefficients between poly variables and AUC variables for SaC>2 
from post treatment polysomnography (n=47)
AUC = area under the curve (variation below maximum), maximum defined as value of Sa02 that 99% of
observations are below. % of observations, and AUC below three thresholds below maximum are compared
here. AHI = apnoea hypopnoea index, mean min Sa02 = mean of minimum values during apnoeas, mean
Sa02 dip = mean of Sa02 drops during apnoea.
AHI Mean min 
Sa02
Mean Sa02 
dip
%observations 2% below maximum 0.074 -0.395** 0.246
%observations 4% below maximum 0.183 -0.542** 0.480**
%observations 10% below maximum 0.094 -0.742** 0.522**
AUC below maximum 0.086 -0.737** 0.494**
AUC 2% below maximum 0.092 -0.748** 0.500**
AUC 4% below maximum 0.073 -0.758** 0.476**
AUC 10% below maximum -0.018 -0.674** 0.332*
** p<0.01, * p<0.05
There were no significant correlations on CPAP between TOI AUC measures and 
conventional poly variables (Table 52). As even without CPAP the only relationship was 
with AHI, this again suggests that most of the TOI variation on CPAP was not related to 
OSA.
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Table 52. Correlation coefficients for relationship between poly variables and AUC 
variables for TOI from post treatment polysomnography (n=47)
AUC = area under the curve (variation below maximum), maximum defined as value of TOI that 99% of
observations are below. % of observations, and AUC below three thresholds below maximum are compared
here. AHI = apnoea hypopnoea index, mean min Sa02 = mean of minimum values during apnoeas, mean
Sa02 dip = mean of Sa02 drops during apnoea.
AHI Mean min 
Sa02
Mean SaC>2 
dip
%observations 2% below maximum 0.176 0.075 0.091
%observations 4% below maximum 0.156 0.044 0.107
%observations 10% below maximum 0.119 -0.032 0.077
AUC below maximum 0.140 0.038 0.123
AUC 2% below maximum 0.110 0.006 0.113
AUC 4% below maximum 0.093 0.033 0.102
AUC 10% below maximum 0.071 0.012 0.058
** p<0.01
11.11 RELATIONSHIP BETWEEN CONVENTIONAL POLY VARIABLES AND 
DIP RATE VARIABLES PRE TREATMENT
Desaturation dip rates are event rates which include some information about extent of 
desaturation and so good correlations with AHI would be expected for both TOI and Sa02. 
There were good correlations between AHI and event related TOI and Sa02 dip rates 
(c=0.79 - 0.91), slightly less good with mean min sat and mean sat dip (c = 0.54-0.70) 
(Table 53).
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Table 53. Correlation coefficients for the relationship between poly variables and dip 
rate variables for SaC>2 and TOI from baseline pretreatment 
polysomnography (n=55)
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, AHI = apnoea hypopnoea index, mean 
min Sa02 = mean of minimum values during apnoeas, mean Sa02 dip = mean of Sa02 drops during apnoea.
AHI Mean min Sa02 Mean Sa02 dip
4% Sa02 diprate 0.913** -0.610** 0.702**
2% TOI dip rate 0.907** -0.542** 0.631**
4% TOI dip rate 0.793** -0.576** 0.660**
** p<0.01
Looking at REM event rates and arousal index, there was a strong relationship between 
REM dip rates for both TOI and Sa02 and REM AHI (Table 54) as both are measuring the 
event rate during the same stage of sleep. The relationship between REM dip rates and 
arousal index was weaker than that with overall AHI.
Table 54. Correlation coefficients for relationship between AHI, AI and REM AHI 
and dip rate variables for Sa02 and TOI from baseline pretreatment 
polysomnography (n=43)
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, AHI = apnoea hypopnoea index, AI =
arousal index, REM = rapid eye movement.
- AHI AI REM AHI
4% Sa02 diprate 0.959** 0.565** 0.651**
4% Sa02 dip rate (REM) 0.650** 0.257 0.896**
2% TOI dip rate 0.945** 0.600** 0.617**
4% TOI dip rate 0.873** 0.632** 0.536**
2% TOI dip rate (REM) 0.631** 0.310* 0.871**
4% TOI dip rate (REM) 0.700** 0.317* 0.888**
** p<0.01, * p<0.05
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11.12 RELATIONSHIP BETWEEN DIP RATE AND AUC VARIABLES PRE
TREATMENT
We were also interested in whether our two ways of summing TOI ranked the OSA 
severity of different subjects in the same order. The two methods differed both in what 
they measured (one an event rate, the other a measure of total desaturation) and in the 
output used to calculate them (one an analogue output to the polysomnography, the other a 
separate digital output).
Overall the two methods of quantifying TOI did not correlate well with each other (Table 
55). “% obs 10% below maximum” correlated with 2% and 4% dip rates. The 4% dip rate 
correlated with some of the AUC measures. These intercorrelations may mean that the 4% 
TOI dip rate and the “% obs 10% below maximum” are the most useful outcomes to use in 
studies.
Table 55. Correlation coefficients for the relationship between TOI AUC variables and 
TOI dip rate variables from baseline pretreatment polysomnography (n=45)
AUC = area under the curve (variation below maximum), maximum defined as value of TOI that 99% of
observations are below. % of observations, and AUC below three thresholds below maximum are compared 
here with TOI dip rates. REM = rapid eye movement
2% dip 
rate
4% dip 
rate
2% dip rate 
(REM)
4% dip rate 
(REM)
%observations 2% below 
maximum
0.158 0.173 -0.137 -0.063
%observations 4% below 
maximum
0.220 0.249 -0.102 -0.067
%observations 10% below 
maximum
0.356* 0.372* 0.016 0.055
AUC below maximum 0.300 0.340* -0.006 0.022
AUC 2% below maximum 0.302 0.336* -0.001 0.034
AUC 4% below maximum 0.296 0.333* 0.000 0.031
AUC 10% below maximum 0.199 0.241 0.005 0.028
** p<0.01 *p<0.05
There were better correlations between the 4% saturation dip rate and Sa02 AUC variables 
(Table 56). However these correlations remain worse than those between the 4% dip rate
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and AHI, suggesting that the 4% dip rate is closer to the event rate than to the most 
sensitive measure of summed desaturation.
Table 56. Correlation coefficients for the relationship between SaC>2 AUC variables 
and SaC>2 dip rate variables from baseline pretreatment polysomnography 
(n=45)
AUC = area under the curve (variation below maximum), maximum defined as value of S a0 2 that 99% of 
observations are below. % o f observations, and AUC below three thresholds below maximum are compared 
here with S a0 2 dip rate variables. REM = rapid eye movement.
4% dip rate 4% dip rate (REM)
%observations 2% below maximum 0.371* 0.232
%observations 4% below maximum 0.518** 0.314*
%observations 10% below maximum 0.729** 0.382*
AUC below maximum 0.716** 0.399**
AUC 2% below maximum 0.713** 0.387*
AUC 4% below maximum 0.707** 0.390*
AUC 10% below maximum 0.640** 0.340*
** p<0.01, *p<0.05 
11.13 SUMMARY
11.13.1 It is possible to use NIR cerebral oxygenation monitoring in unmanned full 
night polysomnography.
We have shown that it is possible to record 8 hours of TOI data from an overnight 
unmanned sleep study, with only 3 sets of data discarded because of technical problems, all 
of whom refused a repeat study. No side effects from the probe were observed.
11.13.2 Summary measures from an overnight study can be calculated for TOI 
which differ from measures based on Sa02 and conventional 
polysomnography measures.
We have described results for two methods of summarizing TOI from overnight studies: 
AUC and dip rates. We have also calculated measures for Sa02 using the same methods.
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We have compared them both to conventional polysomnography measures of OSA 
severity. Our results suggest that in general the AUC measures for Sa02 were more 
closely correlated to conventional polysomnography measures than those for TOI. The 
fact that these correlations exist suggests that the method used for calculating AUC 
(identical for Sa02 and TOI) is not invalid, particularly as correlations with oxygen 
measures (mean min sat, mean sat dip) are closer than those with AHI. The TOI AUC 
measures can only be validated against clinical outcome.
Of the measures of percentage time below a particular saturation, the “% obs 10% below 
maximum Sa0 2 ” seems to correlate best with conventional measures, which supports the 
use of the analogous T90 as a sleep study outcome.
AUC measures on CPAP will be affected by the fact that most fluctuation in saturation on 
CPAP will not be due to apnoea, and so will not correlate well with poly measures of OSA 
severity, however may be appropriate for use in outcome studies, depending on whether 
repetitive desaturation or summed desaturation has the greater effect on 
neuropsychological function.
The event rates AHI, 4% Sa02 dips, 2% and 4% TOI dips, were all (in this study) 
calculated manually from the polysomnography trace, and unlike conventional algorithm 
derived dip rates, were apnoea associated. The values were therefore similar and 
correlated well with conventional measures.
These derived values of TOI and Sa02, both AUC and dip rates, could now be used as 
single measures for each patient to be compared with neuropsychological function in a 
prospective study to see if cerebral oxygenation affects daytime neuropsychological 
function. We have described algorithms for their calculation, and given means and ranges 
in approximately 50 subjects with OSA, on and off CPAP. As is conventional (but maybe 
not meaningful) we have compared these new measures against the conventional measure 
of OSA severity AHI. If TOI does prove to be a predictor of neuropsychological outcome, 
we have shown that it is not well predicted by conventional saturation polysomnography 
variables.
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12. NEUROPSYCHOLOGICAL FUNCTION IN
RESPIRATORY FAILURE SECONDARY 
TO CHRONIC LUNG DISEASE
12.1 INTRODUCTION
So far this thesis has concentrated on obstructive sleep apnoea, where the baseline 
saturation is normal but subjects experience repetitive significant desaturations of short 
duration during the night. Nocturnal desaturation and sleep disruption affect daytime 
function, and it is possible that direct measurement of cerebral saturation with near infra­
red spectroscopy may predict daytime neuropsychological function better than 
conventional sleep studies. The other group of patients in whom desaturation affects 
neuropsychological function is those with respiratory failure. Here the hypoxaemia is 
chronic and various compensatory mechanisms exist. Again it is possible that treatment 
benefit may be predicted by cerebral oxygenation changes so this is a patient group where 
near infrared spectroscopy may be useful.
Chronic obstructive pulmonary disease is characterized by airflow obstruction, which is 
usually progressive, not fully reversible and does not change markedly over several months 
(156). In severe disease hypoxia may result mainly because of ventilation perfusion 
mismatch, although hypoventilation and diffusion impairment may also contribute (157).
In the long term respiratory failure defined by arterial hypoxaemia leads to pulmonary 
hypertension, peripheral oedema and cor pulmonale. The brain is very sensitive to hypoxia, 
but chronic low levels of Sa0 2  are tolerated better than acute changes, probably due to 
adaptive mechanisms. Hence respiratory failure provides a second model in which to 
study the effects of cerebral oxygenation on neuropsychological function. This chapter
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reviews studies in patients with COPD looking at neuropsychological function, the effects 
of supplementary oxygen and cerebral haemodynamics. These studies are not extensive 
and are variable in design, so that conclusions drawn are tentative.
12.2 OXYGEN TRIALS
It was not possible to give long term oxygen at home until a practical portable oxygen 
source was developed in the late 1960s. The early trials of supplementary oxygen in 
COPD used neuropsychological function as an outcome measure. A study carried out in 
1974 of constant administration of oxygen at 21/min to 12 subjects with severe COPD and 
hypoxaemia, demonstrated improvement in exercise tolerance, neuropsychologic 
functioning and ability to carry out activities of daily living despite no change in lung 
function. Highly significant improvement was seen in 9 out of 10 of an array of tests 
designed to assess neuropsychological function (158). Benefits occurred despite partial 
reversal of compensatory mechanisms, ie decreases in hematocrit, haemoglobin, and red 
cell 2,3 DPG. As a result of this and other small studies showing clinical benefit, large 
controlled studies of long term oxygen administration were set up in the USA (Nocturnal 
Oxygen Therapy Trial; NOTT) (159) and the UK (MRC) (160). In the NOTT study 203 
patients with hypoxemic COPD (Pa02 < 55mmHg, or <59mmHg with evidence of cor 
pulmonale) were randomly allocated to either continuous oxygen therapy or 12 hour 
nocturnal oxygen therapy and followed for at least a year. The overall mortality in the 
nocturnal group was 1.94 times that of the continuous group (159). The MRC recruited 87 
subjects who all had COPD, severe hypoxaemia (Pa02 between 40 and 60mmHg), carbon 
dioxide retention and a history of oedema, and gave them oxygen at 21/min for at least 
15hours a day. 19 out of 42 oxygen treated subjects died in 5 years of follow up compared 
to 30 out of 45 controls (160). Long term oxygen prescription for COPD in the UK is 
based on the result of these two trials. The level of hypoxaemia selected for entry into 
these trials is related to definitions of respiratory failure based on the shape of the oxygen 
dissociation curve. The sigmoid shape of the curve means that arterial saturation is 
maintained above 90% until Pa02 falls to about 50mmHg, after which the curve is more 
steep and saturation falls off rapidly. A further trial performed in Poland by Gorecka et al 
showed no increase in survival at 3 years in 135 patients with moderate hypoxaemia (56- 
65mmHg) randomized to LTOT or control and provides the evidence to restrict oxygen 
prescription to patients with severe hypoxaemia (161). As well as improving survival,
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LTOT has other benefits including slowing of deterioration of pulmonary haemodynamics, 
reduction of secondary polycythaemia, improved sleep quality, increase in renal blood 
flow, reduction in cardiac arrhythmias and neuropsychological benefit (162). In the 
NOTT trial, moderate to severe impairment on neuropsychological testing suggestive of 
cerebral dysfunction was found in 42% of patients compared to 14% of controls prior to 
oxygen therapy (163). Subgroup analysis of the trial results showed survival benefit was 
particularly marked in patients with more severe brain dysfunction and mood disturbance 
(159).
It is possible that direct measurement of cerebral oxygenation and changes in relation to 
oxygen therapy may be more helpful in predicting neuropsychological benefit than arterial 
saturation measurements. If neuropsychological dysfunction correlates with cerebral 
oxygenation, it may be possible to identify a group of patients who will particularly benefit 
from oxygen therapy. Adaptation to hypoxia through polycythaemia, 2,3 DPG and 
cerebral blood flow alterations may maintain cerebral oxygenation, despite peripheral 
hypoxaemia, and these adaptive mechanisms may vary between patients.
12.3 NEUROPSYCHOLOGICAL FUNCTION IN COPD
The mechanism for cognitive impairment in hypoxaemic COPD is not known and is 
probably multifactorial. Lack of oxygen may be a possible cause. The proportion of 
subjects with neuropsychological deficit rose from 27% in mild hypoxaemia to 61% in 
severe hypoxaemia in about 300 patients from the combined NOTT and Intermittent 
Positive Pressure Breathing (IPPB) trials (164). This dose response relationship observed 
between hypoxaemia and neuropsychological deficit supports an aetiological role for 
hypoxaemia, particularly as neither pulmonary function tests nor arterial pC0 2  were 
significantly correlated with neuropsychological test scores. There was also no correlation 
with exercise capacity or mood state, suggesting that the correlation with hypoxia is not 
just a non-specific effect of more severe illness. A study of cognitive function in subjects 
with mild to moderate COPD without hypoxia using mini-mental state examination 
suggested no difference to controls (165) which suggests that COPD without respiratory 
failure has no effect on cognitive function, although the mini-mental state exam is not very 
sensitive.
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It has been suggested that neuropsychological deficit in hypoxic COPD may follow a 
specific pattern. Incalzi et al (166) found that 48.5% of 36 patients with COPD had a 
specific pattern of cognitive impairment characterised by a dramatic impairment in verbal 
and verbal memory tasks with well-preserved visual attention. This pattern differed from 
Alzheimer type dementia controls and multi infarct dementia controls. Cognitive 
impairment correlated with age and with duration of hypoxic and hypercapnoeic 
respiratory failure. A more recent study from the same group using mapping of brain 
perfusion with single photon emission computed tomography as well as cognitive testing 
suggested that COPD subjects performed better than Alzheimer subjects and worse than 
controls and that performance correlated with anterior cerebral hypoperfusion (167). 
Reversibility of cognitive deficit with LTOT is probably partial. Patients studied in one 
study cited above (166) had been receiving oxygen therapy “from the start of 
oxyhaemoglobin desaturation” and still had neuropsychological deficit correlating with the 
duration of respiratory failure. This suggests that the cognitive deficit is not preventable 
by current treatment. However in the NOTT trial all measures of neuropsychological 
function improved significantly after 12 mths of oxygen treatment (159), which suggests 
that established deficit can be reversed in part.
If LTOT can partially reverse neuropsychological deficit, another question arises as to 
whether there is an acute effect of oxygen on neuropsychological function (ie does it make 
a difference if the testing is carried out on oxygen or not). Cohen et al (168) found no 
effect on neuropsychological function (memory, learning, sustained concentration and 
motor and visuomotor speed) of discontinuing LTOT treatment for 4 hours in 12 patients, 
serving as their own controls. Heaton et al (169) reporting results of neuropsychological 
follow up in the NOTT trial note that the improvements they observed were not as large as 
in 2 previous small studies where neuropsychological tests were carried out pre treatment 
off oxygen and post treatment on oxygen. The NOTT protocol carried out both tests off 
oxygen, and they suggested in the light of their results that there may be two mechanisms 
underlying the effect of oxygen on brain function. When oxygen was administered to 
normal volunteers in a double blind study, it enhanced cognitive performance compared to 
participants who inhaled air (170). Scalvini et al (171) found that autonomic nervous 
system function was deranged in 11 patients with chronic hypercapnoeic respiratory failure 
and that the abnormalities were partially reversed by oxygen administration.
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Therefore any mechanism for neuropsychological dysfunction in hypoxic COPD seems to 
involve hypoxia, and be partially reversed by both chronic and possibly acute oxygen 
administration.
12.4 MECHANISMS OF NEUROPSYCHOLOGICAL DYSFUNCTION
As previously discussed for OS A it is not clear whether the general mechanism by which 
hypoxia causes neuropsychological dysfunction is direct ischaemia or effects on enzyme 
metabolism. Alterations in cerebral metabolism in COPD have been demonstrated using 
proton magnetic resonance spectroscopy, however correlation between this and 
neuropsychological testing was poor (172).
12.5 CEREBRAL HAEMODYNAMICS IN RESPIRATORY FAILURE
If we propose to measure cerebral oxygenation in COPD, we are interested in determinants 
of cerebral blood flow as well as arterial saturation, as cerebral oxygen supply depends on 
both these factors. Focal changes in cerebral perfusion in hypoxic subjects with COPD 
have been described above (167). One of the main features of respiratory failure in COPD 
is hypercapnoea (Type 2 respiratory failure) which is due to a combination of VQ 
mismatch and inadequate ventilation. Daytime hypercapnoea is rarely seen in OSA unless 
there is associated gross obesity or parenchymal lung disease. Hypercapnoea is one of the 
main stimulants to cerebral blood flow, and so may account for changes in cerebral oxygen 
supply. Although the increased CBF in hypercapnic respiratory failure could be seen as an 
adaptive mechanism, it may be responsible for raised intracranial pressure with 
accompanying papilloedema and headaches if acute. There is some interest in the 
measurement of cerebrovascular reactivity in these subjects to see if they retain the usual 
cerebral blood flow response to changes in pH or pCC>2 despite resting hypercapnia. This 
has been investigated by measuring response to acute changes in carbon dioxide tension in 
17 chronic hypercapnic COPD patients, 16 normocapnic COPD patients and 15 healthy 
subjects using NIRS cerebral blood volume measurements (173). This study showed that 
the slope of the cerebrovascular response to CO2 was significantly lower in both COPD 
groups than in normals, but did not differ between the groups. They also showed absolute 
cerebral blood volume measurements to be reduced in both COPD groups compared to
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controls, and to be significantly lower in normocapnic compared to hypercapnic subjects. 
The reduction in cerebral blood volume measured in the frontal region (because of NIRS 
probe positioning limitations), is consistent with the findings of anterior cerebral 
hypoperfusion by Incalzi’s group. This would therefore fit with either regional 
hypoperfusion or a general effect. Another study by van de Ven et al showed that 
induction of chronic metabolic acidosis and alkalosis had no effect on cerebrovascular 
reactivity in 16 normocapnic and 17 hypercapnic COPD patients also using NIRS CBV 
measurements (174).
Cerebral oxygenation has been measured during exercise in subjects with respiratory 
failure using NIRS and simultaneous MCA Doppler (175). During exercise breathing air, 
cerebral blood flow and deoxygenated haemoglobin increased, oxyhaemoglobin was 
unchanged and Sa02 decreased. During exercise with supplementary oxygen, the CBFV 
increased by a similar amount to that on air, but 02Hb also increased while HHb 
decreased, ie the exercise induced increase in cerebral perfusion was not affected by 
hyperoxia.
Arterial saturation in COPD is known to worsen at night. Cerebral saturation has been 
measured at night using bilateral frontal NIRS probes in 6 subjects with severe COPD 
without OSA who did not fit the criteria for LTOT, and compared with Sa02. Falls in 
Sa0 2  were accompanied by bilateral falls in cerebral tissue saturation, which in one case 
were asymmetrical, with possible evidence of a steal phenomenon (176). The clinical 
relevance of this finding is currently unclear.
12.6 EFFECT OF SMOKING ON CEREBRAL BLOOD FLOW
Almost all patients with COPD have smoked at some stage and many continue to smoke. 
Many patients in the MRC LTOT (160) and NOTT (177) trials were current smokers, as 
smoking was not an exclusion criteria (178). Cigarette smoking has complex effects on 
cerebral vessel function, which appear to be different acutely and chronically, but 
interpretation of the studies is complicated by the fact that a radio-isotope based technique 
is used to measure CBF in chronic studies and Doppler CBFV in acute studies. Regional 
cerebral blood flow by 133-xenon inhalation is reduced in smokers in several studies (179- 
181). Regional CBF also goes down with age (179, 181) and one study showed a 
significant reduction in regional CBF only in elderly smokers (182). The rCBF in subjects 
who quit smoking is between that of current smokers and never smokers (183) and there is
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longitudinal evidence that perfusion improves after lyear (183) and 9 years (184) in small 
numbers of subjects. Long term effects of smoking on cerebral perfusion may be due to 
accelerated atherosclerosis and increased viscosity.
Measurements of CBFV on “volunteers” while smoking cigarettes show an increase in 
Doppler CBFV (185-190). Whether this is due to a true increase in CBF or whether it is 
due to cerebral vasoconstriction is unclear. Smoking increases arterial blood pressure 
(186, 190) and this increased pressure may be associated with increased CBF. However 
nicotine injection in mice reduces cerebral blood flow measured with radionuclides (191) 
and simultaneous measurement of Doppler CBFV and isotope regional CBF in 6 smokers 
showed an increase in the former with a significant fall in the latter (186). Nicotine in 
cigarettes therefore probably causes generalised vasoconstriction including cerebral 
vessels, and the chronic effect of this is to accelerate atherosclerosis.
12.7 SUMMARY OF PREVIOUS NIRS STUDIES IN COPD
In summary there have been several studies in hypoxic COPD using NIRS. Unlike OS A, 
there are no frequent fluctuations in cerebral oxygenation occurring spontaneously, so 
these studies have observed cerebral haemodynamic responses in these patients in response 
to stimuli such as hypercapnoea, exercise and sleep. However the effect of supplementary 
oxygen on cerebral oxygenation has not been well described, and specifically whether 
subjects vary in their responses to oxygen or whether cerebral saturation response can be 
predicted from peripheral pulse oximetry. This issue was addressed in the validation 
studies described in the next chapter, to explore the potential of NIRS as part of the work 
up for LTOT.
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13. USE OF NEAR INFRA-RED
SPECTROSCOPY IN SUBJECTS WITH 
CHRONIC HYPOXIA
13.1 OVERALL HYPOTHESIS
13.1.1 Measurement of cerebral oxygenation using near-infra red spectroscopy 
gives additional valid information when compared to measurement of 
arterial oxygen saturation alone
13.2 HYPOTHESES UNDERLYING ANALYSIS IN THIS CHAPTER
13.2.1 Characteristics of TOI differ from characteristics of arterial oxygen 
saturation.
13.2.2 TOI changes during oxygen challenge cannot be predicted from arterial 
oxygen saturation alone.
13.2.3 Cerebral blood volume can be measured in subjects with COPD using 
oxygen challenge
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13.3 INTRODUCTION
We have seen that patients with chronic hypoxia in association with chronic lung disease 
differ from those with OS A in that they do not undergo frequent spontaneous changes in 
saturation and cerebral blood flow. In order to investigate the relationship of TOI to 
saturation in this group, a stimulus needs to be applied and the response to it recorded. 
Other previous studies using NIRS in COPD have used stimuli such as hypercapnia, 
exercise or sleep. We chose to use supplementary oxygen and measure resulting changes 
in NIRS parameters. This would provide information about the acute effects of oxygen on 
cerebral oxygenation. This is of interest because of evidence that hypoxia does affect 
neuropsychological function and that this effect is partially reversible with LTOT. There is 
a possibility that the cerebral oxygenation response to supplementary oxygen might predict 
neuropsychological improvement on LTOT. First we needed to document TOI changes in 
response to oxygen in subjects who are chronically hypoxic, to show that they could not be 
predicted by Sa02 alone and that they differed between people. No work was done using 
neuropsychological testing in this patient group as part of this thesis.
This chapter describes the changes in NIRS parameters observed during oxygen challenge 
in hypoxic patients with COPD. Absolute cerebral blood volume was calculated from 
oxygen challenge data. Cerebral oxygenation depends on arterial saturation and cerebral 
blood flow. We had no measurements of cerebral blood flow except for changes in total 
haemoglobin (relative blood volume) so relationships between cerebral oxygenation (TOI), 
Sa0 2  and total haemoglobin during oxygen challenge were examined.
13.4 METHODS
This study was performed by myself and Dr Arschang Valipour, Research Associate from 
Vienna, Austria, under the supervision of Professor S Spiro and Dr H Makker, Department 
of Thoracic Medicine, University College London Hospitals, between June 1999 and May 
2000.
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13.4.1 Subject recruitment
A pilot study was carried out on 8 subjects to establish the protocol. These patients 
consisted of 4 patients with COPD, 2 with bronchiectasis and 2 with nocturnal 
hypoxaemia.
CBV measurements were then carried out more formally on 11 subjects, all with COPD, 
and all with an oxygen concentrator or being assessed for provision of home oxygen 
(oxygen saturation <92%). Subjects were recruited from the wards and from out patient 
clinics after giving details of the study to doctors and respiratory nurses in these clinics.
Ethics approval was granted from the UCLH ethics committee and full written consent was 
obtained from each subject. People undergoing oxygen assessment had arterial blood gas 
tensions measured on the day of the study, otherwise the most recent ABG measurement in 
the notes was recorded. We did not have ethical approval to take ABG specimens that 
were not clinically indicated.
When considering cerebral haemodynamics in COPD smoking history needs to be taken 
into account. The policy of the Middlesex Hospital at this time was to assess patients for 
LTOT only if they had given up smoking, so all patients recruited denied current smoking. 
Objective measurements of current smoking eg urinary cotinine measurements were not 
made and it is known that a percentage of people who deny current smoking to a doctor, 
are continued smokers, and up to 20% of patients on LTOT continue to smoke (192). 
However no patients had smoked within 2 hours of the oxygen challenge test and so no 
acute or dynamic effects of cigarette smoking on cerebral haemodynamics would have 
been observed.
13.4.2 Protocol
Subjects undertook the study lying semirecumbent on a bed in a quiet hospital sideroom. 
All subjects were breathing room air (off supplementary oxygen for at least 30mins) at the 
start of the study.
Cerebral oxygenation was monitored using the NIRO300. Optodes were applied to the left 
forehead with a self adhesive pad as described previously. A pulse oximeter probe was
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attached to the left index finger (Pulseox 7 Minolta, now Anandic Medical Systems, 
Diessenhofen, Switzerland). A venturi mask was positioned loosely around the patient’s 
neck, but not connected to oxygen. This was because it was important not to move the 
NIRO probe after recording was started, and in this position the mask could be lifted into 
place without touching the NIRO probe. Recording was then commenced. We did not at 
this time have a working analogue to digital converter enabling simultaneous oximetry and 
NIRO recording, so recordings of oxygen saturation, TOI, OHb, HHb, cytox were 
manually taken from the pulse oximeter and NIRO display every 20-30 seconds. In 
addition the raw data of TOI, OHb, HHb and cytox were downloaded into a computer file 
every 5s. The pulse oximeter averaging time is 5 s. After about 5 minutes of baseline 
recording the oxygen mask was put into position and oxygen was switched on at a flow 
rate of 21/min to give 24% oxygen. Recordings were continued for 5minutes or until the 
TOI and oxygen saturation readings had been stable for 3 successive recordings. The 
venturi attachment was then changed to 35% and the oxygen flow rate increased 
accordingly. Recordings were again continued for 5minutes or until the TOI and oxygen 
saturation readings had been stable for 3 successive recordings. The oxygen was then 
switched off and the mask removed from the face. Recordings were continued until 
oxygen saturation had returned to within 2% of baseline.
13.5 ANALYSIS
Changes in TOI, oxygen saturation, and total haemoglobin were observed during oxygen 
challenge. Relationships between these parameters were examined in each subject and in 
the whole patient group correcting for interpatient differences. Ratio of total Sa02 to total 
TOI change was calculated for each patient. Total change in cytochrome oxidase during 
oxygen challenge was also measured.
Absolute CBV is one of the few absolute measurements that can be derived from standard 
NIRS measurements Ohb and HHb. As an absolute measure it should be comparable 
between subjects and between studies. It can be derived from response to oxygen 
challenge in normal adults, provided a graph of difference between oxygenated and 
deoxygenated haemoglobin against oxygen saturation is a straight line. This assumes there 
is no change in CBF or oxygen consumption in response to increased Fi02. In order to 
achieve the necessary change in SaCh in normal adults, the inspired oxygen is transiently
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reduced. In COPD patients who are hypoxic the necessary 6% change in saturation can be 
brought about by increasing Fi0 2 .
Calculation of CBV was performed using the equation:
where 1.05 is cerebral tissue density, 0.69 is cerebral large to small vessel haematocrit 
ratio, 64,500 is the molecular weight of haemoglobin and gradient is the gradient of a 
graph of Hbdiff in pM against oxygen saturation in fractional change (93). Graphs were 
plotted of Hbdiff against oxygen saturation from the start of recording until the oxygen was 
switched off.
Gradients were considered acceptable if correlation coefficients were >0.5.
DPF (differential pathlength factor) was assumed as 6.26(96).
13.5.1 Statistics
Relationships between parameters during oxygen challenge were examined using scatter 
plots and then simple regression analysis. P<0.05 was taken to be significant. Results 
from different subjects were combined in a two level regression as described previously.
13.6 RESULTS
13.6.1 Preliminary pilot study
This established that there were changes in cerebral oxygenation occurring in response to 
oxygen challenge in all patients, ie that cerebral oxygenation is not maintained by 
autoregulation of blood flow in the short term. One of the patients with severe 
bronchiectasis had a baseline oxygen saturation below 60% (and attended as an outpatient, 
see photocopied oxygen saturation trace Fig 50) - his response to oxygen challenge is 
illustrated in this figure and below (Fig 51). Supplementary oxygen was delivered between 
timepoint A and B. This resulted in a rise in Sa02, TOI and Ohb and a fall in HHb. Note 
that the cytochrome oxidase trace showed a minimal decrease during the oxygen 
administration which did not suggest that his respiratory chain was limited by oxygen
CBV= 64.500 x 100
1,000,000 x 1.05 x 1 0 x 2 x  0.69
x gradient x 100 
(Hb)
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availability even at these low saturations. A rise in total haemoglobin is noted when the 
oxygen is switched off; this is presumably a blood flow response to hypoxia. A rise in 
pulse rate is noted on the oximetry trace at the same time.
Figure 50. Saturation trace during oxygen challenge for subject with severe bronchiectasis and 
hypoxaemia described in text
Photocopied pulse oximeter trace with S a02 scale on y axis from 50% to 100% and clock time on x axis.
Initially lower trace is Sa02 and higher trace is pulse. Oxygen challenge between A and B.
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Figure 51. Changes in NIRS parameters during oxygen challenge in subject with severe bronchiectasis
Units on y axis are pM from an arbitrary baseline for Hb and cytochrome oxidase, and % for tissue oxygenation 
index. Oxygen challenge applied between A and B.
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13.6.2 CBV pilot study
Subjects
Subjects included 5 men and 6 women, all with COPD. Their mean age was 69.4 +/- 7.1 
years.
6 were outpatients, 5 were inpatients; all were stable and not during acute exacerbation. 
Six were already receiving long term oxygen therapy (LTOT), 5 were being assessed for 
LTOT.
Characteristics of the subjects are given in Table 57.
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Table 57. Spirometry and othe characteristics of COPD patients
IP= inpatient, OP = outpatient, FEV1 = forced expiratory volume in the first second, FVC = forced vital 
capacity, LTOT = long term oxygen therapy
ID Age
/yr
diagnosis Arterial 
PO2 /kPa
Arterial
pC 02
C02/kPa
IP/OP FEV1 // FVC n On
LTOT
hi 73/m COPD 9.6 (31) 7.7 op 0.83 2.12 Y
ja 79/f COPD 8.48 8.06 ip Y
la 57/f COPD 7.52 5.17 op 0.7 1.05 N
le 71/m COPD 7.2 5.99 ip 1.09 2.51 Y
ma 63/f COPD 9.59 4.62 ip 0.91 2.12 N
mo 68/m COPD 6.91 6.47 op N
re 60/f COPD 7.38 4.87 ip 0.84 1.79 N
ro 70/m COPD op 0.52 1.47 Y
St 75/m COPD,
CCF
op 0.9 2.01 Y
cz 78/f COPD 12.2(35%) 6.99 ip 0.80 1.63 Y
we 69/f COPD 7.01 8.07 op 0.82 1.61 N
CBV calculations
In 11 patients a plot of Hbdiff against oxygen saturation regressed significantly to a 
straight line (eg Fig 52).
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Figure 52. Hbdiff (pM) against Sa02 (%) in pilot study subject (HI)
Hbdiff = deoxygenated haemoglobin subtracted from oxygenated haemoglobin in pM. Sa02 = arterial oxygen 
saturation in %.
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Calculated CBV values appear to be in the correct range (Table 58) with a mean value of 
2.52 +/- 0.69 ml/lOOg. Previous studies have quoted baseline CBV measurements of 1.1-
8.6 ml/lOOg. There is no relationship between CBV and a single pCC>2 measurement, 
however not all pCC>2 measurements were contemporaneous.
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Table 58. CBV calculations in COPD patients
CBV is calculated from the formula quoted above (93). Gradient is the gradient of a graph of HbDiff in (iM 
against Sa02 in fractional change, the R2 and p values are from this regression graph. HbDiff is the 
difference between oxygenated and deoxygenated haemoglobin. CBV = calculated cerebral blood volume. 
pC02 = arterial partial pressure of carbon dioxide.
Patient Gradient R1 P Hb CBV ml/lOOg recent pC02 kPa
HI 0.911 0.96 <0.05 14.1 2.88 7.68
CZ 0.979 0.89 <0.05 14.0 3.11 6.99
MA 1.04 0.64 <0.05 12.7 3.65 4.62
LE 0.669 0.58 <0.05 13.1 2.27 5.99
MO 0.522 0.60 <0.05 15.4 1.51 6.47
ST 1.174 0.70 <0.05 15.6 3.34 -
LA 0.861 0.76 <0.05 14.4 2.66 5.17
RE 0.792 0.75 <0.05 14.3 2.47 4.87
WE 0.676 0.87 <0.05 13.1 2.30 8.07
RO 0.584 0.64 <0.05 13.3 1.95 -
JA 0.517 0.90 <0.05 14.6 1.58 8.06
TOI changes in relation to saturation changes during oxygen challenge
Baseline oxygen saturations were 80 - 94%, and baseline TOI readings were 53 - 67%. 
There was no correlation between baseline TOI and saturation. During oxygen challenge 
both TOI and Sa02 increased in all patients and then returned to near baseline following 
removal of supplementary oxygen (Eg Figure 53, supplementary oxygen applied between 
A and B). For the purposes of the following analyses only the sections of data during 
oxygen administration were used, and the sections during the recovery period were not 
included.
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Figure 53. Changes in TOI, S a0 2 and total haemoglobin during oxygen challenge (HI).
Sats = Sa02 = arterial oxygen saturation in %, TOI = tissue oxygenation index in %, THb = 
total haemoglobin in arbitrary units.
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Maximum and minimum TOI and Sa02 during oxygen challenge are shown in Table 59. 
Patients differed in the ratio of Sa02 change to TOI change. This ratio tended to increase 
with decreasing baseline Sa0 2  but this was not significant.
Table 59. Sa02 and TOI measurements during oxygen challenge
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, values are absolute minima and maxima 
during oxygen challenge.
Patient baseline 
Sa02 %
max Sa0 2  
%
baseline 
TOI %
max TOI
%
Ratio of Sa02 to 
TOI change
HI 80 96 60 68 2
CZ 91 97 67 72 1.2
MA 88 94 63 71 0.75
LE 93 98 66 72 0.83
MO 84 95 56 63 1.57
ST 94 98 60 70 0.4
LA 86 95 55 66 0.82
RE 89 97 61 64 2.67
WE 88 96 61 69 1.0
RO 88 98 54 62 1.25
JA 82 93 53 60 1.57
213
There was a significant correlation between Sa02 and TOI during the oxygen challenge in 
all patients (27-45 readings per subject) with regression coefficient varying from 0.29 to 
1.30 (Table 60).
Table 60. Relationship between Sa02 and TOI during oxygen challenge in each 
subject, using simple regression.
Sa02 = arterial oxygen saturation, TOI = tissue oxygenation index, regression is of Sa02 against
corresponding values o f TOI during oxygen challenge.
Subject ID Regression coefficient 95% confidence intervals p value R2
1 0.44 0.38-0.50 <0.001 0.86
2 0.45 0.35-0.54 <0.001 0.71
3 0.85 0.71-1.00 <0.001 0.76
4 0.48 0.26-0.70 <0.001 0.38
5 0.69 0.29-1.10 0.002 0.33
6 0.48 0.38-0.58 <0.001 0.71
7 0.29 0.22-0.37 <0.001 0.60
8 0.63 0.45-0.81 <0.001 0.60
9 1.30 0.92-1.69 <0.001 0.58
10 0.66 0.52-0.81 <0.001 0.72
11 0.68 0.59-0.78 <0.001 0.87
Changes in total haemoglobin (relative blood volume) during oxygen challenge
In 6 subjects total haemoglobin (THb) fell during the oxygen challenge, eg Figure 53. 
In 2 subjects total haemoglobin increased during the oxygen challenge, eg Figure 54.
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Figure 54. Example of rise in THb during oxygen challenge (MA)
Sats = Sa02 = arterial oxygen saturation in %, TOI = tissue oxygenation index in %, THb = total haemoglobin in 
arbitrary units, elpsec = elapsed seconds.
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Sa0 2  values were correlated with the corresponding total haemoglobin values (relative 
blood volume) during the oxygen challenge for each subject (Table 61). The regression 
coefficient shows how the two parameters are related and is positive if both increase during 
oxygen challenge and negative if there is a fall in relative THb.
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Table 61. Relationship between SaC>2 and THb for each subject, using simple 
regression.
Sa02 = arterial oxygen saturation, THb = total haemoglobin = sum of oxygenated and deoxygenated 
haemoglobin, regression is of Sa02 against corresponding values of THb during oxygen challenge. Coeff is 
regression coefficient or the gradient of the regression line and is positive for a positive correlation and 
negative for an inverse correlation
Id coeff R^ P
HI -4.21 0.397 0.000
JA -4.51 0.459 0.000
LA -0.259 0.033 0.232
LE -0.273 0.040 0.259
MA 0.638 0.286 0.015
MO -2.09 0.343 0.000
RE -1.09 0.388 0.000
RO 1.489 0.514 0.000
ST 0.199 0.020 0.413
s z 0.378 0.011 0.548
WE -0.134 0.001 0.858
Tissue carbon dioxide is known to be a determinant of cerebral blood flow. We therefore 
examined the relationship between the regression coefficients describing the change in 
CBV during oxygen administration and baseline pCCh recording. There were 5 subjects in 
whom the regression was significant and pCC>2 was available (Table 62).
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Table 62. Regression coefficients for relationship between THb change and SaC>2 
change, and baseline pCC>2
Sa02 = arterial oxygen saturation, THb = total haemoglobin = sum of oxygenated and deoxygenated
haemoglobin, pC 02 = arterial partial pressure of carbon dioxide. The regression coefficient is the gradient of
the regression line for Sa02 against corresponding values of THb during oxygen challenge.and is positive for
a positive correlation and negative for an inverse correlation.
id Regression coefficient pC02/kPa
HI -4.21 7.68
JA -4.51 8.06
MA 0.638 4.62
MO -2.09 6.47
RE -1.09 4.87
A graph plotted of these regression coefficients against pCC>2 showed a significant 
relationship despite so few subjects (Figure 55). The correlation coefficient is -0.97.
Figure 55. Relation between change in THb during oxygen challenge and baseline pC02
THb = total haemoglobin = sum of oxygenated and deoxygenated haemoglobin, pC 02 = arterial partial pressure 
of carbon dioxide. The regression coefficient is the gradient of the regression line for Sa02 against 
corresponding values ofTHb during oxygen challenge.and is positive for a positive correlation and negative for 
an inverse correlation.
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Changes in cytochrome oxidase during oxygen challenge
The following table (Table 63) shows the observed total changes in cytochrome oxidase 
during oxygen challenge, as well as the standard deviations of the cytox measurements. As 
the cytochrome trace starts from an arbitrary baseline, the standard deviation gives a 
further indicator of the variation in the cytochrome trace in addition to that given by the 
absolute change.
Table 63. Cytochrome changes during oxygen challenge
A Sa02 is the total change in arterial saturation during the oxygen challenge, Acytox is the total change in 
cytochrome oxidase, SD cytox is the standard deviation of the cytox trace during oxygen challenge.
id A Sa02 (%) Acytox (arbitrary SDcytox
units)
HI 16 +0.2 0.058
JA 11 +0.2 0.043
LA 9 +0.9 0.247
LE 5 -0.5 0.148
MA 6 -1.3 0.453
MO 11 +0.3 0.071
RE 8 -0.2 0.061
RO 10 -0.3 0.089
ST - 4 +0.9 0.258
sz 6 -1.1 0.238
WE 10 -0.2 0.048
The total change in cytox (Acytox) was related to A SaC>2 as shown in the following table 
(Table 64).
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Table 64. Relation between cytochrome and SaC>2 changes
A Sa02 is the total change in arterial saturation during the oxygen challenge, Acytox is the total change in 
cytochrome oxidase, SD cytox is the standard deviation of the cytox trace during oxygen challenge. Coeff is 
regression coefficient for simple linear regression in 11 subjects.
Independent variable Dependent variable coeff R2 P
A Sa02 Acytox -0.079 0.427 0.029
A Sa02 SDcytox -0.023 0.388 0.041
Pooled data
The effect of changes in CBV and SaC>2 on TOI in the pooled data was looked at in a two 
level regression, to correct for interindividual variation using the xtgee command of stata6 
(146). During the oxygen challenge increasing oxygen saturation was associated with 
decreasing relative blood volume (regression coefficient -0.067, 95% Cl -0.103 to -0.031, 
p<0.001). TOI values were significantly associated both with oxygen saturation 
(regression coefficient 0.56, 95% Cl 0.52 -0.60, p<0.001) and relative blood volume 
(regression coefficient 0.33, 95%CI 0.23 - 0.44, p<0.001) in a multiple regression 
corrected for interpatient differences.
13.7 CONCLUSIONS
13.7.1 Characteristics of TOI differ from characteristics of arterial oxygen 
saturation.
We again observed variation in baseline TOI (53 -  67, median 60), but in this group there 
was also variation in baseline Sa02 (80-94, median 88). The mean baseline TOI was 59.6, 
compared to 66.5 in the OS A subjects. There was no correlation between baseline TOI 
and saturation.
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13.7.2 TOI changes during oxygen challenge cannot be predicted from arterial 
oxygen saturation alone.
We demonstrated that cerebral tissue saturation increased during challenge with 24% and 
35% oxygen in subjects hypoxic from COPD. Although chronically hypoxic patients do 
have some compensatory mechanisms, cerebral blood flow changes clearly do not maintain 
constant cerebral oxygenation.
There was a significant relationship between Sa02 and cerebral tissue saturation during 
oxygen challenge in all subjects, however the regression coefficient differed among 
subjects. This confirmed that TOI did not depend on Sa02 alone in this patient group, and 
therefore suggested that another factor involved in cerebral oxygenation (blood flow or 
oxygen consumption) also alters during oxygen challenge.
Total haemoglobin (relative cerebral blood volume) does not remain constant during 
oxygen challenge. It increases in some subjects and decreases in others. Variations in 
CBV may be due to hypercapnoea and cerebrovascular reactivity. There was some 
suggestion that the change in CBV may be related to baseline pC02. The change in CBV 
per change in sat was related to pCC>2 as follows: patients with high CO2 tended to have a 
fall in CBV on oxygen administration and patients with a low CO2 tended to have a rise. 
The precise reason for this is not clear, particularly as we did not monitor pC02 
continuously. It is possible that subjects with chronic hypercapnoea have cerebral 
vasodilatation and then vasoconstrict as a response to oxygen administration. Subjects 
with normal CO2 may not show this response.
In multiple regression the TOI during oxygen challenge was shown to depend not only on 
Sa02 but also on CBV. This provides additional (weak) evidence to validate TOI as a 
measure of cerebral oxygenation. The evidence is weak because it assumes that CBV 
changes measured using NIR can be used as a proxy for CBF changes and are not subject 
to extracranial contamination.
An important conclusion follows these findings. We have shown that cerebral blood
volume does not remain constant during supplementary oxygen administration in
chronically hypoxic patients. We have also shown that both CBV and Sa(>2 affect cerebral
oxygenation. It follows that the effect of supplementary oxygen on cerebral oxygenation
will be modified by changes in CBV occurring during oxygen administration. This
conclusion suggests that the effect of LTOT on cerebral oxygenation will be modified by
cerebral blood flow changes and will not be predictable from the saturation response alone.
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13.7.3 Cerebral blood volume can be measured in subjects with COPD using 
oxygen challenge
We also demonstrated that it is possible to estimate absolute CBV in hypoxic patients 
using oxygen challenge, where the previously described method involves induced hypoxia 
(154). The importance of CBV measurement lies in the fact that it is one of the only 
absolute measures available from NIRS, however its clinical significance is unclear. It 
may be relevant to ventilatory responses to changes in CO2 in COPD patients. Variations 
in cerebral blood flow will alter the relationship between arterial pC0 2  and CO2 tension at 
central chemoreceptors with the latter as principal determinant of ventilatory response 
(193). We obtained a mean CBV of 2.52ml/100g with a standard deviation of 
0.69ml/100g. A previous study using an induced fall in Sa02 of <5% which is closer to 
the method originally described (154) measured CBV (ml/lOOg) of 2.41 ± 0.66 in 
normocapnic patients and 2.90±0.6 in hypercapnic patients with COPD (173). We did not 
demonstrate a relationship between pC02 and CBV in our patients but numbers were small 
and not all ABG measurements were contemporaneous. The variation in observed results 
may still be due to pC02. Accuracy of the results will be reduced because the technique 
assumes no change in CBV during oxygen challenge, and there probably are some changes 
in most subjects as evidenced by changes in total haemoglobin. Differences in smoking 
history may account for some of the observed variation in measured CBV because of the 
reduction in cerebral-perfusion related to smoking (179-181). The values obtained may 
vary because the technique is not reproducible. A study on reproducibility of the NIRS 
desaturation-resaturation measurement to measure CBV in healthy subjects performed 4 
replicate measurements in each of 2 trials, one with and one without disconnecting the 
equipment (194). They found a coefficient of variation of 12.6% and 10.0% respectively in 
the two trials on a mean value of 3.60±0.82 ml/lOOg. The same group also obtain lower 
values in their COPD patients (173), which may be due to age and asymptomatic 
cerebrovascular disease secondary to smoking.
2 2 1
Compared to the work done on OSA, the pilot studies in COPD were limited and there is a 
risk that we may overestimate their importance. However because of the limited amount 
of data on NIRS in lung disease, and more particularly the novelty of the TOI saturation 
measurement, these observations in a different patient group are worthwhile.
2 2 2
14. CONCLUSIONS
14.1 DISCUSSION OF FINDINGS
The work described in this thesis aimed to show that NIRS gives additional valid 
information when compared to measurement of arterial oxygen saturation alone in subjects 
with OS A and COPD. Cerebral oxygenation (tissue oxygen supply) depends on arterial 
oxygen saturation and cerebral blood flow, assuming oxygen consumption is constant.
In our validation studies we attempted to validate TOI as a measure of cerebral 
oxygenation in OSA. As described previously in the chapter on NIRS validation in 
general, there is no established non-invasive way of measuring cerebral tissue saturation 
from the region of interest. Hence we aimed to describe changes in TOI during OSA and 
show them to depend on Sa02 and CBF.
Arterial oxygen saturation Cerebral blood
f lo w
Cerebral oxygenation
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14.1.1 First validation study -  TOI and saturation
In the first validation study we looked at the relationship between arterial oxygen 
saturation and TOI in subjects with OSA.
Arterial oxygen saturation 
(Pulse oximeter)
Cerebral blood
flow
Cerebral oxygenation 
(NIRO300 TOI)
In 13 subjects with moderate to severe OSA we observed a reduction in regional cerebral 
tissue oxygenation index (TOI) during each obstructive apnoea and hypopnoea. The 
magnitude of the drop in cerebral tissue saturation during an obstructive event was related 
significantly to peripheral arterial Sa0 2  drop, but, independently of this association, longer 
apnoeas and apnoeas occurring during REM sleep were also associated with greater drops 
in TOI. There was considerable variation between individuals in the change in TOI which 
occurred in response to a given saturation change. Mean event related dips in TOI ranged 
from 1.4 to 6.85%, where mean oxygen desaturation dips ranged from 3.8 to 22.3% in the 
13 subjects. The clinical significance of small changes in TOI is not known, although as 
values of haemoglobin saturation in tissues are on the steep part of the haemoglobin 
dissociation curve, the corresponding changes in p02 will be relatively large. Small 
changes in intracellular redox state may affect neurotransmitter metabolism (77). The 
mean change in TOI observed on clamping the internal carotid in the Cambridge validation 
study was -7.8% (111). Using a similar NIRS derived tissue saturation in subjects 
undergoing carotid endarterectomy under local anaesthetic, the mean saturation in 10 
subjects who displayed neurological symptoms on clamping the internal carotid fell from 
63.2+/-8.4% to 51 +/-11.6%, compared to 65.8+/-8.5% to 61.0 +1-93% in 90 subjects who 
were symptomfree (127).
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There have been two previous studies measuring cerebral oxygenation using NIRS in 
OSA. The first established that changes in cerebral oxygenation occurred and that cerebral 
blood flow changes did not entirely compensate for saturation changes during apnoea (83). 
Like us they showed significantly greater falls in OHb in apnoeas during REM sleep and a 
significant relationship with apnoea duration. However they did not relate cerebral 
haemoglobin changes to oxygen saturation changes, and so were unable to conclude 
whether cerebral oxygenation measurement added any information to pulse oximetry, as 
apnoea duration and REM sleep are also associated with increased oxygen desaturation. In 
addition their NIRS machine did not give a cerebral saturation measurement, and so OHb 
changes have to be interpreted in conjunction with total haemoglobin changes in order to 
give information about redox changes. Another study has looked at cerebral saturation 
versus peripheral saturation in 4 sleep apnoeics and 4 snorers using NIRS (the machine 
was a Criticon 2020) and described the two measurements as paralleling each other, with 
cerebral saturation being 20-30% lower than peripheral saturation (84). They suggest that 
the difference between the values was due to the use of different monitoring techniques. 
Our results did not suggest parallel changes in peripheral arterial oxygenation and cerebral 
oxygenation, and this would not be predicted theoretically, because of cerebral blood flow 
changes. Their findings suggest a problem with the intracranial selectivity of their 
particular NIRS instrument, or with their analysis.
14.1.2 First validation study -  cerebral blood volume and TOI
From the first validation study we had no direct measurement of cerebral blood flow so 
we used NIR total haemoglobin and calculated changes in cerebral blood volume as proxy 
measurements. There is considerable precedent for this in previous NIR literature (83).
Arterial oxygen saturation Cerebral blood flow 
(Total haemoglobin)
Cerebral oxygenation 
(NIRO300 TOI)
225
In the 8 subjects from the initial validation study who had sufficient consecutive apnoeas 
for analysis, we observed significant correlations between the magnitude of changes in 
cerebral oxygenation measured as TOI and changes in CBV, as well as between TOI dip 
duration and both CBV and Cytox changes. We observed two patterns of temporal 
relationship between changes in cerebral blood volume and TOI: in some apnoeas the THb 
peak coincided with TOI minimum and in others with TOI maximum. Reduction in 
perfusion may explain the correlation in apnoeas in which TOI minimum and CBV 
minimum coincide. However the effect of CBV change on TOI change is significantly 
greater in the second pattern, where CBV maximum coincides with HHb maximum and 
TOI minimum. This suggests that the CBF increase itself may be worsening cerebral 
oxygenation if it occurs when arterial blood is poorly saturated and causes an influx of 
relatively deoxygenated blood.
If we ignore the complexities of the time relationships, the simple correlations between 
CBV changes and TOI changes support the basic hypothesis in the above figures.
However the possibility that a surge in CBF at a time when arterial blood is at a saturation 
of around 60 or 70% might have an adverse effect on cerebral oxygenation is entirely 
plausible.
The two temporal relationships between changes in THb and TOI were seen in the same 
patient as well as in different patients. These two relationships can be explained by 
whether oxygenated haemoglobin was rising or falling during the THb rise (OHbratio). 
Where the CBV increase occurs while oxygenated haemoglobin is rising, we can assume 
that the incoming blood is relatively oxygenated, and when OHb falls during the CBV rise, 
that the incoming blood is relatively deoxygenated. We did not have the facility to look at 
THb measurements synchronised with polysomnography measurements of apnoea to 
establish whether the THb rise always occurred at the same time relative to the apnoea. 
From the literature the CBF increase occurs during the final third of the apnoea. Looking 
at the patterns of TOI change on the polysomnography trace in patient 1 where most 
apnoeas are in one pattern and in 8 where most apnoeas are in the other, it does appear that 
maximum THb does occur at the end or just after the apnoea in both. Hence the 
occurrence of the CBV rise at different times during the apnoea does not appear a likely 
explanation for the different patterns.
The two patterns are more likely to be because of the different extent of desaturation 
during apnoea in different subjects. The extent to which incoming blood is deoxygenated
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at the time of the CBV increase will depend on length of apnoea and rate of desaturation. 
Both of these variables have been extensively researched in OSA. Apnoea termination 
may be triggered by chemoreceptors or mechanoreceptors (137). Rate of desaturation will 
depend on underlying lung disease, lung volumes or occurrence of apnoea in inspiration or 
expiration (135, 195). REM sleep stage will affect apnoea duration and extent of 
desaturation, and may explain the differences seen. Patient 1 was in REM sleep for some 
of the section analysed, and patient 8 had no REM sleep during his recording.
We are left with no more than an interesting idea about the ways that arterial saturation 
changes and cerebral blood flow changes could combine during apnoea to produce 
differing effects on cerebral oxygenation. Unfortunately this idea is based on 
interpretation of total haemoglobin changes as blood flow changes, and even though in 
later pilot studies we measured CBFV changes using Doppler, we still had no more 
sophisticated way of measuring the oxygenation of the incoming blood than using simple 
NIR OHb and HHb measurements during the THb rise. The observation of the two time 
relationships is new and was not commented on by Hayakawa (83) who only illustrated 
one trace. Overall this work supports the hypothesis that TOI measurement gives more 
information than that available from arterial saturation alone.
14.1.3 Second validation study -  CBFV, arterial saturation and TOI
In the second validation study we looked at the interrelationship of Sa02, CBFV and TOI.
Cerebral blood flow
(Doppler CBFV)
Arterial oxygen saturation 
(pulse oximetry)
Cerebral oxygenation 
(NIRO300 TOI)
We demonstrated both quantitative and temporal correlations between changes in CBFV 
and changes in cerebral tissue saturation measured as TOI in 7 patients. The relationship 
between CBFV and TOI remained significant after Sa02 was included in the regression 
equation. In one subject who had isolated CBFV changes, TOI changes accompanied
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these CBFV changes and correlated in amplitude with them, but not with ABP or SaC  ^
changes. We therefore showed that the changes in SaC>2 and in CBFV both influence 
cerebral oxygenation in obstructive sleep apnoea.
During obstructive sleep apnoea cerebral blood flow is reduced by the reduction in 
intrathoracic pressure, and then increases towards the end of the apnoea due to blood gas 
changes and autonomic arousal. It is known that this mixture of passive and 
autoregulatory blood flow changes does not fully compensate for the oxygen desaturation 
during apnoea (1, 83). It is unclear from previous literature whether the dominant effect of 
the CBFV changes on cerebral oxygenation is to compensate for or exacerbate the hypoxia 
caused by arterial desaturation. A previous NIR study found an increase in total 
haemoglobin during apnoea, despite reduction in cerebral oxyhaemoglobin, (83), which 
was interpreted to mean that CBF changes incompletely compensated for SaC>2 changes. A 
second study also found a predominant increase in CBFV during the desaturation (24). 
Reduced perfusion during apnoea was found in other studies (18, 22). In 2 studies where 
changes during individual apnoeas were not resolved, reductions in CBFV (19) and in CBF 
measured using inhaled xenon 133 (25) were observed during sleep in OSA subjects 
compared to control subjects. For the first time in this study we have been able to measure 
cerebral oxygenation simultaneously with Sa02 and CBFV, and have shown that despite a 
partial compensatory effect of the CBFV increase at the end of apnoea (visible in Figs 39 
and 40), a bigger change in CBFV is associated with a bigger drop in TOI in the multiple 
regression. This suggests that the overall effect of the CBFV changes is to exacerbate the 
cerebral tissue hypoxia caused by arterial desaturation. The large increase in CBFV at the 
end of the apnoea occurs when the arterial blood is maximally desaturated and may not 
therefore compensate for the reduced perfusion early in the apnoea when the blood is more 
fully saturated. Our work on individual apnoeas using THb measurements as proxy for 
CBF changes suggested that both compensation and exacerbation were possible, we were 
unable to corroborate this when we measured CBFV directly, but the finding that the 
dominant effect of CBF changes is to exacerbate hypoxia does not rule out the fact that 
some compensation may also occur.
One subject had repetitive changes in CBFV during sleep associated with 
changes in TOI and ABP, without changes in Sa02. This subject was known to be a snorer 
with mild OSA (dip rate 16), but did not demonstrate obstructive events during this 
daytime nap of 52mins. CBFV changes in this subject may have been due to upper airway
228
resistance and associated arousals. These changes in cerebral oxygenation would have 
been missed by isolated pulse oximetry monitoring. It is possible that upper airway 
resistance syndrome (UARS) may cause changes in cerebral oxygenation because of 
changes in CBFV associated with intrathoracic pressure changes and arousal. Further 
investigation is necessary to find out whether these changes in cerebral oxygenation are 
clinically relevant.
14.1.4 Intracellular redox changes
Arterial oxygen saturation Cerebral blood flow 
(Doppler CBFV)
“Cerebral oxygenation” 
Intracellular redox state
(NIRO cytochrome oxidase)
Cerebral oxygenation 
Tissue haemoglobin saturation 
(NIRO300 TOI)
In order to examine the metabolic effects of tissue hypoxia in OSA we looked at changes 
in cytochrome oxidase redox state in relation to tissue saturation of haemoglobin with 
oxygen (TOI), Sa02 and CBFV. Cytochrome oxidase can be seen as the enzyme 
responsible for the conversion of oxygen to water, or simply a reflection of mitochondrial 
oxygen availability, relevant to other intracellular enzyme systems.
Changes in cerebral cytochrome oxidase redox state during apnoea using near infra-red 
spectroscopy were observed during 15 episodes of daytime sleep in subjects with moderate 
to severe OSA. The magnitude of these changes varied from 0.08 to 0.48pM. Changes in 
cytochrome oxidase correlated with changes in brain tissue saturation measured as TOI, as 
well as with peripheral arterial oxygen saturation and cerebral blood flow velocity changes. 
The observed quantified changes in cytochrome redox state were small. Absolute adult 
human cytochrome oxidase concentration is not known but it was found to be 5.5pM in the 
adult rat (196). The adult human has a lower cerebral oxygen consumption rate than the 
rat so this value would be expected to be the upper limit of the concentration in humans
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(153). Hence our observed changes are between 1 and 10% of the predicted total 
concentration. Cerebral blood flow changes will have little effect on the baseline 
concentration as red blood cells do not contain mitochondria. Therefore the absolute 
cytochrome oxidase concentration is unlikely to change in the timescale of our recordings 
and so these changes can be interpreted as redox changes. In the only study looking at 
cytochrome oxidase changes and neuropsychological function in 41 adult subjects 
undergoing cardiac surgery with cardiopulmonary bypass, the 4 subjects who had marked 
cognitive deficit post operatively had a mean maximum fall in cytochrome oxidase 
oxidation of 4.5pM (124). No other measured parameter significantly predicted 
neuropsychological dysfunction in this study. There are little other published data on 
quantification of cytochrome oxidase changes in adults. Changes were observed in 
hypoxic volunteers in one study (102). Hypoxia was induced by rebreathing to a minimum 
SaC>2 of 70%, and significant changes in cytochrome concentration were observed below 
an SaC>2 of 88%, but were not quantified. The literature regarding cytochrome changes in 
human infants is more extensive, but the baseline concentration may be different. Changes 
similar to the observed changes in our first validation study (0.48 -  0.13 pM) were seen 
during periodic breathing in normal infants (mean 0.32pM), (197); in ventilated neonates 
during manipulation of pC02 and p02 (0.09-0.33pM), (198); in infants undergoing cardiac 
surgery (1.14pM assuming infant DPF of 3.85), (199) and in infants receiving 
indomethacin for treatment of patent ductus arteriosus (0.18-0.92pM), (200). These 4 
studies illustrate that changes in cerebral haemodynamics, pC(>2 and to a lesser extent p02 
are associated with small changes in cytochrome oxidase redox state in infants, but in none 
of these studies were the subjects followed up to look for physiological consequences of 
these changes. The study on adults quoted above (124) showed neuropsychological 
consequences of much larger changes. The clinical significance of smaller changes is 
unknown.
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14.1.5 NIR in chronic hypoxia
Arterial oxygen saturation 
(pulse oximetry)
Cerebral blood flow 
(Total haemoglobin)
Cerebral oxygenation 
(NIRO300 TOI)
In subjects with chronic hypoxia due to COPD it was possible to look at the relationship 
between cerebral oxygenation, total haemoglobin and Sa0 2  during oxygen challenge.
From the point of view of validating the NIRO300, we showed that TOI was related to 
both total haemoglobin and Sa02- From a clinical viewpoint we showed that the same 
increase in Sa0 2  did not always result in the same percentage increase in cerebral 
saturation, and that THb (and presumably CBF) changes accounted for some of the 
discrepancy.
Although the TOI is a tissue saturation, it clearly depends to a great extent on cerebral 
haemodynamics, and this makes it a particularly appropriate tool for the study of OSA, 
where there are changes in CBF occurring every apnoea, and probably less appropriate for 
study of chronic hypoxia, where there may be chronic compensatory mechanisms 
maintaining cerebral oxygen delivery (polycythaemia, 2,3DPG changes, changes in CBF). 
Monitoring of stable patients will give little information, and responses to oxygen 
challenge are difficult to interpret without simultaneous monitoring of pCC>2 and absolute 
CBF. Our pilot work in this patient group was very limited. Other groups have looked at 
the measurement of CBV in COPD, and cerebrovascular reactivity using NIR(173), in an 
attempt to define whether subjects with increased pC0 2  have a different cerebrovascular 
response to changes in pC02- There has been little work on the effect of supplementary 
oxygen on cerebral oxygenation, or the clinical relevance of cerebral oxygenation
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measurement. This issue is of interest because the original LTOT trials showed benefit of 
supplementary oxygen particularly in people with neuropsychological dysfunction (159, 
160). Because baseline TOI is so variable in different people, the measurement derived 
from TOI which would be appropriate for comparison in a prospective study of 
neuropsychological function on LTOT is not obvious. The change in TOI in response to 
supplementary oxygen is a possible candidate, and this could be expressed as a fraction of 
baseline TOI. Our pilot work was designed to explore the changes in TOI during oxygen 
challenge, with a view to eventually setting up a prospective study attempting to relate 
these changes to improvement in neuropsychological function on LTOT. Although time 
constraints and methodological problems prevented us from pursuing this further, it would 
still be a worthwhile project for future work. When we provisionally considered this 
project, we became aware of the very limited use of NIR in awake thinking subjects, where 
thought processes may cause changes in regional blood flow picked up by NIR. Most 
work has been carried out on ITU or in the operating theatre where subjects are 
unconscious, and there is a growing interest in the use of NIR for functional imaging, 
where the purpose is to pick up regional blood flow changes during cerebral activity. Thus 
the assumption that local frontal cerebral oximetry is representative of global changes may 
break down in awake subjects and thus NIR may be easier to interpret in asleep subjects 
with OSA than awake subjects with COPD.
14.2 LIMITATIONS OF THE RESULTS IN THIS THESIS
14.2.1 Validation
Problems with validation with NIRS lie not in its validation as an oximeter, but with its 
validation as a cerebral oximeter. The diagrams of reflectance spectroscopy with light 
traveling across the scalp, skull, meninges, skimming the surface of the brain tangentially 
and then battling its way out the other side make it difficult to believe that the predominant 
tissue sampled is brain. There is a much cited article showing that a different NIR machine 
sampled predominantly extracerebral tissue (201). Use of near infrared spectroscopy as a 
cerebral oximeter assumes that (a) it is imaging brain and (b) the local changes in cerebral 
oxygenation represent global changes occurring in response to a global hypoxaemic or 
haemodynamic challenge. Spatial resolution of NIRS is poorly defined and the NIRO300
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is no exception. Because it purports to measure regional cerebral oxygenation, direct 
validation (for example against jugular bulb saturations) is not possible, and the only 
current validation study for the NIRO300 uses its response to alterations in intracerebral 
and extracerebral blood flow. Using sequential clamping of internal and external carotids 
in 60 patients during carotid surgery, TOI changes were seen in 49 subjects; during 
external carotid clamping in 8, and during internal carotid clamping in 41. TOI correlated 
significantly with cerebral blood flow velocity (r=0.56) but not with cutaneous laser- 
Doppler flowmetry (r=0.13). Discounting the 8 subjects in whom clamping the external 
carotid affected systemic blood pressure and CBFV, the sensitivity of TOI to intracranial 
and extracranial changes was 87.5% and 0% respectively, and specificity was 100% and 
0% respectively (111). Hence the NIRO300, certainly in this clinical context, appears to 
be selective for intracranial blood flow changes.
The second assumption, that local changes are representative of global ones, holds 
provided that the subjects have no focal cerebral disease, and that there is no focal 
stimulation of parts of the cortex. This assumption probably holds true for the OSA 
subjects, who had no history of cerebrovascular disease, and were asleep during the 
recordings. Cerebrovascular disease cannot be ruled out on history alone. Davies et al (72) 
found MRI findings consistent with cerebrovascular disease in OSA patines and normal 
controls. As we measured changes in TOI during individual apnoeas from a moving 
baseline, any regional changes in cerebral blood flow during sleep would only affect the 
interpretation of our findings if they occurred on a timescale of individual apnoeas. 
Regional abnormalities in CBF including frontal hyperperfusion have been shown in 
subjects during periods of apnoeas, using SPECT imaging (202). However the time 
resolution of this technique is not sufficient to show whether there are regional cerebral 
blood flow changes during individual apnoeas. As the COPD subjects were awake 
regional blood flow changes may have occurred due to cerebral activation during the 
oxygen challenge and may account for the different THb changes during the challenge. 
This possibility does not affect the demonstration of the responsiveness of TOI to both 
Sa02 and THb changes.
14.2.2 TOI variability and reproducibility
Baseline TOI measurements are variable despite similar baseline arterial oxygen 
saturations, both in our study and in 60 subjects undergoing carotid endarterectomy (mean
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baseline TOI 67.8% (SD=8.8, range 49 - 93) (111). Table 65 illustrates baseline TOI 
saturations from the available literature on NIRO300.
Table 65. Baseline TOI values from studies using NIR0300
TOI = tissue oxygenation index
Number o f Mean baseline SD Range Reference
subjects TOI
60 67.8 48.7-93.0 an)
30 48-85 (119)
10 64.9 5.1 (121)
19 66 8 (122)
13 50.2-75 (1)
7 73.2 60.8-84.0 (203)
56 66.5 43.3-78.8 Our study 
OSA subjects
This variability seems to upset chest physicians who see cerebral oxygenation 
measurement as a similar type of measurement to arterial saturation more than 
neurosurgeons, who see it more as a haemodynamic measurement. Cerebral oxygenation 
depends on cerebral blood flow as well as Sa0 2 , and the 60 neurosurgical subjects also 
demonstrated a range of middle cerebral artery flow velocities. In addition the relative 
arterial and venous contributions to the signal vary from person to person and with site 
(204). Local blood flow variations, changes in tissue oxygen consumption and global 
cerebral blood flow changes will introduce variability in the signal from one subject over 
time. Factors affecting variability in INVOS 4100 cerebral saturation were examined in 
111 anaesthetised patients and age, haemoglobin concentration and probe position were 
found to affect rS02 values (205). There were no significant correlations with weight, 
height, head size and sex. The relation with age may well be true, as it also occurs with 
SaC>2, and the different algorithms mean that the association with haemoglobin 
concentration may well not hold true for the NIRO300. A similar study has not been 
published for NIRO300, however our experience showed that head curvature had a definite 
effect on TOI, as the algorithm assumed a fixed intra probe distance of 4 or 5 cm which 
would be reduced by curvature. Apart from this, in the absence of a way of independently
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measuring cerebral oxygenation, it is difficult to say that TOI variations with probe 
position are not true. Because of the baseline variability some groups report changes in 
cerebral saturation as a fraction of the baseline values (127), and others report absolute 
changes (111). Clearly if the baseline variability is not artifactual but true, then the 
absolute changes are more physiologically relevant, and on this basis we used absolute 
rather than fractional changes in our analysis.
14.2.3 Interpretation of cytochrome oxidase
The extent to which cross talk between the haemoglobin signals and the cytochrome signal 
affects cytochrome oxidase results is ill defined. The two signals can be distinguished in 
animal studies (129, 206), but in in vivo studies it may be difficult to be certain that an 
observed change is not artifact, especially if it is small and occurs at the same time as a 
large change in one of the haemoglobins (153). Cytochrome oxidase changes due to 
hypoxia have been shown experimentally to occur at saturations in the region of 50%
(128), but the reduced SaC>2 in OSA may be compounded by reductions in CBF. Our 
observed changes may not be due to cross talk because their magnitude is within a 
physiologically appropriate range, they occur in association with significant oxygen 
desaturations, and they do not show precise temporal correlation with OHb or HHb. 
Because the cytochrome measurements are made relying on basic NIRS and not spatially 
resolved spectroscopy, they are more likely to suffer from significant extracranial 
contamination. Luckily however mitochondria are absent in red cells, so that the signal is 
unlikely to be significantly contaminated by the extracranial blood flow changes that occur 
during apnoea. Total haemoglobin measurements are similarly liable to extracranial 
contamination and will be affected by blood flow changes, so that where there is a 
discrepancy between changes in THb and in CBFV, the latter are assumed to be correct. In 
fact wherever the cytochrome changes are coming from, their very existence suggests an 
effect of sleep apnoea on mitochondrial metabolism, which is a new finding whether or not 
some of the signal is coming from mitochondria in extracranial tissues. Worries about 
spatial resolution thus take second place to worries about the relevance of small 
cytochrome changes occurring at the same time as large haemoglobin changes. Lack of 
confidence in interpretation has meant that the cytochrome signal in adult studies is 
frequently ignored. Our changes are biologically plausible, and it seems that only by
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reporting cytochrome changes more frequently in adults, can we come to understand their 
physiological significance.
14.2.4 Size of changes
The size of the changes in TOI and cytochrome oxidase are small, compared to those 
observed in animal studies and in subjects undergoing cardiopulmonary bypass. However 
our collaborators working on NIRO were keen to work on OSA because of the size of the 
spontaneous desaturations in some subjects. In cytochrome work it is difficult ethically to 
induce desaturation to the extent that cytochrome changes are observed in humans. Much 
of the NIRO validation has been done on subjects undergoing carotid endarterectomy, 
where clearly the aim is to avoid cerebral desaturation due to internal carotid clamping on 
which TOI validation is based. Increasingly subjects in whom this desaturation is likely, 
are undergoing intraoperative shunt procedures prior to clamping so these NIRO studies 
can no longer be carried out. The repeated nature of apnoeas also provides multiple 
replications of events for analysis. All traces were analysed manually and visualized 
graphically, as is the norm with polysomnography. Hence we are in no doubt that the 
changes observed, although small, are apnoea related rather than due to noise. Whether or 
not these repetitive changes are associated with clinical outcome was not the subject of this 
pilot work.
14.2.5 Appropriate summary measures
In order to perform a study to see if measurement of TOI predicted neuropsychological 
function in subjects with OSA, it was necessary to measure TOI during full overnight 
polysomnography, and derive some output from the TOI trace that could be compared 
between subjects. We faced the problem that if our study showed no relationship between 
TOI and neuropsychological outcome, this could be due to the use of the wrong summary 
measure, and would not necessarily negate the hypothesis. We should remember that 
clinical validation of sleep study measures has rarely been performed, and most are 
validated against AHI, which itself is poorly correlated with symptoms. The area under the 
curve and dip rate calculations both had limitations. Both were calculated assuming TOI 
as an absolute measure, ie that 1% change in TOI is equivalent in all subjects and does not
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need to be corrected for baseline. If this were false it would affect the AUC measurements 
more than the dip rates. The TOI trace was noisier than the saturation in some subjects. 
AUC measurements picked up all variations including movement artifact, and because the 
digital output was not recorded simultaneously with the poly it was not possible to remove 
periods of wake from the recording. The maximum baseline value was defined arbitrarily 
as the value that 99% of observations were below, and clearly an error of 1% in this would 
make a big difference to the final values. It is known that sleep studies vary considerably 
from night to night and that the first night is often not representative of the average. 
Because of our limited resources we were not able to perform more than one night study 
for each subject. Somewhat inevitably we ended up comparing subjects who had only 
slept for 3 hours to others who slept for 10 hours, and subjects who displayed no REM 
sleep with those that did. The dip rate calculations were performed manually from the poly 
trace and therefore were apnoea associated rather than computer calculated dips. They 
were therefore less subject to noise than the AUC measurements. We plan to repeat 
analysis using measurements corrected for baseline TOI.
14.2.6 Sleep disruption and arousal.
One of the main stimuli to blood pressure changes and thus to CBF changes during apnoea 
is the autonomic arousal. It is possible that the CBF changes are an epiphenomenon of 
arousal, and that their effect on symptoms due to their effect on cerebral oxygenation is 
trivial, compared to the effect on symptoms caused by sleep disruption. We may be 
kidding ourselves that by using NIRO we are looking at the effect of cerebral oxygenation 
independent of sleep disruption, when in fact the contributions of hypoxia and arousal to 
sleep apnoea symptoms are as inseparable as ever. It has been recently shown for 
hypertension that the arousal related swings at night are associated with daytime blood 
pressure changes (42), and so it remains possible that CBF changes may affect symptoms 
independent of arousal.
14.3 MAIN FINDINGS
The main new findings from this experimental work are the following:
NIRO TOI responds to changes in both CBF and Sa02 in OSA.
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The changes in cerebral blood flow that occur during obstructive apnoea tend to exacerbate 
rather than compensate for arterial desaturation, ie thay cannot be viewed as a 
predominantly homeostatic mechanism.
Changes in intracellular redox state, exemplified by changes in cytochrome oxidase 
oxidation state, occur during OSA in some patients.
The last two findings contribute new information to the understanding of the 
pathophysiology of obstructive sleep apnoea.
14.4 CLINICAL SIGNIFICANCE.
The ultimate test of the usefulness of measurement of cerebral oxygenation using 
NIRO300 in subjects with obstructive sleep apnoea will come from the results of the 
prospective study using overnight NIRO measurements in association with objective 
neuropsychological testing before and after treatment. Our validation and 
pilot work described in this thesis established that the NIRO measurement picked up 
changes in both CBFV and Sa02 during obstructive sleep apnoea, and so would be 
expected to provide more information about cerebral oxygenation than pulse oximetry 
alone. As so many of the symptoms of OSA are neuropsychiatric we would expect 
measurement of cerebral oxygenation to be relevant to symptomatology. We derived 
summary TOI measures for sleep studies and validated them against AHI as is 
conventional. We planned to use these TOI measures with conventional polysomnography 
variables in multiple regression with neuropsychology score as an outcome.
The work on cytochrome oxidase has perhaps the most potential, as illustrating an 
intracellular effect of tissue hypoxia, and also providing a human model of repetitive 
cytochrome changes, which we assume occur because of simultaneous changes in CBF and 
SaC>2 (as the saturation changes alone are probably insufficient to affect cytochrome 
oxidation state on the basis of previous experimental work). We collected cytochrome data 
on all the overnight sleep studies for the prospective neuropsychological study. 
Unfortunately it was much more difficult to calculate an overnight cytochrome score than a 
TOI score, comparable between subjects, because of the arbitrary baseline as well as drift 
and noise. Ideally we would aim to enter an overnight value into multiple regression with 
neuropsychological score as outcome, to see if the cytochrome measurements predict
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outcome better than TOI. With the help of Medical Physics at UCL we hope that some 
cytochrome analysis from the prospective study may be performed in the future.
Work on chronic hypoxia was more limited, but we were able to show changes in cerebral 
blood volume occurring acutely in response to oxygen, which may influence the effect of 
supplementary oxygen on cerebral oxygenation. Again neuropsychological improvement 
associated with increased survival was seen in the original trials of long term oxygen 
therapy.
Future work on chronic hypoxia could include a study of whether the TOI response to 
oxygen challenge predicts neuropsychological improvement using LTOT. We thought of 
performing neuropsych tests on and off oxygen, but the use of NIRO300 in this context 
could confuse its role as a cerebral oximeter with that as a measure of cerebral activation. 
Overall OSA proved itself more appropriate for study with NIRO because of the cerebral 
haemodynamic changes occurring with each apnoea.
14.5 PERSONAL VIEW
Learning to use and understand the technology of near infra-red spectroscopy in this 
project was an exciting “voyage of discovery” for me involving many disciplines 
previously little known to me. From a background of respiratory medicine with an 
intercalated degree in biochemistry, I extracted papers from journals in neurology, 
neuropsychology, neonatology, cardiothoracics, anaesthesiology, and medical physics, and 
visited the National Hospital for Neurology and Neurosurgery at Queen Square, 
neurosurgical theatres at Addenbrookes, as well as holding discussions at UCL with people 
in Medical Physics and Paediatrics, where the prototype NIRO was developed, and then in 
the Dept of Health Psychology to develop the protocol for the neuropsychological 
validation study. I had no idea when I first started the project how controversial the 
technique of NIRS was, and of how much argument surrounded each measurement. I 
started with the clinician’s idea that if you connect a machine to a patient and a number 
comes up, then that number is a valid measure of whatever the machine claims to measure, 
provided it is properly connected. I gradually learnt about how a new measurement 
technique is validated, of the statistical techniques used (and the correct interpretation of 
simple correlations), and of the mysteries of calibration and analogue to digital converters.
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I learnt to appreciate just how much data the average sleep study computer is able to 
analyse for a single sleep study, and to understand why it took so many years and computer 
advances between the discovery of the EEG and a full night polysomnography. I learnt the 
advantages and disadvantages of computer algorithms for eg dip rate analysis, and have 
now a much better ability to interpret sleep study results, after being forced to use manual 
analysis for the NIRO.
The future of NIRS is still unclear in the literature, even 5 years on from when we started 
working with it. It is still a way away from being a routine intraoperative or ITU 
monitoring tool. Using it in sleep apnoea was relatively easy, and to our surprise we were 
able to leave it on unsupervised overnight without major problems. Because of repetitive 
changes in Sa02 and CBF, and because of prominent neuropsychological symptoms, 
unexplained by current markers of severity, OSA seems an ideal clinical scenario in which 
to test the clinical relevance of NIRS measurements. The theory behind the method is 
elegantly simple, and I have been lucky to meet a few enthusiastic “believers” in it, who 
spurred me on to complete this thesis.
At the time we received our NIRO300 there was only one published paper using it. In a 
way I feel privileged to have had to assimilate myself the necessary knowledge and 
contacts to be able to use this new and complex instrument in a properly designed and 
piloted study. I am sure that the knowledge I have acquired about medical instrumentation, 
sleep studies, and design of a clinical study will be useful in my future career as a chest 
physician with special interest in sleep and respiratory failure.
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EPWORTH SLEEPINESS SCALE
How likely are you to doze off or fall asleep in the following situations, in contrast to just feeling tired? 
This refers to your usual way of life in the last few weeks. Even if you have not done some of these 
things recently, try to work out how they would have affected you.
Use the following scale to choose the most appropriate number for each situation.
0 = Would never doze
1 = Slight chance of dozing
2 = M oderate chance of dozing 
2 = High chance of dozing
Situation Score
Sitting and reading
Watching television
Sitting inactive in a public place (eg a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down in the afternoon, when circumstances permit
Sitting and talking to someone
Sitting quietly after luncfr without alcohol
Driving a car, while stopped for a few minutes in the traffic
Total =
2
Sample recruitment letters for second validation study
DEPARTMENT OF THORACIC MEDICINE
The Middlesex Hospital
Mortimer Street, London W IN 8AA
UNIVERSITY COLLEGE LONDON HOSPITALS
UC1
HOSPITALS
  
   
   
   
  
 
Dear
I am writing to let you know about a research study which is taking place at the 
Middlesex Hospital and to invite you to take part. It would involve you coming up to 
Campbell Thompson Ward during the day, having some monitors attached, and going 
to sleep for an hour or two. Lf you are on CPAP treatment you would have to stop 
using it for one or preferably two nights before the study so you are able to sleep 
during the day. We are aiming to find out more about how obstructive sleep apnoea, 
the condition you suffer with, affects the supply o f oxygen to the brain. We are using a 
machine that can measure brain oxy genation by measuring light changes through the 
skull and a second machine that measures blood flow using an ultrasound technique. 
There are no known adverse effects from these machines.
The study w ill be taking place on 29th September and 2nd to 6th October. I 
will try to contact you by phone nearer the time see if  you are interested in helping us 
and to confirm a time if  you are. If you would like more information, would like to 
arrange a time, or wish not to be contacted further, please fill in the attached slip. 
Alternatively you can ring the lung function lab on 9243.
Thank you,
I am willing to stop using CPAP one/two nights before I
I would prefer not to be contacted further in relation to this study □
Please return to Dr Anne McGown at the above address. I am away until 17th 
September but will be able to contact you the week after that to confirm dates.
University College London Hospitals ts an NHS Trust incorporating University College Hospital. The Middlesex Hospital, The Elizabeth Garrett Anderson Hospital 
and Hospital for Women. Soho. The National Hospital for Neurology 4 Neurosurgery. The Eastman Denial Hospital and The Hospital for Tropical Diseases
Camden and Islington Health Authority
Yours sincerely
Dr Anne McGown (Research Registrar to Prof Spiro)
I would like more information
I would like to take part. The day that would suit me best is
I would prefer morning □ or afternoon
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UNIVERSITY C O LLEG E LO ND ON  H O SPIT A L S
DEPARTMENT OF THORACIC MEDICINE
The Middlesex Hospital
Mortimer Street, London WIN 8AA
m kS B
U C L
HOSPITALS
 
 
 
 
 
 
 
 
 
  
 -  
Dear
Thank you for offering to take part in our study on the impact o f obstructive sleep 
apnoea on brain oxygenation.
Please can you attend on Campbell Thompson ward a t  on .........................
where 1 will be meeting you.
We will be connecting you to some monitors and then asking you to go to sleep for 
one or two hours. Please allow for spending 3-4 hours in total in the hospital. We 
would like you not to use your CPAP machine if you have one for at least one and 
preferably 2 nights prior to the study, so that you will be able to sleep during the day. 
I enclose an information sheet about the study.
If there are any problems with this date or if you have any further questions, please can 
you contact me on 020 7636 <333 Ext 4133 or Ktmta on 7380 9243. Please say if you 
wish to change or cancel the appointment. We are running the study from 29* 
September until 6* October.
I am away until the 17* September but will try and phone to confirm with you the 
week after that.
Thank you for your help and I look forward to seeing you.
Your sincerely
•Dr Anne McGown (Research Registrar to Prof Spiro)
Hull 1 1 ^  C 4 » | l  l o « 4 —  H h ^ 4  »  • "  MMS T*«“  O h ieen it, C —«» e Mewhtrf. The >« « < « ■■ M h P « .  T he E W eheth  G»«ee nnrt*~*“ "
ii l " n fa-‘ * - *** Sehe The Neiieejh Met e**  te< MemUm  4  Nee»e»«ei«iv. The e w h w O e M U h w iu ih e  The Heipe* T«eeic»!
C » « i4 e n s e e  ts lin g lo e  H caM i < m »
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Patient information for second validation study
Impact of obstructive sleep apnoea on cerebral oxygenation measured by 
near infra-red spectroscopy -  validation pilot study.
PATIENT INFORMATION LETTER
You are being asked to take part in a study looking at a new way of measuring brain 
oxygenation in people with sleep disordered breathing.
You have a condition called obstructive sleep apnoea which may cause you 
problems with memory and concentratioa Your condition was diagnosed by measuring 
the oxygen levels using a probe on the finger. We have a new technique now that 
measures oxygen levels in the brain through die skin and we think this may be better.
Last year we studied this new technique alongside the old one in some subjects with your 
condition and measured the changes in brain oxygenation while they were asleep. Now 
we would like to make sure these really are coming from the brain using some
other monitors that we will describe below.
We would like you to come up to the sleep side room at the Middlesex Hospital 
for half a day so that we can monitor you while you have a nap. If you are on CPAP we 
will ask you not to use it for 2 days before, so you are more likely to sleep during the day. 
The monitoring we will use consists of the following probes.
1. We will be using a technique called near-infra red spectroscopy to assess brain 
oxygenation. This involves shining invisible (infrared) light about as bright as a torch 
beam across the head. By measuring changes in the light absorbed it is possible to 
estimate changes in brain oxygenation. You will have 2 leads attached to your 
forehead using a self adhesive sticker and a cloth band. Measurements are entirely 
painless, but occasionally the site gets a little red if the probe is on for a long time. 
There are no other side effects.
2. We will use a probe just in front o f your ear that picks up signals about blood flow to 
the brain using an ultrasound technique. This is called transcranial Doppler 
ultrasound.
3. We will use another Doppler ultrasound probe on your forehead to monitor skin blood 
flow.
4. We will measure changes in oxygen saturation levels using a probe on your finger.
5. We will measure changes in blood pressure also from a probe on your finger.
6. We will monitor airflow using a probe close to your nose.
7. We will monitor how deeply asleep you are using some little probes stuck on your 
head with tape or glue.
None of the monitoring equipment has any side effects or causes more than mild 
discomfort.
We will ask you to lie down and go to sleep if you can for 1 to 2 hours. We will then 
take off the equipment and you will be able to leave. We will collect the information 
from the monitors and use it to validate the new technique.
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If you agree we also do a routine blood test to measure haemoglobin which is the 
substance that carries oxygen in the blood.
If you have any questions either now or at any time please ask. Your participation 
in the dial is entirely voluntary and if at any time you wish to stop taking part you may do 
so. This will not affect your subsequent clinical care in any way.
You can contact the investigators, Dr Makker or Dr McGown, by leaving a 
message with the lung function lab (0171 3SO 9243) or on voice mail (0171 636 8333, ext 
413S), and we will return your call as soon as we can.
All proposals for research using human subjects are reviewed by an ethics 
committee before they can proceed. This proposal was reviewed fay the Joint UCL/UCLH 
Committees on the Ethics o f Human Research.
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Sample GP letter for prospective study
STUDY OF NEUROPSYCHOLOGICAL DYSFUNCTION IN OBSTRUCTIVE SLEEP APNOEA
Dear GP
Thank you for referring your patient for investigation of possible sleep disordered 
breathing. We are currently running a study of neuropsychological performance in 
obstructive sleep apnoea in collaboration with the department of Psychiatry and 
Behavioural Science, University College, London. All new referrals are being invited 
to participate in this trial. If they consent, they will all have a set of 
neuropsychological tests performed prior to their screening sleep study. Following 
their sleep study, simple snorers will have a further set of neuropsychological tests 
performed after about a month, and will have appropriate treatment arranged in the 
usual way. People with obstructive sleep apnoea (OSA) will have polysomnography 
performed with cerebral oxygenation measurement using near infra-red spectroscopy 
(NIR). This technique measures cerebral oxygenation non-invasively by transmitting 
NIR light through tissue and measuring changes in the absorption spectra of the 
haemoglobins and cytochrome oxidase. Following the polysomnography all patients 
with OSA will be offered continuous positive airway pressure (CPAP) therapy. After 
a month of treatment, neuropsychological testing, polysomnography and cerebral 
oxygenation measurement will be repeated on treatment. Following the study, they 
will be managed under the sleep clinic at Grays Inn Road in the usual way.
The mechanism of neuropsychological dysfunction in OSA is not known, and our 
study will allow us to correlate direct measures of cerebral oxygenation with results of 
cognitive testing. We hope that the information we obtain will help in making 
decisions about which patients with sleep disordered breathing should be treated. We 
will be offering CPAP to all patients with OSA in the study, on the basis of a trial by 
the Edinburgh sleep research group which showed improvement in 
neuropsychological function even in mild OSA after 28 days CPAP treatment. 
Following the study, alternative treatment options including oral appliances will be 
available to patients as usual.
If you have any further questions please do not hesitate to contact us.
Yours sincerely
Dr H Makker
Consultant in Respiratory Medicine
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Patient information letter for prospective study
STUDY OF NEUROPSYCHOLOGICAL DYSFUNCTION IN OBSTRUCTIVE SLEEP APNOEA
PATIENT INFORMATION LETTER 
You are being asked to take part in a study looking at memory and concentration in 
people with sleep disordered breathing.
You are being investigated for a condition called obstructive sleep apnoea. In this 
condition people have repetitive collapse of the upper airway during sleep, causing a 
fall in oxygen reaching the brain, which is ended when the person jerks awake and 
starts breathing again. The main symptoms consist of snoring, disturbed sleep and 
daytime sleepiness, but some people also notice problems with memory, 
concentration and ability to think. We don't know what causes these problems, but we 
do know that they may be improved by treating even mild forms of obstructive sleep 
apnoea. We would like to find out how the lack of oxygen reaching the brain at night 
affects thought processes during the day and so we are asking you to take part in this 
study.
If you agree to take part, we will do two blood tests (full blood count and thyroid 
function tests) and a lung function test (involving blowing as hard as you can) on your 
first visit. These tests are done routinely to rule out other causes of tiredness and 
breathing problems at night. Before you have your screening sleep study we will 
arrange for you to have some neuropsychological tests (tests of memory and 
concentration) and tests of sleepiness during the day.
The screening sleep study will tell us in most cases whether you have obstructive 
sleep apnoea or just simple snoring.
If it shows just snoring we will ask you to attend for a second visit in about a month 
for a second set of neuropsychological tests and tests of sleepiness. Your treatment for 
snoring will be arranged in the usual way.
If you have sleep apnoea we will ask you to have a full sleep study or 
polysomnography. This is the gold standard test to tell us how bad your sleep apnoea 
is and monitors the sleep stage, abdominal and chest movements, air flow, body 
position and oxygen saturation. We will also be using a technique called near-infra 
red spectroscopy to assess brain oxygenation during this study. This involves shining 
invisible (infrared) light about as bright as a torch beam across the head. By 
measuring changes in the light absorbed it is possible to estimate changes in brain 
oxygenation. The technique has been used for more than 10 years,and it has been 
entirely safe. You will have 2 leads attached to your forehead using a self adhesive 
sticker and a cloth band. Measurements are entirely painless, but occasionally the site 
gets a little red if the probe is on for a long time. There are no other side effects.
The following morning you will be given a continuous positive airway pressure 
machine (CPAP), to use until we finish the study (4-6weeks). This is the best 
treatment we know for obstructive sleep apnoea and can give benefit in even mild 
cases. After about a month you will have a second set of neuropsychological tests and
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tests of sleepiness as well as a second polysomnography sleep study with the cerebral 
oxygenation measurements on CPAP treatment to see how you have improved.
If you have any questions either now or at any time please ask. Your participation in 
the trial is entirely voluntary and if at any time you wish to stop taking part you may 
do so. This will not affect your subsequent clinical care in any way.
You can contact the investigators, Dr Makker or Dr McGown, by leaving a message 
with the lung function lab (0207 380 9243) or on voice mail (0207 636 8333, ext 
4135), and we will return your call as soon as we can.
All proposals for research using human subjects are reviewed by an ethics committee 
before they can proceed. This proposal was reviewed by the Joint UCL/UCLH 
Committees on the Ethics of Human Research. All personal information, results and 
records of the study will be kept confidential.
Extra time needed for study
The neuropsychological tests and tests of sleepiness take about 40 minutes each. 
Sleep studies require an overnight stay in the Middlesex Hospital.
Summary of hospital visits required
Visit 1 (today) Sleep research clinic 
Consent
Blood test, lung function test
Visit 2 (day) Neuropsychological tests 
Tests of sleepiness
Visit 3 (night) Screening sleep study
Visit 4 (night) Polysomnography sleep study 
(OSA only) Cerebral oxygenation measurement 
Loan of CPAP machine
Visit 5 (day) Neuropsychological tests 
Tests of sleepiness
Visit 6 (night) Polysomnography sleep study 
(OSA only) Cerebral oxygenation measurement
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Sample first appointment letter for prospective study
UNIVERSITY COLLEGE LONDON HOSPITALS
D EPARTM ENT OF TH O RACIC M EDICINE
The Middlesex Hospital
Mortimer Street, London WIN 8AA
 
 
 
 
 
 
 
 
 
 
 
 
  3
 
Hospital Number ...................................
Date...........................................................
Dear
Thank you for agreeing to take part in our study on neuropsychological {unctions and bram oxygenation m 
obstructive sleep apnoea
Please can you attend the sleep study room on Campbell Thompson Ward at the Middlesex Hospital
On .............................................................................................
At ......................................................... ...............................
YWicre one of die .deep Technicians will be meeting you.
This appointment a for tests of sleepiness and tests of memory and concentration. It will take a maximum of 
2 hours
P le a s e  u y  to  a v o id  d r in k s  c o n ta in in g  c a f fe in e  (c o f fe e ,  te a ,  c o la )  a n d  a lc o h o l o n  th e  d a y  o f  th e  tcsL
You can contact the Sleep Technicians (Kern or Kanta) by leaving a message in the Lung Function 
Laboratory (020 7380 9243) if you wish to change or cancel the appointment, or if you have any questions 
We will return your call as soon as we can.
Occasionally due to pressure on beds, we are told to cancel day patients at the last minute. We will therefore 
ring you on the morning of the appointment if the room is not available. If you prefer you can ring us on die 
numbers aboves>ain time after 9.30am
Yours sincerely
D r H  K Makker
Consultant Respiratory Medicine
University College London Hospitals is an NHS Trust incorporating University College Hospital. The Middtesex Hospital. The Elizabeth Garrett Anderson Hospital 
and Hospital lor Women. Sc no. The National Hospital lor Neurology & Neurosurgery. The Eastman Dental Hospital and The Hospital lot T topical Diseases
Camden and Islington Health Authority
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Sample consent form for prospective study
U N IV ERSITY  C O L L E G E  L O N D O N  H O S P IT A L S
DEPARTMENT OF THORACIC MEDICINE 
The Middlesex Hospital 
Mortimer Street, London WIN 8AA
 
    
  
  
h T
FAX  CONSENT FORM
STUDY OF NEUROPSYCHOLOGICAL DYSFUNCTION 
IN OBSTRUCTIVE SLEEP APNOEA
UCL
Have you read the information sheet about this study?
yes □ no □
Have you had an opportunity to ask questions and discuss this study?
yes □ no □
Which investigator did you discuss the study with?
Have you received satisfactory answers to all your questions?
yes □ no □
Have you received enough information about this study?
yes □ no □
Which doctor have you spoken to about this study?
Do you understand that you are free to withdraw from this study....
*at any time
yes □ no □
•without giving a reason for withdrawing
yes □ no □
•without affecting your future medical care? (if relevant)
yes □ no □
Do you agree to take part in this study?
yes □ no □
Signature of patient/voiunteer........................................................................................ Date.
Signature of investigator............................................................................................. Data...........................................
 
 
Sample patient information letter for COPD study 
ASSESSMENT OF CEREBRAL OXYGENATION USING NEAR-INFRARED 
SPECTROSCOPY 
PILOT STUDY
You are being asked to take part in a study on brain oxygenation in chronic lung disease.
At the moment prescription of oxygen depends on blood tests, but it is not completely clear where the 
cut off should be. It is possible that measuring brain oxygenation could help with this. Near-infrared 
spectroscopy (NIRS) is a technique which involves shining invisible (infrared) light about as bright as a 
torch beam across the head. By measuring changes in the light absorbed it is possible to estimate 
changes in brain oxygenation.
The technique has been used for more than 10 years mainly on special care babies and 
volunteers. You will have 2 leads attached to your forehead using a self adhesive sticker and a cloth 
band. Measurements are entirely painless but you will have to stay as still as possible for periods of 
about 15 minutes while we are recording. The whole study will take about an hour and you will be 
breathing air some of the time and 24% (controlled) oxygen some of the time. We will also be 
monitoring your oxygen saturation with a finger probe. Occasionally people find the leads a little 
uncomfortable, but not normally if the recording periods are less than 1 hour.
Your participation in the trial is entirely voluntary and if at any time you wish to stop taking 
part you may do so. This will not affect your subsequent clinical care in any way.
If the doctor looking after your lung disease wants you to have an arterial blood test we will do it at the 
same time as the trial. However we will not be doing any blood tests unless they are requested by the 
clinician looking after you.
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Sample consent form for COPD study (printed on headed paper)
CONSENT FORM
ASSESSMENT OF CEREBRAL OXYGENATION USING NEAR-INFRARED
SPECTROSCOPY
PILOT STUDY
Have you read the information sheet about this study? yes □
Have you had an opportunity to ask questions and discuss this study? yes □
Have you received satisfactory answers to all your questions? yes □
Have you received enough information about this study? yes □
Which doctor have you spoken to about this study?
Do you understand that you are free to withdraw from this study....
*at any time yes □
‘without giving a reason for withdrawing yes □
‘without affecting your future medical care? (if relevant) yes □
Do you agree to take part in this study? yes □
Signature of patient/volunteer. 
Date............................................
Signature of investigator. 
Date...................................
no □ 
no □ 
no □ 
no □
no □ 
no □ 
no □
no □
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Sample recruitment letter for COPD study
Dear
We (Dr Makker and I) are doing a pilot study on the use of near-infrared spectroscopy 
to measure cerebral oxygenation changes in patients with COPD who may require 
home oxygen, to see if the technique is likely to yield any useful information.
If you see anyone in clinic over the next few weeks (until end May1999) who 
you would like to have an ABG done on as a work up for LTOT (ie anyone with a 
saturation < 91% or so); or who is already on LTOT but you think might be willing to 
take part, please can you put them in contact with me (Anne McGown bleep 2015). I 
will give them an appointment for ABG and for an hour or so of NIRS if they agree.
I enclose a copy of the patient information sheet.
We have obtained ethical approval for this project.
Thank you for your help.
Yours sincerely,
Dr AD McGown
14
Relevant section of Compumedics manual referring to respiratory analysis
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RESPIRATORY ANALYSIS
Introduction
The automatic respiratory analysis software on the S Sanaa Sloop System 
system uses a period and peak to peak detection routine to identify abnormal 
respiratory patterns.
Channels Used
The default primary channel used is the Airflow (or CPAP if Airflow is not 
available).
The default secondary channels are the Thoracic and Abdominal Respiratory 
Movements.
These defaults can be altered from the Respiratory Parameters configuration 
menu..
The two secondary channels are analysed separately. These two channels 
are not summed, so there is no possibility of cancelling out if they are out of 
phase with each other by 180*.
Event Classification
Fifl-1, Flowchart of Automatic Respiratory Analysis, briefly details how the 
events are classified.
16
No
No Vk
S O
Pgriod detaction on
Fig.1, Flowchart of Automatic Respiratory Analysis
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